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ABSTRACT 
This thesis is divided into seven Chapters. The first 
Chapter presents introductory information, Chapters 2-6 present 
experimental results and Chapter 7 represents the conclusion. 
Chapter 2 describes the location of neutralisation 
epitopes in the primary amino acid sequence of the envelope 
glycoprotein E2 of the prototype T48 strain of the alphavirus 
Ross River virus (RRV). Using four neutralising monoclonal 
antibodies (mabs) T1E7, T10C9, NB3C4 and TlBl, fourteen 
neutralisation-resistant variants of RRV T48 were isolated 
(frequency of isolation, -10-5 ). Sequencing of the structural 
protein genes showed that point mutations had occurred in the 
E2 gene of all variants; in each case these resulted in a 
predicted non-conservative amino acid substitution in E2. No 
mutations were detected in the genes coding for El, E3, C or 
the 6K proteins except in one variant where a silent mutation 
occurred in the El gene. Variants resistant to mab Tl0C9 were 
altered at residue 216 of E2, T1E7 variants were altered at 
residues 246, 248 or 251, NB3C4 variants at residue 234 and 
T1Bl variants at residue 246. Thus three neutralisation 
epitopes were defined around amino acids 216 (epitope I), 234 
(epitope II) and 246-251 (epitope III). Cross-neutralisation 
tests of the mab-resistant variants showed that variants 
altered in one epitope were neutralised by mab interacting with 
a different epitope. 
The three neutralisation epitopes lie between the only 
two predicted asparagine-linked glycosylation sites in the 
( IV) 
primary amino acid sequence of E2. Comparison of the primary 
amino acid sequences of RRV, SFV and SIN in this region of E2 
showed that there are short sequence stretches which are 
conserved between the three alphaviruses. The amino acids 
which were altered in the mab-resistant variants were located 
within regions which were not conserved between RRV, SFV and 
SIN or were immediately adjacent to these regions. Examination 
of the hydropathy profile of RRV E2 showed that epitope I was 
located in a moderately hydrophilic domain of E2 whereas 
epitopes II and III were in two major hydrophilic domains which 
were conserved as to position and hydrophilicity profile 
between RRV, SFV and SIN. 
Multi-epitope variants with amino acid changes in all 
three epitopes were isolated by sequential selection with three 
different mabs. Sequencing of two such variants showed that a 
change in epitope I led to a restriction on the type of change 
that could be introduced in epitopes II and III indicating that 
the three epitopes may be conformationally connected. 
RRV T48 is highly virulent for young mice whereas 
another natural isolate, RRV NB5092, is avirulent. Sequence 
comparisons of mab-resistant variants of the two strains showed 
that the location of the three neutralisation epitopes was same 
for each strain. 
In Chapter 3 the biological properties of the mab-
resistant RRV T48 variants were examined in cultured cells and 
in mice. There were no significant differences between RRV T48 
and epitope I and II variants in growth, or in RNA or protein 
synthesis in BHK cells. However epitope III variants showed a 
( V ) 
slight retardation of growth, and of RNA and protein s ynthesis 
in BHK cells compared to RRV T48 together with an altered rate 
of "penetration" as measured by the rate of acquisition of 
neutralisation resistance of the infecting virus to polyclonal 
antibody. No variants altered in epitopes I or II showed 
changes in virulence (measured as Lo 50 and the average survival 
time, AST, of infected mice) compared with RRV T48. However, 
three of seven epitope III variants examined had slightly 
reduced virulence for week-old mice. An hypothesis relating 
alterations in E2 to changed biological properties of the virus 
is presented. 
During the course of sequencing the 26S RNA of RRV T48, 
Dalgarno et al. (1983) obtained evidence for the presence, 
the virus stock, of a mutant with a 21-nucleotide deletion 
the E2 gene. Subsequently RRV dE2, the predicted deletion 
in 
. in 
mutant, was isolated from the stock and the mutation confirmed 
by sequencing the appropriate region of E2 (L. Dalgarno and 
S.G. Faragher, unpublished data). In Chapter 4 we examine 
certain aspects of the biological properties of this mutant 
with particular emphasis on its virulence and growth in mice. 
In day-old mice RRV dE2 produced less severe symptoms than did 
RRV T48. The mutant had a slight increase in Lo50 and AST 
compared to RRV T48 indicating a slight attenuation. RRV dE2 
grew to peak titers which were approximately 3-4 log units 
lower in blood, brain and hind leg muscle tissues of day-old 
mice compared to RRV T48. Although there were no differences 
in the Lo50 and the AST values for RRV T48 between the day-old 
and the week-old mice, RRV dE2 was apparently totally aviru lent 
( VI ) 
in week-old mice. Thus the mutant induced no detectable 
symptoms even when injected at high doses (-8x10 6 PFU). In 
week-old mice, peak RRV dE2 titers in hind leg muscle, brain 
and blood, respectively, were 2,5, and 5 log units lower than 
the corresponding titers for RRV T48. Peak RRV T48 titers in 
blood (-10 10 PFU/ml) and in hind leg muscle (-10 12 PFU/g) were 
similar in day-old and week-old mice, however peak RRV T48 
titers were -3 log units lower in the brain of week-old mice 
than in day-old mice. Similarly peak RRV dE2 titers in blood 
(-10 5 PFU/ml) and in hind leg muscle (-10 8 PFU/g) were similar 
in day-old and in week-old mice whereas peak titers in brain 
were -3 log units lower in week-old mice compared to day-old 
mice. Since the major difference in RRV dE2 titers between 
week-old and day-old mice, and between RRV dE2 and RRV T48 
titers in week-old mice was in brain tissue it appears that the 
outcome of RRV infection was probably determined by the extent 
of replication in neural tissue. 
In Chapter 5 we attempt to define genetic and 
biological changes associated with the attenuation of RRV T48 
virulence for mice which occurs on passaging the virus in 
cultured cells. Attenuated variants of RRV T48 were obtained 
with 12 serial passages in BHK cells. In week-old mice the 
passaged-variants showed 4-30 times greater LD 50 s and about two 
times greater ASTs than RRV T48. Growth of one of four such 
attenuated variants was examined in week-old mice. There was 
no significant difference between the titers of RRV T48 and the 
variant in hind leg muscle tissue, although the variant reached 
titers which were -2 log units less than RRV T48 in blood and 
( VII ) 
brain tissue suggesting a change in tissue tropism. In BHK 
cells, attenuated variants showed more rapid "penetration" than 
RRV T48. No differences were detected in viral growth rates 
and protein synthesis when comparing variants and RRV T48 in 
BHK cells, although rates of AMD-resistant RNA synthesis in 
cells infected with variants were approximately three times 
greater than those in RRV T48-infected cells. No mutations 
were detected in the structural protein genes of the variants. 
The non-structural protein genes were not sequenced. 
Chapter 6 examines the evolution of the envelope 
glycoprotein E2, the neutralisation antigen, during the 
epidemic spread of RRV in a non-immune human population in the 
South Pacific during 1979-81. Sequencing revealed that only 
limited evolution took place in the E2 gene during the 
epidemic. There were only two nucleotide changes selected in 
the E2 gene as the virus moved from Fiji to American Samoa and 
to the Cook Islands. One of these resulted in an amino acid 
change (Thr~Ala) at residue 219 in epitope I. 
Previous studies of Faragher et al. ( 1985a) based on 
HaeIII and TaqI restriction digest analysis suggested that 
strains of RRV isolated in the South Pacific epidemic were 
closely related to an RRV isolate obtained from mosquitoes in 
the Narran Lake area of New South Wales. Sequence studies on 
the E2 gene of these isolates indicated that the Narran Lake 
isolate of RRV was closely related, but not identical, to the 
South Pacific RRV isolates. 
During a recent outbreak of polyarthritis in 
Rockhampton, patients showed a similar unusual disease pattern 
( VIII ) 
to that seen in the South Pacific outbreak. Comparison of the 
E2 gene sequences of RRV from the two areas showed that RRV 
isolates obtained from humans in Rockhampton were closely 
related, but not identical, to RRV isolates obtained from 
humans in the South Pacific. 
In the final part of Chapter 6 we have examined, for a 
small number of natural RRV isolates, the positions of 
predicted amino acid differences in E2. Comparing within this 
group and with RRV T48, a total of eight amino acid differences 
were detected in the various RRV isolates. Half of these were 
located in the domain containing the neutralisation epitopes 
which comprises only -15% of the E2 protein. 
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CHAPTER 1 
GENERAL INTRODUCTION 
1 
1.1 Alphaviruses and their medical significance 
Alphaviruses, previously known as group A arboviruses, 
are classified as a genus of the family Togaviridae. Sindbis 
(SIN) is the prototype alphavirus (Westaway et al., 1985). 
Alphaviruses are arboviruses; they are maintained in nature 
principally by transmission between susceptible vertebrate 
hosts via blood-feeding arthropods. These viruses possess the 
ability to multiply in both vertebrate and invertebrate hosts 
and in cell cultures derived from them. Alphaviruses are 
almost exclusively mosquito-borne, and are found in tropical 
and temperate regions of the world (Chamberlain, 1980). 
There are 25 recognised alphaviruses (Westaway et al., 
1985) which have been classified serologically into complexes, 
types and subtypes (Calisher et al., 1980; Chamberlain, 1980; 
Porterfield, 1980). Calisher et al. (1980) have listed six 
complexes within the alphavirus genus: the Eastern equine 
encephalitis virus (EEE), Middleburg virus (MID), Ndumu virus 
(NDU), Semliki Forest virus (SFV), Venezuelan equine 
encephalitis virus (VEE) and Western equine encephalitis virus 
(WEE) complexes. The first three complexes contain a single 
virus. Each of the other three includes several viruses which 
are antigenically closely related but are serologically 
distinguishable (Table 1.1). Ross River virus (RRV), the 
subject of this thesis, belongs to the SFV complex. 
Of the 25 alphaviruses, 16 are proven or suspected 
agents of disease in humans or domestic animals (Shope, 1980; 
Table 1.1 Serological classification of alphaviruses. 
Complex Species Subtypes 
Eastern equine 
encephalitis (EEE) EEE 
Middleburg (MID) MID 
Ndumu (NDU) NDU 
Semliki Forest (SFV) SFV 
Chikungunya (CHIK) CHIK 
Venezuelan equine 
encephalitis (VEE) 
Western equine 
Getah (GET) 
Mayaro (MAY) 
VEE 
encephalitis (WEE) WEE 
Highlands J (HJ) 
Fort Morgan (FM) 
Sindbis (SIN) 
Aura (AURA) 
From Calisher et al. (1980) . 
O'Nyong Nyong (ONN) 
GET 
Sagiyama (SAG) 
Bebaru (BEB) 
Ross River (RRV) 
MAY 
Una (UNA) 
VEE 
Everglades (EVE) 
Mucambo (MUC) 
Pixuna (PIX) 
Cabassou (CAB) 
SIN 
Whataroa (WHA) 
Kyzylagach (KZL) 
2 
Monath and Trent, 1981). There are two maJor types of disease 
syndrome induced by alphavirus infections. Encephalitis is 
associated with infections by EEE, VEE, WEE and SFV whereas 
arthritis, fever and rash are associated with infections by 
chikungunya (CHIK), O'Nyong-Nyong (ONN), Mayaro (MAY) and RRV. 
CHIK and ONN cause the most significant alphavirus disease of 
humans and have been responsible for epidemics in Asia and 
Africa affecting millions of people (Shope, 1980). 
RRV-induced epidemic polyarthritis (EPA) has occurred 
in eastern Australia at regular intervals since the syndrome 
was first described in 1928 (Nimmo, 1928). Every year several 
hundred cases of EPA occur in Australia; however during 
epidemics the number reaches several thousand (Marshall and 
Miles , 1 9 8 4 ) . Symptoms of EPA include rash, joint and muscle 
pain with or without mild fever (Anderson and French, 1957; 
Mataika, 1981; Mudge and Aaskov, 1983). The disease is 
reported mainly in adults and is rare in children (Marshall and 
Miles, 1984). Based on serological surveys, Aaskov et al. 
(1981a) reported a subclinical to clinical ratio of about 50:1 
for RRV infection in humans in Fitzroy and Far North divisions 
of Queensland. 
RRV has Australia-wide distribution (Mudge and Aaskov, 
1983). About 50% of human sera collected in Queensland during 
1957-64 had detectable RRV antibodies (Doherty et al., 1966). 
Sera from about 13% of the population in New South Wales 
contained RRV antibodies in 1981-82 (Boughton et al., 1984). 
Until 1979 RRV activity was limited to Australia, New Guinea 
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and the Solomon Islands (Tesh et al., 1975, Kanamitsu et al., 
--
--
1979). However, during 1979-81 RRV spread to a non-immune 
population in the South Pacific islands (Aaskov et al., 1981b; 
Rosen et al., 1981; Tesh et al., 1981; Fauran and Le Conidec, 
1982). EPA was first reported in Fiji in April 1979. During 
the RRV epidemic in Fiji an estimated 300,000-500,000 people, 
representing about 50-80% of the island's population, were 
infected. In August 1979 the disease spread to American Samoa 
where about half the population was affected. Then in February 
1980 EPA was reported from the Cook Islands (for a review, see 
Marshall and Miles, 1984). 
RNA viruses may evolve rapidly as demonstrated for 
poliovirus which underwent 1-2% nucleotide substitutions during 
a one-year epidemic in a non-immune population (Nottay et al., 
1981). No information exists on the evolution, at the 
nucleotide sequence level, of an alphavirus during an epidemic. 
The defined sequential spread of RRV in a non-immune population 
in the South Pacific provides an opportunity to investigate the 
evolution of an alphavirus during an epidemic. 
examined in a section of this thesis. 
This is 
There are no vaccines available for humans against any 
medically important alphavirus. An experimental vaccine for 
CHIK has been developed and tested in limited fashion, but is 
not available commercially (Craven, 1984). However, vaccines 
against EEE, VEE and WEE are currently in use in horses. A 
live virus vaccine against VEE uses a tissue culture passaged 
equine-attenuated strain (TC-83) of VEE. This vaccine is not 
ideal, for vaccine virus has been isolated from mosquitoes 
suggesting a high viraemia in some horses. Formalin-
inactivated vaccines are being used against EEE and WEE, but 
vaccination needs to be repeated every year (for a review see 
Gibbs, 19 7 6) . 
The lack of alphavirus vaccines for humans is partly 
due to the only sporadic epidemics of these viruses in recent 
years. However, the RRV epidemic in the South Pacific 
indicates that under the right circumstances alphaviruses can 
pose serious problems. Information on the structure and 
location of the neutralising epitopes in alphavirus proteins 
may be useful in designing control measures against these 
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' viruses. In a section of this thesis we determine the location 
of RRV neutralising epitopes in the primary amino acid sequence 
of the structural proteins. 
1.2 Structure of the alphavirus virion 
The most detailed structural studies of alphaviruses 
have been on SIN and SFV. In electron micrographs, negatively 
stained alphaviruses appear as spherical particles of about 50-
55 nm diameter, to which 7 nm long spikes are attached in 
radial orientation (Figure 1.1). In thin sections an 
icosahedral nucleocapsid surrounded by a lipid bilayer can be 
visualised (see Murphy, 1980). 
The alphavirus nucleocapsid consists of about 300 
molecules of capsid protein (mol. wt. -30K) complexed with 
Capsid protein 
Phospholipid bilayer ~ 
Nu cleocaps id 
F igur e 1-.1 Diagrammatic r epr esentation of 
the alphavirus virion. 
(From Faragher, 1 982 and 
1cCarthy and Harrison, 1977) 
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single stranded 49S genomic RNA (Friedman, 1968; Scheele and 
Pfefferkorn, 1969; Soderlund, 1973). This is surrounded by an 
envelope of host derived plasma membrane (Strauss and Strauss, 
1977; Murphy 1980). The envelope membrane contains 
phosholipids together with two or three (El, E2 and in the case 
of SFV, E3) glycosylated viral proteins which constitute the 
surface "spikes" of the virion ( Simons et al., 19 8 0) . The 
apparent mol. wt. of the envelope glycoproteins El and E2 is 
45-59K (Martin et al., 1979; for a review, see Simons et al., 
--
1980). On an SDS-polyacrylamide gel SIN El and RRV El migrate 
more slowly than E2 (Schlesinger and Schlesinger 1972; Short 
and Dalgarno, unpublished data) whereas for SFV the reverse is 
true (Simons et al., 1980). A third envelope glycoprotein, E3 
(apparent mol. wt. -lOK) is found in SFV in equimolar amounts 
with El and E2 (Garoff et al., 1974). E3 is not part of the 
mature SIN virion (Welch and Sefton, 1979). Whether or not E3 
is associated with the RRV virion has not been established. 
Sefton et al. ( 197 3) showed that when SIN is iodinated 
enzymatically using lactoperoxidase, E2 is more iodinated than 
El, suggesting that E2 may be more exposed on the virion 
surface than El. This may not be the case, however, . since the 
extent of iodination will depend upon the number of tyrosine 
residues exposed to the outer environment in the three 
dimensional structure. 
Treatment of intact SFV virions or of detergent 
solubilised glycoproteins with bifunctional reagents leads to 
the covalent cross linking of El and E2 (Ziemiecki and Garoff, 
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1978). Similar observation were made for SIN (Rice and 
Strauss, 1982a). Since such bifunctional reagents are capable 
of establishing cross links within a distance of about 11 
angstroms (Bickle et al., 1972) it was suggested that El and E2 
--
may exist as heterodimers in SFV and SIN (Ziemiecki and Garqff, 
1978; Rice and Strauss, 1982a). Kielian and Helenius (1985) 
have demonstrated that in SFV El and E2 interact with each 
other to form stable heterodimers; the interactions are 
concentrated in or near the transmembrane domains of the two 
proteins (see Section 1.5). It has been observed that binding 
of anti-El or anti-E2 antibodies to Triton XlOO solubilised El-
E2 complexes can induce rearrangement leading to their 
disruption (Ziemiecki and Garoff, 1978; Rice and Strauss, 
1982a). 
1.3 The alphavirus genome 
The alphaviruses contain a single stranded RNA genome 
of positive polarity which can serve as mRNA in infected cells. 
Expression of the genome does not require a virus-associated 
polymerase (reviewed in Kennedy, 1980a). 
SIN is the only alphavirus for which the complete 
genome sequence has been determined; the genome is 11,703 
nucleotides in length excluding the poly(A) tail, with a 
calculated mol. wt. of 4 x 10 6 (Strauss et al., 1984) and a 
sedimentation coefficient of -49S (Kennedy, 1980a). 
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Figure 1.2 Alphavirus genome and replication strategy. 
(from Meek, 1986) 
The figure is a schematic representation of the alphavirus 
genome, and the-~ranslation and processing of the proteins. 
Untranslated regions of the genome are shown as a single line, 
and the translated regions as an open box. The subgenomic 26S 
RNA is expanded below using the same convention. The final 
protein products are indicated with heavy lines. For the 
structural proteins the complete processing is shown. For the 
non-structural proteins the initial polyprotein and the final 
products only are shown. The opal codon following the nsP3 
gene in SIN is indicated by '7. 
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In common with many eukaryotic mRNAs, the 5'-end of the 
alphavirus genome is capped and methylated (Dubin et al., 
1979). 5' to the initiation codon for the non-structura l 
protein (nsP) genes there is an untranslated region (Figure 
1.2) which is 42-86 nucleotides in length, depending on the 
virus (Ou et al., 1983). The non-structural proteins are 
encoded in the 5' two-thirds of the 49S RNA. For SIN (Collins 
et al., 1982; Lopez et al., 1985) and SFV (Keranen and 
Ruohonen, 1983) four non-structural proteins have been 
identified. 
nsP4-3'. 
These are encoded in the order: 5'-nsP1-nsP2-nsP3-
The structural proteins are encoded in the 3' one-third 
of the 49S RNA in the order: 5'-C-E3-E2-6K-El-3' in SIN (Rice 
and Strauss, 1981), SFV (Garoff et al., 1980a,b) and RRV 
(Dalgarno et al., 1983). Between the structural protein genes 
and the non-structural protein genes there is a short 
untranslated region (the "junction region") which varies in 
length between alphaviruses from 47-50 nucleotides (Ou et al., 
1982a). 
The alphaviruses also have a 3'- untranslated region 
which, depending upon the virus, is 264-524 nucleotides in 
length and contains repeat sequence blocks (Ou et al., 1981, 
1982b; Dalgarno et al., 1983). The RRV T48 3'- untranslated 
region contains four repeats of around 50 nucleotides each. 
Interestingly, the 3'- proximal repeat sequence is conserved in 
all geographic isolates of RRV examined. However, 5' to this 
region deletions, insertions, sequence rearrangements and 
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single nucleotide substitutions are observed between RRV 
isolates (Faragher and Dalgarno, 1986). These workers 
suggested that the conserved 3'-proximal sequence block h as a n 
important role in virus replication. 
At the 3' terminus the alphavirus genome contains a 
poly(A) tract of 50-120 nucleotides (Eaton et al., 1972; 
Johnston and Bose 1972a,b; Clegg and Kennedy, 1974). The 
biological significance of this poly(A) tail is unknown, but it 
may play a role in the stability, translation or replication of 
the RNA (Kennedy, 1980a). 
1.4 Alphavirus replication 
Alphaviruses replicate in the cytoplasm of vertebrate 
or invertebrate cells over a temperature range of 20-41°c 
(Pfefferkorn and Shapiro, 1974; Follet et al., 1975; Strauss 
and Strauss, 1977). At 37°c the one-step growth curve is 
complete 6 to 10 hr post infection (pi) (Dulbecco and Vogt, 
1954; Rubin et al., 1955; Veckenstedt and Wagner, 1973). 
Multiplication of alphaviruses in vertebrate cells usually 
causes cytopathic effects and the host cell dies 10-12 hr pi at 
37°c (Hardy and Brown, 1961; Acheson and Tamm, 1967; Erlandson 
et al., 1967). In a cytolytic infection, up to 20,000 progeny 
particles are released from the cell into the medium 
(Pfefferkorn and Shapiro, 1974; Tuomi et al., 1975; Strauss and 
Strauss, 1977). In Aedes albopictus (mosquito) cells 
alphaviruses establish a persistent infection and do not 
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generally produce cytopathic effects (Raghow et al., 1973; 
Davey and Dalgarno, 1974; for a review see Stollar, 1980). The 
various steps involved in alphavirus replication are reviewed 
below. 
Entry of virus into the cell. Initiation of infection 
of vertebrate cells by alphaviruses is thought to be by 
adsorption to specific cellular receptors through the virus 
envelope glycoproteins (Fries and Helenius, 1979; Marsh and 
Helenius, 1980; for reviews see Choppin and Scheid, 1980; 
Dimrnock, 1982). However little is known about the cellular 
receptor or the receptor binding site on the virus (the anti-
receptor site). Although binding studies have shown that 
histocompatibility antigens can bind SFV (Helenius et al., 
1978), SFV grows in cells lacking histocompatibility antigens 
showing that they are not necessary for SFV attachment 
(Oldstone et al., 1980). 
It is not clear whether El, E2 or both are involved in 
virus attachment to the cell. However Barie et al. (1981) have 
presented evidence that E2 plays a role in penetration. These 
workers, following 11 serial passages of SIN in BHK cells, 
isolated an attenuated mutant which had an increased 
"penetration rate" measured as the rate of acquisition of 
resistance by infecting virus to neutralisation by polyclonal 
antibody during infection of BHK cells. The mutant had altered 
reactivity to neutralising anti-E2 mabs; an epitope in E2 was 
identified as a region important in the process of 
"penetration" since penetration revertants of attenuated SIN 
also reverted with respect to reactivity with anti-E2 mabs 
(Olmsted et al., 1986). 
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After attachment, SFV and SIN are internalised by 
adsorptive endocytosis into coated vesicles and transferred to 
prelysosomal endocytotic vesicles or endosomes where the acid 
pH triggers the fusion of viral and endosomal membranes, 
releasing the nucleocapsid into the cytoplasm (Helenius et al., 
1 9 8 0 ; Marsh et a 1 . , 1 9 8 3 ; Ca s s e 1 et a 1 . , 1 9 8 4 ) . 
The fusion activity probably resides in El, since 
purified El causes hemolysis in vitro due to membrane fusion 
(Chanas et al., 1982). The low pH in endosomes may induce a 
conformational change in El such that a fusion domain (see 
Section 1.5) is exposed; this could insert into a neighbouring 
lipid bilayer to initiate fusion and release the nucleocapsid 
into the cytoplasm (Garoff et al., 1980a). The 49S RNA is 
released from the viral nucleocapsid by an unknown mechanism. 
Translation of 49S RNA. The released 49S RNA acts as an 
mRNA for the synthesis of the non-structural proteins during 
the first 3 hr of infection (Friedman and Grimley, 1969; 
Scheele and Pfefferkorn, 1969; Wengler and Wengler, 1975). The 
four non-structural proteins (nsPl-4) are derived by cleavage 
of a precursor polyprotein (Keranen and Ruohonen, 1983; Strauss 
et al., 1984). In SIN, translation of nsP4 is controlled by an 
opal (UGA) termination codon at the 3' end of the nsP3 gene. 
Occasional read through of this codon allows synthesis of a 
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polyprotein containing nsP4 (Strauss et al., 1984). SFV, 
however, does not have this opal codon (C.M. Rice, personal 
communication). Although the precise functions of the non-
structural proteins are unknown, they must include activities 
controlling recognition of replicase binding sites for minus-
and plus-strand 49S RNA synthesis and the 26S RNA synthesis. 
They may also include a virus specific protease to process the 
polyprotein (Strauss and Strauss, 1983). 
Viral RNA synthesis. Plus-strand 49S RNA is copied by 
the viral polymerase to form minus-strand 49S RNA. It has been 
proposed that minus-strand synthesis is initiated by the 
replicase binding to a conserved 19 nucleotide sequence 
adjacent to the poly(A) tail (Ou et al., 1981). Minus-strand 
49S RNA is made only in small amounts and its synthesis ceases 
early in infection as the polymerase enzymes are short lived 
(Sawicki and Sawicki, 1980). The encapsidation of the plus-
strand 49S RNA may also reduce the availability of template 49S 
RNA for minus-strand synthesis. 
Minus-strand 49S RNA acts as template for synthesis of 
both plus-strand 49S RNA and subgenomic 26S RNA. The 3'- end 
of the minus strand 49S RNA must contain a replicase binding 
site for the synthesis of plus-strand 49S RNA although the 
sequence involved has not been identified (Ou et al., 1983). 
--
Initiation of transcription of 26S RNA from minus-strand 49S 
RNA is probably by binding of transcriptase to a conserved 21 
nucleotide sequence in the "junction region" (Ou et al., 
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1982a). This sequence is not homologous to that at the 3'-end, 
suggesting that different enzymes function for synthesis of 26S 
RNA and minus-strand 49S RNA. 
The molar ratio of 49S to 26S RNA synthesis varies 
between 0.2 and 0.8 depending upon the virus and cell system 
used (see Kennedy, 1980b). Since much of the 49S RNA enters 
nucleocapsids and is unavailable for translation, up to 90% of 
viral messenger RNA in infected cells may be 26S RNA (Kennedy 
1980b; Strauss and Strauss, 1983). 
Translation and processing of structural proteins. The 
subgenomic 26S RNA is translated in a single long open reading 
frame as a precursor polyprotein (p130) which is then processed 
by proteolytic enzymes to form viral structural proteins 
(Figure 1.2) (Schlesinger and Kaariainen, 1980). The C protein 
is probably cleaved from the nascent polyprotein by an 
autoproteolytic activity (Hahn et al., 1985) and remains 
transiently associated with the 60S ribosomal subunit before 
complexing with 49S RNA to form nucleocapsids (Soderlund and 
Ulmanen, 1977). The remaining polypeptide (p95) contains E2 
and El, together with their respective signal sequences (E3 and 
the 6K proteins). Removal of the capsid protein from p130 
exposes the signal sequence at the N-terminus of E3, which 
results in the integration of p95 into the endoplasmic 
reticulum (Wirth et al., 1977). Cleavage of the precursor of 
E2 (PE2, containing E2 and E3) from p95, possibly by signalase 
(Rice and Strauss, 1981), exposes a signal sequence in the 6K 
13 
protein which inserts the 6K protein and El into the 
endoplasmic reticulum (Hashimoto et al ., 1981). Signalase may 
cleave the 6K protein from the El-6K complex (Rice and Strauss, 
1981). In SIN replication both E3 and the 6K proteins are 
released into the culture medium (Welch and Sefton, 1979) 
whereas for SFV the 6K protein is released into the medium 
(Welch and Sefton, 1980) while E3 is incorporated into the 
mature virion (Garoff et al., 1974). 
Asparagine-linked glycosylation of envelope proteins 
takes place by host cell enzymes in the lumen of the 
endoplasmic reticulum during their synthesis (Burge and Huang, 
1970; Grimes and Burge, 1971; Keegstra et al., 1975; 
Schlesinger et al., 1976; for a review see Schlesinger and 
Kaariainen, 1980). The tripeptide sequence Asn-X-Ser or Asn-X-
Thr, where Xis any amino acid, serves as the recognition 
sequence for asparagine-linked glycosylation (Mayne et al., 
1985) which involves the en bloc transfer of a mannose and N-
acetylglucosamine oligosaccharide (the "simple" carbohydrate 
chain) from a dolichol pyrophosphate intermediate to the 
potential attachment site in the envelope protein (Waechter and 
Lennarz, 1976). Trimming of these carbohydrate chains and 
addition of different glycosides to form a "complex" type chain 
occurs during transport through the Golgi apparatus (Mayne et 
al., 1985). Fatty acid acylation of El and E2 also probably 
occurs during transport through the Golgi apparatus (Schmidt 
and Schlesinger, 1980). 
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Assembly, maturation and release. The viru s enve lop e 
proteins are probably transported to the plasma membrane fr om 
the Golgi apparatus by membrane vesicles which fuse with the 
cell surface (Garoff et al., 1982). Cleavage of PE2 by a 
cellular protease may occur during the transport (Garoff et 
al., 1982). Virus RNA and capsid protein aggregate to form 
nucleocapsids in the cytoplasm; these migrate to and associate 
with the cytoplasmic side of the host cell membrane which has 
been modified by the insertion of virus-specified proteins 
destined to become the glycoproteins of the viral envelope. 
Envelopment of the nucleocapsid in the modified membrane is 
followed by budding which results in release of virus from the 
cell (reviewed by Brown, 1980). 
Effect of viral replication on the host cell. 
Replication of alphaviruses in vertebrate cells is generally 
cytolytic. Host DNA, RNA and protein synthesis are shut down 
and cell division is inhibited, leading to cell death (Lust, 
1966; Mussgay et al., 1970; Atkins, 1976; Wengler and Wengler, 
1976; Wengler, 1980). 
Various mechanisms have been proposed for host protein 
synthesis inhibition during alphavirus infection. SIN 
infection of chick cells leads to an increase in intracellular 
Na+ concentration and a decrease in intracellular K+ 
concentration. This favours viral mRNA translation and 
inhibits translation of the great majority of cellular mRNAs 
(Garry et al., 1979a,b). Van Steeg et al. (1984) showed that 
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SFV capsid protein can interfere specifically with binding of 
host mRNAs into initiation complexes thus causing the shut down 
of host protein synthesis in neuroblastoma cells. It is not 
known whether these different mechanisms operate only in the 
different cells examined or whether both mechanisms operate 
simultaneously. 
1.5 Functional domains in alphavirus envelope proteins 
The complete amino acid sequences of the envelope 
proteins of three alphaviruses, SFV (Garoff et al., 1980a), SIN 
(Rice and Strauss, 1981) and RRV (Dalgarno et al., 1983) have 
been deduced from the sequence of the 26S RNA which encodes 
these proteins. Comparison of the deduced amino acid sequences 
of RRV, SFV and SIN structural proteins has identified a number 
of domains which are conserved either as to amino acid 
sequence, hydropathy characteristics or in the position of 
predicted asparagine-linked glycosylation sites (Dalgarno et 
al. , 19 8 3) . Since SIN, SFV and RRV are thought to have evolved 
by divergence from a common ancestor (Bell et al., 1984) this 
conservation of sequence in the face of evolution is thought to 
reflect the functional importance of these regions. Thus 
different domains in the envelope proteins have been predicted 
to be associated with various important biological functions 
(Dalgarno et al., 1983). 
A section of this thesis examines aspects of the 
biological role of RRV E2. This involves an examination of the 
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biological properties of a number of RRV mutants altered in E2 . 
In order to assist in interpreting the results we describe 
below the important features of different domains of alphavirus 
E2. Since in virions E2 and El exist as heterodimers, it is 
possible that they constitute a functional dimer. We, 
therefore, also review features of various domains in El. 
Glycoprotein E2. The amino acid sequence of E2 deduced 
from the nucleotide sequence of the 26S RNA predicts that E2 is 
423 amino acids long for SIN (Rice and Strauss, 1981) and 422 
amino acids long for SFV (Garoff et al., 1980a) and RRV 
(Dalgarno et al., 1983). Predicted amino acid sequence 
homology between RRV E2 and SFV E2 is 69%; it is 42% between 
RRV E2 and SIN E2 (Dalgarno et al., 1983). The overall degree 
of amino acid sequence conservation in E2 is less than that in 
El (see below) . This together with the fact that E2 carries 
type specific neutralisation activity (Dalrymple et al., 1976) 
suggests an evolutionary function of E2 in generating strain 
diversity (Dalgarno et al., 1983). 
E2 has a conserved hydrophobic membrane-spanning domain 
(residues 364-389) near the C-terminus which is poorly 
conserved at the amino acid sequence level (Dalgarno et al., 
1983). This domain contains covalently attached palmitic acid 
residues (Schmidt et al., 1979; Rice et al., 1982b) the precise -
-
position and role of which is unknown. 
C-terminal to the transmembrane domain is a stretch of 
approximately 30 hydrophobic amino acids which form the 
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cytoplasmic domain. Amino acid sequence conservation is higher 
in the cytoplasmic domain than in the transmembrane domain 
(Dalgarno et al., 1983). This domain may interact with the 
capsid during maturation (Simons et al., 1980; Brown, 1980; 
Rice and Strauss, 1981; Strauss and Strauss, 1985). 
In RRV, SFV and SIN, E2 has two potential attachment 
sites for asparagine-linked oligosaccharides (Dalgarno et al., 
1983; Mayne et al., 1985). The first of these (at Asn 196 for 
SIN and Asn 200 for SFV and RRV) is conserved as to position. 
The second site is not conserved as to position since it is at 
Asn 262 in SFV and RRV and at Asn 318 in SIN (Dalgarno et al., 
1983). For SIN the first site is always linked to a "complex" 
carbohydrate whereas the second may be linked to a "simple" or 
"complex" carbohydrate depending upon the host cell (Mayne et 
al., 1985). The conservation of the location of the first site 
and the conservation of the nature of the carbohydrate attached 
to it may suggest the importance of the first glycosylation 
site in virus maturation (Mayne et al., 1985). Datema et al., 
(1984) showed that in SIN infection cleavage of PE2 to E2 is 
inhibited by the presence of a glucosidase inhibitor which 
prevents processing to "complex" chains, thus indicating the 
importance of a "complex" carbohydrate chain at the first site 
in virus maturation. 
Amino acids 1-363 constitute the external domain of E2 
which does not contain any strongly conserved sequences. 
parts of the external domain will be exposed to the outer 
Since 
environment this may contain amino acid sequences involved in 
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virus-cell interaction. Barie et al. (1981) showed that SIN E2 
is involved in penetration (Section 1.4). Thus E2 may contain 
the receptor binding site. However the region of E2 involved 
in penetration or the location of receptor binding site has not 
been identified. 
The E2 protein contains antigenic sites which induce 
and react with neutralising antibodies (Dalrymple et al., 1976; 
Schmaljohn et al., 1983; Boere et al., 1984; Stanley et al., 
1985; Stec et al., 1986). However the location of neutralising 
antigenic site(s) has not been determined in the primary amino 
acid sequence of E2 for any alphavirus. In this thesis we 
determine the location of RRV neutralisation epitopes in the 
primary amino acid sequence of E2. 
There are reports in literature of alphavirus mutants 
with large deletions in E2 (Bracha and Schlesinger, 1978; Leone 
et al., 1980). However the precise location of these deletions 
and their effect on biological properties of the mutants are 
not known. A mutant of RRV T48 has been isolated which, on the 
basis of nucleotide sequencing, has been predicted to have a 
deletion of seven amino acids between residues 55-61 in E2 
(Dalgarno et al., 1983; S.G. Faragher, unpublished data). In a 
subsequent Chapter of this thesis we examine the effect of this 
deletion on the biological properties of the virus in an 
attempt to understand the biological role of E2. 
Glycoprotein El. El is predicted to be 430 amino acids 
long for SIN (Rice and Strauss, 1981) and 438 amino acids long 
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for SFV (Garoff et al., 1980a) and RRV (Dalgarno et al., 1983). 
Amino acid homology between RRV El and SFV El is 79%; for RRV 
and SIN the corresponding figure is 51% (Dalgarno et al., 
1983). 
Towards the N-terminus of El there is a stretch of 
hydrophobic amino acids (residues 80-96) which is highly 
conserved between RRV, SFV and SIN and which may be responsible 
for the fusion activity of the virus and of El (Garoff et al., 
1980a, Rice and Strauss 1981, Dalgarno et al., 1983). This 
domain lies within a larger conserved region (residues 45-108). 
The transmembrane domain of El (residues 413-436 in RRV 
T48) is strongly hydrophobic and is close to the C-terminus; it 
is not well conserved between alphaviruses at the sequence 
level (Dalgarno et al., 1983). This domain is followed by two 
C-terminal arginine residues which are believed to represent a 
small cytoplasmic "stop transfer" signal (Rice et al., 1982b). 
The transmembrane domain contains covalently attached palmitic 
acid residues (Schmidt et al., 1979; Rice et al., 1982b); the 
location of the attachment site is unknown. Schmidt and 
Lambrecht (1985) have suggested an involvement of protein-bound 
fatty acids in the induction of membrane fusion by SFV. 
El has one or two asparagine-linked glycosylation sites 
depending upon the virus. SIN, SFV and RRV all have a 
"complex" carbohydrate chain attached to Asn 139 (SIN) or Asn 
141 (SFV, RRV) of El and thus the "complex" chain site is 
conserved as to position. SIN has a second, "simple" 
carbohydrate chain at Asn 245 (Mayne et al., 1985; Strauss and 
Strauss, 1985). Since the l ocation of the first site is 
conserved it appears that this may be essential for virus 
maturation (Mayne et al., 1985). 
El contains antigenic sites which induce 
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haemagglutination inhibiting (HI) antibodies (Dalrymple et al., 
1976; Chanas et al., 1982; Schmaljohn et al., 1983; Boere et 
al., 1984; Stanley et al., 1985; Stec et al., 1986). However 
the location of these sites is yet to be identified. 
This view of the biological function of E2 and El may 
be complicated if the two proteins exist as a functional unit, 
in which case alteration(s) in either protein may affect the 
function(s) attributed to another protein. 
1. 6 Antigenic analysis of alphavirus envelope proteins 
One of the first reports on the antigenic structure of 
alphaviruses was that of Pederson and Eddy (1974) on the 
antigenic characterisation of VEE structural proteins. They 
showed that rabbit antiserum against VEE E2 neutralised virus 
infectivity in plaque reduction neutralisation tests (PRNT) and 
inhibited haemagglutination; anti-El serum did not possess any 
significant HI activity or neutralising activity. Dalrymple et 
al. (1976) observed that polyclonal rabbit antiserum raised 
against purified SIN El inhibited haemagglutination but did not 
neutralise virus infectivity in PRNT; rabbit anti-E2 serum 
neutralised SIN infectivity in PRNT and lacked HI activity. 
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Helenius et al. (1976) showed that antibodies against SFV El 
had HI activity. Thus in general antibodies to E2 neut ralise 
virus infectivity and antibodies against El inhibit 
haemagglutination. It should be noted that the antigenic 
properties of VEE, where both neutralisation and 
haemagglutination activities are located in E2, are different 
from that of SIN and SFV. 
Monoclonal antibodies (mabs) have been extensively used 
in studying virus antigenic structure (for a review see Yewdell 
and Gerhard, 1981). Competitive binding assays (CBAs) have 
been used to provide information on the topographic arrangement 
of the antigenic sites in a protein. CBAs have limitations, 
however, as they do not discriminate between two independent 
but physically close epitopes since binding of a mab to an 
epitope may sterically hinder the binding of another mab to a 
physically close epitope, thus defining the two discrete 
epitopes in the same antigenic site. 
A number of spatially distinct antigenic sites on El 
and E2 of alphaviruses have been demonstrated by CBAs. 
for SIN, Schmaljohn et al. (1983) defined five sites on 
Thus 
purified El and one site on purified E2. However, in the SIN 
virion only one site on each of El and E2 could be detected 
indicating that four out of the five SIN El sites are masked in 
intact virion; mab binding to either of these two sites 
neutralised virus infectivity (Schmaljohn et al., 1983). More 
recently, the same group of workers with a further anti-E2 mab 
defined an additional neutralisation site on SIN E2, thus 
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giving a total of two neutralisation sites on E2 and one on El 
(Stec et al., 1986). The existence of a neutralisation site on 
SIN El has also been demonstrated by Chan as et al . ( 1982) . 
For SFV, using intact purified virus in CBAs Boere et 
al. (1984) demonstrated a total of 11 antigenic sites, six on 
El and five on E2; mabs to three of the sites on El and two on 
E2 neutralised virus infectivity. Using a similar method 
Roehrig et al. (1982) defined seven antigenic sites for VEE, 
four on El and three on E2; one site on E2 was involved in 
neutralisation. For RRV, C. Fernon and R.C. Weir (unpublished 
data) have detected at least two antigenic sites on E2, mabs to 
one of these sites were neutralising; no anti-El mab 
neutralised virus infectivity. 
Thus it appears that both anti-El and anti-E2 mabs can 
neutralise alphavirus infectivity. However, the number of 
neutralisation sites and their distribution on El and E2 is 
different between different alphaviruses. The difference could 
be partly explained in terms of the different number of mabs 
used to study the antigenic structure of different alphaviruses 
(e.g. Stec et al., 1986). 
Although the studies based on CBAs have provided 
information on the topographic arrangement of the antigenic 
sites in alphavirus structural proteins, there is no 
information on their structure and location in the primary 
sequence of the proteins. In a Chapter of this thesis we 
investigate the location of neutralising epitopes in the RRV 
structural proteins. 
1.7 Alphavirus virulence and the role of the 
structural proteins 
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The virulence of a virus is a measure of its ability to 
cause disease in the host (Mims and White, 1984); the term 
refers · to those properties of a virus which lead to serious 
disease symptoms in the host by overcoming the host defences. 
Therefore virulence is a compound of the reactions of host and 
virus. The question of what properties of a virus determine 
its degree of virulence is important in developing effective 
control measures against the virus. In general, rapid growth 
of the virus is considered important in determining whether a 
virus will overcome the host's immune response and fully 
express its "inherent virulence" (Schlesinger, 1980). 
Our understanding of virulence determinants is most 
advanced for myxo-, paramyxo- and reoviruses. For these 
viruses, growth rates and tissue tropisms are determined, at 
least in part, by differences in envelope proteins which are 
involved in receptor recognition, virus attachment and 
penetration, and membrane fusion to initiate the infection 
(Homma and Oguchi, 1973; Nagai et al., 1976; Gething et al., 
1978; Bosch et al., 1979; Huang et al., 1980; Fields and Green, 
1982; Webster et al., 1982; Webster et al., 1986). 
A number of approaches have been used to investigate 
virulence determinants of alphaviruses at the molecular level. 
These have involved a comparison of the growth of virulent and 
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avirulent strains in cultured cells and in mice, a brief r eview 
of which is presented below. 
Comparison of virulent and avirulent alphaviruses 
in cultured cells. Atkins (1983) examined the replication of 
mouse-virulent and avirulent SFV isolates in BHK cells where 
the avirulent strain grew to higher titers than the virulent 
strain although the virulent SFV made more virus-specific RNA 
than the avirulent strain. The avirulent strain grew poorly 
compared to the virulent SFV in Cl300 cells of neuronal origin. 
This was consistent with the observation that the avirulent 
strain did not infect neurons in mice. 
A major problem in comparing such naturally occurring 
isolates is that many mutations unrelated to virulence may have 
accumulated during the separate evolution of the two isolates. 
More useful comparisons can be made using clonally related 
variants of different levels of virulence. 
Mecham and Trent (1983) compared the replication of the 
equine-virulent TRD strain of VEE with the avirulent vaccine 
strain TC-83 derived from TRD by 83 tissue culture passages. 
In Vero cells the two strains had similar latent periods, 
although TC-83 grew more slowly than the TRD strain for first 
12 hr; at later stages the two reached similar titers. The TRD 
strain made more viral RNA than TC-83 and caused more rapid 
shut down of host protein synthesis. Mecham and Trent (1983) 
suggested that reduced virus replication rates in cultured 
cells may be related to the reduced virulence in equines; they 
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suggested that changes may have occurred in sections of genome 
controlling RNA replication although genetic differences 
between the two strains were not examined. 
Barie et al. (1981) compared growth and RNA synthesis 
in BHK cells of mouse-virulent SIN and its BHK cell passaged 
derivative (see Section 1.4) which was attenuated for mice. 
The attenuated SIN "penetrated" (for definition see Section 
1.4) faster, had a reduced latent period and grew to higher 
titers than virulent SIN in BHK cells. Attenuated SIN had a 
peak viral RNA synthesis rate twice that of virulent SIN in BHK 
cells. This difference in RNA synthesis rates did not co-vary 
with virulence since the virulent revertant of attenuated SIN 
maintained a higher rate of RNA synthesis in BHK cells (Olmsted 
et al., 1984). However, rapid "penetration" in BHK cells was 
correlated to attenuation in mice and an alteration in 
neutralisation epitope(s) in E2 was associated with the changed 
"penetration" and virulence (Olmsted et al., 1986). It should 
be noted that a change in the sequence of E2, El or even C 
protein could affect the conformation of an epitope in E2. 
However the change in attenuated SIN was not localised to a 
specific protein by sequencing. 
Meek (1986) compared growth and RNA synthesis in BHK 
cells, of mouse-avirulent RRV NB5092 and clonally related 
variants of markedly enhanced virulence derived from it by ten 
serial passages in mice. The virulent variants did not grow 
more rapidly in BHK cells than RRV NB5092 but did have higher 
RNA synthesis rates. Meek (1986) showed that one or two amino 
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acid changes had occurred in E2 of seven out of these eight 
virulence variants. Thus, in five variants, single amino acid 
changes occurred at positions 212, 232 or 251; in two variants 
there were two amino acid changes in each at positions 27 and 
172, and at 72 and 234. No changes were found in El, E3, C, 
the 6K protein or in the 3'- untranslated region of the 26S RNA 
of two of the variants sequenced. No extensive sequence data 
was obtained for the non-structural protein genes of the 
variants although changes in RNA synthesis rates suggested that 
mutations had occurred in regions of genome controlling RNA 
replication. 
Comparison of virulent and avirulent alphaviruses in 
mice. The mouse has been the most common laboratory host for 
alphavirus studies in vivo (Shope and Sather, 1979). The 
virulence of a virus can be measured in terms of lethal dose 
(LD 50 ), the average survival time (AST) of the infected mice, 
and the time of onset and severity of disease symptoms. 
In most cases alphavirus infection of mice is 
neurotropic, i.e. neuronal tissue is the primary site for virus 
replication, e.g. SFV (Atkins et al., 1985). Comparison in 
mice of SFV mutants of different virulence levels shows that 
mutants of reduced virulence have reduced replication in brain 
tissue (Pusztai et al., 1971; Bradish and Allner, 1972; 
Fleming, 1977; Barrett et al., 1980). Reduced growth in brain 
also correlates with attenuation of virulence of WEE (Takayama 
and Nakano, 1975) and VEE (Krieger et al., 1979) for mice. 
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RRV infection of mice is myotropic, the hind leg muscle 
being the primary site of virus replication (Murphy et al., 
1973; Seay et al., 1981). Taylor (1972) compared the growth of 
mouse-virulent RRV T48 and of mouse-avirulent RRV NB5092 in 
different tissues of day-old mice. The highest titers for both 
strains were reached in hind leg muscle although RRV NB5092 
grew more slowly and to lower titers than RRV T48 in blood, 
brain and muscle tissues of mice (Taylor, 1972, Mims et al., 
1973; Murphy et al., 1973). Recently, Meek (1986) has reported 
on the growth in mice of clonally related virulent variants of 
RRV NB5092 altered in E2 (see above); he observed that the 
virulent variants attained a significantly higher titer 
brain tissue than did avirulent RRV NB5092. 
' in 
The studies described in this Section suggest that 
alphavirus structural proteins are one of the important 
determinants of virulence. However, in no case was the crucial 
genetic difference between virulent and avirulent strains 
established conclusively. A start towards investigating the 
relationship, if any, between changes in alphavirus structural 
proteins and virulence was made by Meek (1986). However, in 
these studies unidentified genetic differences in the non-
structural protein genes may have been responsible for, or have 
contributed to virulence enhancement. To investigate the role 
of E2 as a virulence determinant we examine in this thesis the 
virulence and growth characteristics of mab-resistant variants 
of RRV T48 with defined point mutations in E2. In another 
section we examine the biological properties of an RRV T48 
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mutant with a seven amino acid deletion in E2 (see Section 
1 . 5) . Since these mutants were altered, we believe, only i n E2 
a change in their biological properties could more meaningfully 
be related to the known genetic change. 
1. 8 Genetic and the biological variants of RRV in nature 
It has been demonstrated that in nature antigenically 
distinct RRV strains exist which differ in their mouse 
virulence (Woodroofe et al., 1977). For example, RRV NB5092 
and RRV T48, isolated from mosquitoes at Nelson Bay in coastal 
New South Wales and at Townsville in northern Queensland 
respectively, had marked differences in their mouse virulence. 
Thus RRV T48 killed near 100% of day-old, one week- and two 
week-old mice; in contrast, RRV NB5092 had only a 24% 
mortality rate for day-old mice and caused no disease symptoms 
in week-old mice (Gard et al., 1973; Taylor and Marshall 
1975a). It is thought that these two RRV antigenic types are 
enzootic to their respective regions and have evolved in 
isolation from a common ancestral virus (Woodroofe et al., 
1977; Marshall et al., 1980). Recently, neutralising mabs have 
also demonstrated antigenic differences between RRV isolates 
from different geographical locations in Australia and the 
South Pacific (C. Fernan and R.C. Weir, unpublished data). 
Further evidence for the existence of genetically 
different, enzootic strains of RRV has been presented by 
Faragher et al. (1985a) who compared TaqI and HaeIII 
restriction digest profiles of cDNA to the genomic RNA of 15 
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isolates of RRV from eastern Australia and the Pacific islands. 
They grouped the isolates into three genetic types on the basis 
of similarities in restriction digest profiles. RRV T48 and 
RRV NB5092 were placed in genetic types I and III respectively . 
RRV isolates from human EPA cases in Fiji, American Samoa and 
the Cook Islands showed identical restriction digest profiles 
(Faragher et al., 1985a). Thus it was concluded that a single 
RRV genetic type was involved in the outbreaks of EPA in the 
South Pacific islands. Interestingly, RRV NL26301 isolated 
from mosquitoes collected at Narran Lake in northern New South 
Wales, appeared to be closely related to the Pacific isolates 
and all were placed in genetic type II. Faragher et al. 
(1985a) estimated that nucleotide sequence divergence between 
the strains within a genetic type was <1.5% and was 1.5-5.0% 
between genetic types. Nucleotide sequencing of the 26S RNA of 
RRV T48 (genetic type I) and RRV NB5092 (genetic type III) has 
shown that the sequence divergence between these two strains is 
2.3% (Meek, 1986). 
Although isolated frequently from mosquito pools . in 
Australia, RRV had not been isolated from an EPA patient until 
the South Pacific epidemic of 1979-81 (Aaskov et al., 1981b; 
Rosen et al., 1981; Tesh et al., 1981; Fauran and Le Conidec, 
1982). Recently RRV was isolated for the first time from 
Australian EPA patients in Rockhampton (Aaskov et al., 1985). 
Interestingly an important common feature of the Pacific and 
Rockhampton EPA cases was that the patients did not have 
detectable RRV antibody when the first symptoms of disease 
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appeared (Rosen et al., 1981; Aaskov et al., 1985). This was 
in contrast to previous Australian cases where sera had RRV 
antibodies when symptoms of EPA first appeared (Clarke et al., 
1973). This leads to several questions. Firstly, was virus 
isolable from human serum because of the changed properties 
(e.g. more rapid growth) resulting in viraemia before the 
appearance of antibody, or was isolation a result of a change 
in viral immunogenicity resulting in a delayed or poor immune 
response? Secondly, are the Pacific and Rockhampton RRV 
isolates genetically similar, and what is the relationship 
between them and endemic RRV isolates? And thirdly, do the 
isolates from the Pacific and Rockhampton represent a strain of 
RRV which is particularly virulent to humans? Aspects of 
these questions will be addressed in a subsequent Chapter of 
this thesis. 
1.9 Outline of the thesis 
A major aim of the studies described in this thesis is 
to locate the neutralisation antigenic sites of RRV in the 
primary amino acid sequence of the viral structural proteins. 
Chapter 2 describes (i) the isolation of variants of RRV T48 
and RRV NB5092 resistant to neutralising mabs, and (ii) 
sequencing studies on the structural protein genes of these 
variants to locate the neutralisation epitopes. 
Since the RRV T48 mab-resistant variants had point 
mutations in E2 their biological properties were examined to 
determine the effect of these changes on the biological 
properties of the virus. Chapter 3 describes studies on the 
growth of these RRV variants in cultured cells together with 
studies on their virulence and growth in mice. 
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RRV dE2, a mutant of RRV T48, has a predicted seven 
amino acid deletion in E2. This provided an opportunity to 
examine the effect of a major change in E2 on the biological 
properties of the virus. Chapter 4 compares the growth 
properties of RRV dE2 and RRV T48 in cultured cells together 
with comparative studies on the virulence and growth of the two 
in mice. 
Chapter 5 uses another approach to understand the role 
of viral structural proteins in RRV virulence. Attenuated 
variants of RRV T48 were isolated by serial passage in BHK 
cells as described for SIN by Barie et al. (1981). The 
biological properties of the variants were examined in cultured 
cells and in mice and attempts made to locate changes in the 
structural protein genes. 
Chapter 6 describes sequence studies on the E2 gene of 
RRV isolates from humans obtained at various stages of the 
epidemic of polyarthritis in the non-immune population in the 
South Pacific. Studies were directed at examining the extent 
and location of evolutionary changes in the E2 gene. Chapter 6 
also describes the genetic relationship between the Pacific 
isolates, those obtained from human EPA patients in Australia 
and a number of enzootic strains obtained from mosquitoes in 
Australia. To this end, sequence studies on the E2 gene of 
these various isolates were carried out. 
CHAPTER 2 
LOCATION OF NEUTRALISATION 
EPITOPES IN 
RRV STRUCTURAL PROTEINS 
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2.1 INTRODUCTION 
Competitive binding assays with mabs have been used to 
study the neutralisation antigenic sites of a number of 
alphaviruses (Chapter 1). However there is no published 
information on the precise location of these sites in viral 
structural proteins. The work described in this Chapter aims 
at locating the neutralisation epitopes of RRV in the primary 
amino acid sequence of the structural proteins. 
A number of mabs have been generated against RRV, a 
small number of which neutralise the virus (R.C. Weir, 
unpublished results). These mabs were used to locate the 
neutralisation epitopes of RRV using the following strategy. 
RRV variants were selected which were resistant to 
neutralisation by individual mabs. The nucleotide sequence of 
the genes encoding the structural proteins of the variants was 
determined by the dideoxy method of Sanger et al. (1977) using 
synthetic oligodeoxynucleotide primers based on the RRV T48 26S 
RNA sequence (Dalgarno et al., 1983). The sequence of the 
variants was compared with that of the parental virus and the 
amino acid substitution(s) responsible for the mab resistant 
phenotype of the variants identified by comparing the deduced 
amino acid sequence of the structural proteins of the variants 
and the parental virus. The structural and functional 
relationship between different epitopes, identified in this 
way, was investigated by selecting and sequencing RRV antigenic 
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variants resistant to two or three mabs. Properties of the 
domain harbouring the neutralising epitopes were examined by 
comparing the primary amino acid sequences of RRV, SFV and SIN 
in the appropriate region. The hydropathy profile and the 
predicted secondary structure of the protein containing the 
neutralisation epitopes were generated to examine the 
structural features of the domain containing the neutralisation 
epitopes. 
2.2 MATERIALS AND METHODS 
2. 2. 1 Virus 
The prototype T48 strain of RRV (Berge, 1975) was from 
the Yale Arbovirus Research Unit. The virus had been passaged 
ten times in mice when received. It was subjected to two 
plaque purification steps to remove a small plaque former (see 
Chapter 4). RRV NB5092 was from Dr. I.D. Marshall (John Curtin 
School of Medical Research, The Australian National 
University). The virus had been isolated from a pool of 50 
Aedes vigilax mosquitoes collected at Nelson Bay, NSW in 1969 
(Gard et al., 1973) and had been plaque purified twice by A.D. 
Meek before use. Working stocks of virus were tissue culture 
supernatants derived by growth in baby hamster kidney (BHK) 
cells infected at low multiplicity (-0.01). 
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2.2.2 Cell culture 
BHK cells were propagated in Glasgow Modified Eagle's 
BHK medium (GMEM) supplemented with 8% heat-inactivated bovine 
serum. African green monkey kidney (Vero) cells were grown in 
Medium 199-Lactalbumin hydrolysate (M199-LAH; Commonwealth 
Serum Laboratories, Australia) supplemented with 10% heat-
inactivated bovine serum as previously described (Davey and 
Dalgarno, 1974). Cells were maintained at 36°c in 5% co
2
/95% 
2.2.3 Infection of cells 
Cells were seeded on 35 mm plastic dishes (TC grade, 
Corning Technical Product, USA). Infecting virus was diluted 
in Hank's balanced salt solution (HBSS). Mock infections were 
with HBSS. Adsorption was for 1 hr at room temperature in the 
dark. Excess inoculum was removed by washing the cells with 
phosphate buffered saline (PBS). Zero time was taken as the 
time of addition of the inoculum to the cells. Following 
infection, medium was added and cells were incubated at 36°c 
an atmosphere of 5% co2 /95% 
2.2.4 Plaque assay 
. in 
Virus was assayed in duplicate by plaque formation on 
Vero cells in 6-well plastic trays (TC grade, Linbro Scientific 
Inc., USA). Virus (0.1 ml) was adsorbed for 60 min and 
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overlayed with 3.5 ml of overlay (Medium 199-LAH, 20 mM Hepes, 
0.2% DEAE-Dextran, 2% foetal calf serum, 8% bovine serum, 1% 
agar). The trays were incubated at 36°c in 5% co2 /95% air. 
After 2 days, 1.5 ml of staining medium (0.2% each of agar and 
neutral red in distilled water) was added to each well and 
plates incubated overnight before counting the plaques. 
2.2.5 Virus purification 
Virus for enzyme linked immunosorbent assay (ELISA) and 
RNA extraction was purified as described by Martin et al. 
(1979). Briefly, BHK cell monolayers in roller bottles were 
infected at a moi -0.25. Infected cell supernatants were 
harvested at 24 hr pi and virus was precipitated with 8% 
polyethylene glycol, followed by resuspension in 0.2 M NaCl, 
0.05 M Tris-HCl (pH 7.4), 0.001 M EDTA. Virus was purified by 
sucrose gradient centrifugation and stored in sucrose at -70°c. 
Purified virus in sucrose was diluted appropriately in PBS for 
use in ELISA and immunoprecipitation. However, the virus was 
pelleted by centrifugation for RNA extraction (see Section 
2.2.13). 
2.2.6 Preparation of amino acid labelled virus 
Confluent monolayers of BHK cells in roller bottles 
were infected (moi -1). After adsorption cells were incubated 
with 100 ml Eagle's minimal essential medium (EMEM) containing 
one-tenth the normal concentration of amino acids and 10 µCi/ml 
[3HJ-amino acid mixture (Arnersham) at 37°c. The culture 
supernatant was harvested at 24 hr pi and virus purified as 
above. 
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2. 2. 7 Production of hybridomas secreting anti-RRV monoclonal 
antibodies (Fazekas de St.Groth and Scheidegger (1980) 
Briefly, 6-week old female Balb/C mice were injected 
intra-peritoneally (i.p.) with -10 5 PFU of purified virus ' in 
0.1 ml gelatin saline (0.5% gelatin in PBS). Six weeks later, 
immunised mice were boosted with -3xl0 7 PFU of virus injected 
' i. p. Two weeks later, 4 days before the cell fusion, mice were 
again boosted with -3xl0 7 PFU of virus injected intravenously. 
Approximately 5xl0 7 mouse myeloma cells (X63.Ag8.653) were 
fused with -3xl0 7 spleen cells from an immunised mouse using 
50% polyethylene glycol. Fused cells were pelleted and 
resuspended in RPMI 1640 medium (Gibco; supplemented with 15% 
heat-inactivated foetal calf serum, 200 mM L-glutamine, 100 mM 
sodium pyruvate, 0.6% penicillin, 1.0% streptomycin and 0.05 mM 
2-mercaptoethanol) mixed with HAT (final concentration: 0.1 mM 
hypoxanthine, 0.4 µM aminopterine and 0.016 mM thymidine). 
Cells were distributed in 96-well tissue culture plates and 
cultivated in RPMI 1640-HAT for two weeks to select hybridomas. 
This was followed by the cultivation in RPMI 1640 medium 
(supplemented as above) in presence of HT (final concentration: 
0.1 mM hypoxanthine, 0.016 mM thymidine) for one week. By this 
stage successfully fused cells had grown to about 50-80% 
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confluency in the well. After an initial ELISA screening (see 
below), cells from those wells producing anti-RRV antibodies 
were subcultured and grown in 24-well plates. After an ELISA 
screening of the 24-well plates anti-RRV antibody producing 
cells were subcultured and grown in larger amounts in tissue 
culture bottles. Hybridomas producing anti-RRV antibodies were 
cloned by limiting dilution. Clones arising from a single cell 
were grown in tissue culture and the supernatant screened for 
RRV neutralising activity by plaque reduction neutralisation 
tests (PRNT, see below). Hybridomas secreting neutralising 
mabs were injected i.p. in pristane-primed-mice where they grew 
as ascites. The ascitic fluid was harvested and centrifuged to 
obtain supernatant containing mab which was stored at -20°c. 
2. 2. 8 Detection of anti-RRV antibody activity by ELISA 
(R.C. Weir, personal communication) 
Approximately 10 7 PFU of sucrose gradient purified RRV 
T48, appropriately diluted in PBS+ 0.02% sodium azide, was 
used to coat 96-well polyvinyl chloride microtiter plates (25 
µ1/well). Plates were incubated in a humid atmosphere at 37°c 
for 2 hr. They were stored at 4°c un{il required (for up to 
one week). Before use, liquid from the wells was aspirated and 
the wells washed (x3) with 240 µl PBS containing 0.5% bovine 
serum albumin (or PBS containing 5% dried commercial defatted 
powdered milk) and 0.02% sodium azide. Hybridoma supernatant 
(25 µl) was added to each well and the plates incubated at 
38 
37°c. Polyclonal RRV-antiserum and RPMI 1640 respective ly were 
used as positive and negative controls. After 2 hr, 
supernatant was removed and the wells washed (x3) with PBS 
containing 0.05% Tween-20 and 0.02% sodium azide. Urease-
conjugated rabbit anti-mouse immunoglobulin (CSL, Australia) 
diluted in PBS containing 0.5% bovine serum albumin (or 5% 
dried milk powder), 0.05% Tween-20 and 0.02% sodium azide was 
added (25 µl) and the plates incubated at 37°c for 30 min. 
Conjugate was removed and plates washed (x6) with PBS 
containing 0.05% Tween-20 and 0.02% sodium azide followed by 
six washings with distilled water. Urea substrate (CSL, 
Australia) was added (50 µ1/well) and plates incubated at 37°c 
for 30 min. Positive (purple colour) and negative (yellow 
colour) anti-RRV antibody activity was detected visually. For 
determination of end point titers, 10-fold dilutions of culture 
supernatant or ascitic fluid containing the mab were used. The 
highest dilution giving a positive reaction was taken as the 
titer of the mab. 
2.2.9 Plaque reduction neutralisation test (PRNT) 
Virus (100 µl; -200 PFU) was incubated with an equal 
volume of ascitic fluid containing mab (diluted 1:10 in HBSS) 
in an Eppendorf tube at 37°c for 1 hr and assayed for 
infectivity on Vero monolayers (Section 2.2.4). HBSS was used 
in place of mab in controls. 
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2.2.10 Production of polyclonal RRV antiserum 
Polyclonal antiserum to RRV T48 was produced as ascitic 
fluid in Balb/C mice by Dr. L. Dalgarno using the method of 
Tikasingh et al. (1966) . 
2.2.11 Protein specificity of monoclonal antibodies reacting 
with intact virus (R.C. Weir, personal communication) 
[3HJ-amino acid labelled purified RRV T48 (10 µl, 
-400 cpm) was incubated with an equal volume of undiluted mab 
in 0.5 ml Eppendorf tubes at 37°c. After 1 hr, 3 µl of GTNE 
buffer (200 mM glycine, 50 mM Tris, 100 mM NaCl, 1 mM EDTA; pH 
7.4) containing 1% NP40 (Sigma) was added. After 10 min, 25 µl 
of 50% Protein-A Sepharose (Pharmacia) in GTNE buffer was added 
and the tubes incubated at room temperature for l hr. The 
tubes were centrifuged and the pellet washed (x3) with 250 µl 
GTNE buffer containing 1% NP40. The pellets were dissolved in 
30 µl of electrophoresis sample buffer (Laemmli, 1970) 
containing mercaptoethanol and analysed by electrophoresis on a 
10-20% gradient polyacrylamide slab gel (King and Laemmli, 
1971). Radiolabelling was detected by impregnating gels with 
PPO, drying under vacuum, and exposing at -7o 0 c to pre-flashed 
Fuji Medical X-ray film (Bonner and Laskey, 1974; Laskey and 
Mi 11 s, 19 7 5) . 
2.2.12 Selection of RRV variants resistant to neutralisation 
by monoclonal antibodies 
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Approximately 5 x 10 6 PFU of RRV T48 or RRV NB5092 in 
100 µl of HBSS was incubated (37°c, 1 hr) with an equal volume 
of ascitic fluid containing mab (diluted 1:10 in HBSS). The 
mixture was diluted in HBSS (xlO) and used to infect Vero 
monolayers. After 1 hr adsorption overlay was added and the 
plates incubated at 36°c for 3 days. Virus which escaped 
neutralisation formed normal size plaques. No unusually small 
or large plaques were seen. Unstained plaques were picked, 
grown in BHK cells and tested for resistance to neutralisation 
by the selecting mab. The resistant virus was further plaque 
purified and grown in BHK cells to prepare seed stocks of the 
variants. 
2.2.13 Extraction of virion RNA for sequencing 
(Ou et al., 1981) 
Virus from peak gradient fractions (Section 2.2.5) was 
pelleted by centrifugation in an SW41 rotor at 36,000 rpm for 3 
hr and resuspended in 0.01 M Tris-HCl (pH 7.4), 0.06 M NaCl, 
0.001 M EDTA and 1% SDS. Virion RNA was extracted once with 
phenol and twice with chloroform/isoamyl alcohol (99:1, v/v), 
and precipitated 3 times with ethanol. RNA was suspended at a 
concentration of 2 pmole/7 µl (1.14 µg/µl in 5 mM Tris-HCl, pH 
8.2, + 2.5 mM EDTA) and stored at -7o 0 c. RNA concentration was 
determined by spectrophotometry. The yield was 10-18 µg 
RNA/roller bottle. 
2.2.14 Extraction of RNA for sequencing from RRV infected 
BHK cells (Shine and Dalgarno, 1973) 
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Dideoxy sequencing of RRV RNA using specific primers 
could be carried out with high molecular weight RNA from virus-
infected BHK cells (A.D. Meek, personal communication). For RNA 
extraction BHK cell monolayers in 140 mm glass petri dishes 
were infected with virus (moi -1). At 17 hr pi nucleic acids 
were extracted with a mixture of sodium p-amino salicylate and 
phenol/m-cresol/8-hydroxyquinoline. After extraction, nucleic 
acids were precipitated with ethanol and dissolved in 0.45 ml 
water. TNE buffer (50 µl; 0.12 M Tris-HCl, pH 7.4, 1.2 M NaCl, 
0.01M EDTA) was added followed by 0.5 ml of 4 M LiCl to remove 
DNA and low mol. wt. RNA. After vigorous vortexing high mol. 
wt. (viral and ribosomal) RNA was pelleted by centrifugation. 
After a further LiCl precipitation, two ethanol precipitations 
of RNA in the presence of 0.3 M sodium acetate (pH 5.6) were 
performed. RNA was finally suspended at a concentration of 
11.4 µg/µl (i.e. ten times the concentration of virion RNA, 
above) in 5 mM Tris-HCl (pH 8.2) containing 2.5 mM EDTA and 
stored at -7o 0 c. The RNA concentration was determined by 
spectrophotometry. The RNA yield from one petri dish was 400-
600 µg. 
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2.2.15 Dideoxy sequencing of viral RNA 
The method of Sanger et al. (1977) as described by 
Faragher and Dalgarno (1986) was used. RRV T48 or RRV NB5092 
RNA was sequenced in parallel when sequencing RRV variants. 
Occasionally a cross band, corresponding to a single 
nucleotide, was seen in all four lanes of the sequence ladder. 
If this was present in the same position in the RRV T48 or RRV 
NB5092 sequence ladder the nucleotide was considered to be the 
same as in RRV T48 (Dalgarno et al., 1983) or RRV NB5092 (S.G. 
Faragher and A.D. Meek, unpublished data) respectively, 
otherwise it was recorded as an unidentified nucleotide (N). 
Details of the method are described below. 
Reaction mixture. Reaction mixtures contained in a 
final volume of 10 µl, 50 mM Tris-HCl (pH 8.3), 8 mM MgC1 2 , 50 
mM KCl, 0.4 mM dithriothreitol (Sigma), 50 mM dATP, dTTP and 
dGTP, 2.5 µM dCTP (all dNTPs from Boehringer-Mannheim), 10 µCi 
of [a-32PJ dCTP (3000 Ci/mmole; Amersham), either 10 µM ddATP, 
5 µM ddTTP, 2 µM ddGTP or 0.25 µM ddCTP (all ddNTPs from 
Boehringer-Mannheim), 1 µl primer-template mix (see below) and 
12 units of AMV reverse transcriptase (Molecular Genetic 
Resources, USA). Incubation was at o0 for 20 min, followed by 
60 min at 42.5°c. One microlitre of a solution which was 0.5 
mM in all dNTPs was then added and incubation continued at 
42.5° for 20 min. Reactions were stopped with 4. volumes of 
formamide-dye mix (96% deionised formamide; 25 mM Tris-borate; 
0.5 mM Na2 EDTA; xylene cyanol and bromophenol blue dyes), 
followed by heating at 90° for 2 min. 
Electrophoresis. Reaction products were separated on 
80 cm long, 0.4 mm thick 5% polyacrylamide gels 
(acrylamide:bisacrylamide, 19:1). Gels were exposed at 
-20°c to Fuji RX medical X-ray film. 
Primer-template mix. ' ' virion 3.5 µ1 of RNA (1 pmole) 
43 
or 
infected cell RNA (11.4 µg of total RNA which contained 
approximately 1 pmole of virion RNA) was mixed with 1 pmole of 
primer (in 1 µl, see below) and incubated for 5 min at 56° or 
for 90 sec at 80°c. The mixture was quick cooled and KCl (0.5 
µl; 0.8M) added. 
The concentration of primer (diluted in 5 mM Tris-HCl, 
pH 7.4, 0.05 mM EDTA) was generally 1 pmole/µl which gave a 
molar ratio in the primer-template mix of 1:1 when virion RNA 
was the template. With primers E2/3559 and E2/1635 (Table 2.1) 
a ratio of 10:1 improved the quality of the sequence ladder. 
Primers. Synthetic 15- or 17-residue 
oligodeoxynucleotide primers complementary to appropriate 
regions of RRV T48 26S RNA (Dalgarno et al., 1983) were from 
Biotechnology Research Enterprises, S.A. Pty. Ltd., Adelaide, 
South Australia (Table 2.1). Computer searches of RRV T48 26S 
RNA were conducted to check that the primers would not prime at 
a second site. These were done by A.D. Meek and S.G. Faragher 
Table 2.1 Synthetic oligonucleotide primers used to 
sequence RRV antigenic variants. 
Primer* 
C/14 
C/587 
E3/963 
E2/1455 
E2/1635 
E2/1990 
E2/2350 
El/2755 
El/3181 
El/3559 
3'UT/4024 
Nucleotide sequence 
5'-GGTGTAACCATAGTA-3' 
5'-AGGCGTCGGACTTCA-3' 
5'-TTGTCTTCCAGCATC-3' 
5'-GGUGGGUAGAGAGAAGU-3' 
5'-TTGTACCTGATAGTC-3' 
5'-GATGATGCGCTCAGA-3' 
5'-GGTTTTGTTCTCGTC-3' 
5'-TCCACCCCACATGAA-3' 
5'-GTATGGCACATGCAC-3' 
5'-CGCCGTGGAAAAGTG-3' 
5'-TCTATTTGTCTACTT-3' 
Priming site in 
RRV T48 26S RNAt 
141-155 
587-601 
963-977 
1455-1471 
1635-1649 
1990-2004 
2350-2364 
2755-2769 
3181-3195 
3559-3573 
4024-4038 
*The region in 26S RNA which contains the priming site is indicated; this is followed by the position of the first 
nucleotide of the priming site in RRV T48 26S RNA (Dalgarno et al., 1983). 
tStretch of nucleotides in RRV T48 26S RNA to which the primer is complementary. 
using the SEQUENCE program on the VAX 11/750 computer at the 
Research School of Biological Sciences, ANU. 
2.2.16 Hydropathy analysis of E2 
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Hydropathy profiles of RRV, SFV and SIN E2 protein 
published by Dalgarno et al. (1983) together with that for RRV 
NB5092 using sequence data from S.G. Faragher and A.D. Meek 
(unpublished data), were generated on a VAX 11/750 computer 
using a program based on the algorithm of Kyte and Doolittle 
(1982). A seven residue moving segment was used to scan the 
sequences. 
2.2.17 Secondary structure prediction of RRV T48 E2 
This was performed on the above computer using a 
program based on the algorithm of Chou and Fasman (1978, 1979). 
2. 3. 1 
2.3 RESULTS 
Production of hybridomas secreting neutralising 
monoclonal antibodies 
Hybridomas secreting anti-RRV mabs were produced by 
fusion of RRV-immunised mouse spleen cells with X63.Ag8.653 
mouse myeloma cells (Methods). Three separate fusions performed 
by Dr. R.C. Weir were with spleen cells from mice immunised . 
with RRV T48; one used cells from mice immunised with RRV 
Table 2.2 Characterisation of anti-RRV neutralising 
monoclonal antibodies. 
Virus used Monoclonal ELISA titer 
to immunise Fusion antibody of ascitic Protein 
mice number isolated* fluidt specificitytt 
RRV T48 RW-1 TlE7 10-5 E2 
RW-2 TlDll 10-5 E2 
RW-3 Tl0C9 10-4 E2 
RW-3 T4D2 10-4 E2 
SV-1 TlBl 10-4 E2 
RRV NB5092 RW-4 NB3C4 10-4 E2 
*The virus against which the monoclonal antibody was isolated is indicated by T (RRV T48) or NB (RRV NB5092); this is followed by the well number from which the hybridoma was isolated. 
tAgainst RRV T48. 
ttDetermined by immunoblotting of SDS-disrupted RRV T48 (C. Fernan and R.C. Weir, unpublished data) except f or TlBl where the specificity was determined by 
antibody binding to the purified and intact RRV T48 in 
an immunoprecipitation test. 
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NB5092. From the four fusions, five hybridomas secreting RRV 
neutralising mabs were obtained. Neutralising mabs T1E7, T10C9, 
T1Dll and T4D2 (for nomenclature see legend, Table 2 .. 2) were 
produced against RRV T48; NB3C4 was produced against RRV 
NB5092. These mabs were provided by Dr. Weir as mouse ascitic 
fluids. All these mabs belonged to the IgG class and bound to 
RRV T48 E2 in immunoblotting experiments using SDS-disrupted 
RRV T48 (C. Fernon and R.C. Weir, unpublished data). 
From one fusion reaction, performed by the author using 
spleen cells from an RRV T48 immunised mouse, 14 hybridomas 
producing anti-RRV mabs were isolated. Of these, one clone, 
TlBl, produced a neutralising mab. TlBl was subcloned and 
injected into a pristane-primed Balb/C mouse to obtain ascitic 
fluid. Mab TlBl and the other neutralising mabs described 
above bound to E2 in purified intact RRV T48 
immunoprecipitation tests (data not shown). 
. in 
All the antibodies described above neutralised both RRV 
T48 and RRV NB5092 infectivity in PRNT although there were 
differences in the reactivity patterns (see Section 2.3.7). 
The ELISA titers of the mab stocks used in the present study 
are shown in Table 2.2. 
2. 3. 2 Isolation of RRV T48 variants resistant 
to neutralisation by monoclonal antibodies 
In order to locate the epitopes in E2 to which the 
neutralising mabs bound, RRV T48 variants resistant to 
Table 2.3 Isolation of neutralisation resistant variants 
of RRV T48. 
Monoclonal Frequency of 
antibody used isolation of 
for selection variants* Variants isolatedt 
T1E7 1.0 X 10-5 TVl, TV2, TV3, TVS 
T10C9 0.8 X 10-5 TV31, TV33, TV35, TV42 
NB3C4 1.4 X 10-5 TV61, TV62, TV63, TV64 
TlBl 0.8 X 10-5 TV51, TV59 
*An average of three independent determinations for each antibody. 
tTV indicates an RRV T48 variant. 
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neutralisation by mabs TlE7, Tl0C9, T1Dll, T4D2, TlBl and NB3C4 
were selected. 
For each selection approximately 5 x 10 6 PFU of RRV T48 
was incubated with neutralising mab at 37°c for 1 hr. 
Antigenic variants were selected by plaque formation on Vero 
cell monolayers. With mabs TlE7, Tl0C9, TlBl and NB3C4 the 
isolation frequency of the variants was 0.8 x 10-S - 1.5 x 10-S 
(Table 2.3). These variants were stable through 2-3 cycles of 
growth in BHK cells, although no experiments specifically 
designed to test for reversion were performed. With mabs T1Dll 
and T4D2, apparently neutralisation-resistant virus appeared at 
frequencies of 10-3 and 10-2 respectively but after a growth 
cycle in BHK cells virus was not resistant to the selecting 
mab. These mabs were not used in further studies. 
A total of 14 stable antigenic variants of RRV T48 were 
isolated which were resistant to neutralisation by the 
selecting mab (Table 2.3). Four variants, TVl, TV2, TV3 and 
TVS were isolated using mab T1E7. Variants TV31, TV33, TV35 
and TV42 were isolated with mab T10C9. Two variants, TV51 and 
TV59, were selected with mab TlBl. Variants TV61, TV62, TV63 
and TV64 were isolated using mab NB3C4. All variants were 
neutralised by polyclonal RRV T48 antiserum, confirming that 
they were isolates of RRV (data not shown). 
2.3.3 Nucleotide sequences of the structural protein genes 
of RRV T48 antigenic variants 
The structural protein genes of the RRV T48 antigenic 
Table 2.4 Comparison of the sequence of the structural 
protein genes of RRV T48 used in this study 
with the published sequence (Dalgarno et al., 1983). 
Nucleotide* 
Position RRV T48 
in (Dalgarno 
26S RNAt et al., 1983) 
1135 N 
1174 C 
1293 C 
1365 y 
1547 A 
2272 C 
2391 p 
3200 C 
3971 y 
RRV T48 
used in 
this study 
u 
u 
u 
u 
G 
u 
A 
A 
u 
Protein/ 
Amino 
acidtt 
E2/ 29 
E2/ 42 
E2/166 
E2/408 
El/235 
Amino acid 
RRV T48 
(Dalgarno 
et al., 1983) 
? 
Pro 
Glu 
Pro 
Pro 
*N=uniden~tfied nucleotide; Y=pyrimidine; P=purine. 
RRV T48 
used in 
this study 
Tyr 
Ser 
Gly 
Ser 
Glu 
tNurnbered from the 5'-end of RRV T48 26S RNA (Dalgarno et al., 1983). 
ttNumbered from the N-terminus of each protein (Dalgarno et al., 1983). 
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variants were sequenced in order to identify t he genetic 
changes responsible for the neutralisation resistant phenotyp e . 
Sequencing was by the dideoxy-chain termination method using 
virion RNA as template and synthetic oligodeoxynucleotide 
primers (Table 2.1) based on the RRV T48 sequence (Dalgarno et 
al . , 19 8 3) . 
For all 14 RRV T48 variants, the genes coding for El, 
E2, E3 and the 6K proteins were sequenced. In addition, the 
capsid protein genes of TVl, TV42, TV51 and TV61 were 
sequenced. These four were chosen as representatives of the 
four groups of variants resistant to each of the selecting 
mabs. To facilitate comparison of sequence ladders, RRV T48 
RNA was sequenced in parallel in each set of reactions. In the 
course of sequencing RRV T48, four ambiguities in the published 
sequence (Dalgarno et al., 1983) were resolved and five 
differences from the published sequence observed (Table 2.4). 
Four amino acid differences from the published sequence are 
predicted. These are in E2 at residues 42, 166 and 408, and in 
El at residue 235 (Table 2.4). These differences may reflect 
errors in the published sequence or mutations in the RRV T48 
stock. 
Sequence studies on T10C9-resistant variants. Four 
variants (TV31, TV33, TV35 and TV42) selected with Tl0C9 were 
sequenced. All variants had a single, identical nucleotide 
change (C---,U) in the E2 gene at position 1697 (Figure 2.1) which 
led to a predicted non-conservative Thr---,Ile substitution at 
Table 2.5 Mutations in monoclonal antibody resistant 
variants of RRV T48. 
Monoclonal 
antibody 
used for 
selection 
Tl0C9 
NB3C4 
T1E7 
TlBl 
Variant 
TV31 
TV33 
TV35 
TV42 
TV61 
TV62 
TV63 
TV64 
TVl 
TV2 
TV3 
TVS 
TV51 
TV59 
Mutation 
and positiont 
ACC~AUC (1697) 
ACC~AUC (1697) 
ACG-.:::,ACA ( 3 4 62) 
ACC~AUC (1697) 
ACC--,AUC (1697) 
AAA~CAA (1750) 
AAA--,AUA (1751) 
AAA-.:::, AA U ( 1752) 
AAA~GAA (1750) 
GAU-.:::,AAU (1786) 
AGG-.:::,AGC (1800) 
ACA--,CCA ( 1792) 
GAU-.:::,GUU (1787) 
GAU-.:::,AAU (1786) 
GAU-.:::,AAU (1786) 
Amino acid 
substitution 
and positiontt 
Thr~Ile* ( 216) 
Thr~Ile* (216) 
No change 
Thr~Ile* ( 216) 
Thr--,Ile* (216) 
Ly s-.:::,G l u. * (234) 
Lys-.:::,Ile* (2 34) 
Ly s-.:::,Asn * ( 2 3 4) 
Lys-.:::,Glu* (2 34) 
Asp-.:::,Asn * ( 2 4 6) 
Arg~Ser* ( 251) 
Thr--,Pro* ( 2 4 8) 
Asp-.:::,Val * ( 2 4 6) 
Asp--,Asn* ( 2 4 6) 
Asp-.:::,Asn * ( 2 4 6) 
tNumbered from the 5'-end of RRV T48 26S RNA (Dalgarno 
et al., 1983). 
--
ttNumbered from N-terminus of E2 (Dalgarno et al., 1983). 
*Non-conservative change; the following changes are designated as conservative: Arg=Lys, Ser=Thr, Asp=Glu, Gln=Asn, Val=Leu=Ile=Met, Ala=Gly, Ala=Val, Tyr=Phe. 
Figure 2.1 Sequence ladders for RRV T48 variants 
selected with T10C9. 
Virion RNA from purified virus was sequenced using 
primer E2/1990 (Table 2.1). The position of the 
changed nucleotide in the cDNA sequence ladder is 
indicated by an arrow. 
TV 31 
CTAG 
TV 33 
CTAG 
RRV T48 TV 35 
CTAG CTAG 
TV 42 
CTAG 
Figure 2.2 Sequence ladders for RRV T48 variants 
selected with NB3C4. 
Virion RNA from purified virus was sequenced using 
primer E2/1990 (Table 2.1). The position of the 
changed nucleotide in the cDNA sequence ladder is 
indicated by an arrow. 
TV64 
CTAG 
TV63 
CTAG 
RRV T48 
CTAG 
TV62 
CTAG 
TV61 
CTAG 
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residue 216 in E2 (Table 2.5). No changes were found in the 
El, 6K or E3 genes of any of the variants except for TV3 ~ where 
an additional nucleotide substitution (G~A) was found at 
position 3462 in the El gene (data not shown). This was a 
silent, third position change. For TV42 the C protein gene was 
also sequenced which showed no difference from that of RRV T48. 
Sequence studies on NB3C4-resistant variants. Four 
variants of RRV T48 (TV61, TV62, TV63 and TV64) selected with 
NB3C4 were sequenced. All variants had single nucleotide 
substitutions in the E2 gene. The substitutions were non-
identical but all involved the same codon (AAA). They were at 
positions 1750, 1751, 1752 and 1750 in TV61, TV62, TV63 and 
TV64 respectively (Figure 2.2). They each resulted in a 
different amino acid change in E2 at position 234. The amino 
acid substitutions were non-conservative and were Lys~Gl~ in 
TV61, Lys~Ile in TV62, Lys~Asn in TV63 and Lys~Glu in TV64 
(Table 2.5). None of the variants had mutations in genes 
coding for El, 6K and E3. No mutation was detected in the C 
gene of TV61. 
Sequence studies on T1E7-resistant variants. Variants 
TVl, TV2, TV3 and TVS resistant to T1E7 were sequenced. 
Single nucleotide substitutions were detected at positions 
1786, 1800, 1792 and 1787 in the E2 gene of TVl, TV2, TV3 and 
TVS respectively (sequence ladders not shown). In each case 
this led to a different predicted amino acid substitution in E2 
Figure 2.3 Sequence ladders for RRV T48 variants 
selected with TlBl. 
Virion RNA from purified ,virus was sequenced using 
primer E2/1990 (Table 2.1). The position of the 
changed nucleotide in the cDNA sequence ladder is 
indicated by an arrow. 
RRV T48 
CTAG 
TV51 TV59 
CTAG CTAG 
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(Table 2.5). In TVl the change was Asp~Asn at position 246. 
TV2 was changed at position 251 (Arg~Ser). In TV3 the change 
was at position 248 (Thr~Pro). In TVS the change was Asp~Val 
at residue 246. All these amino acid substitutions were non-
conservative (Table 2.5). There were no changes found in the 
El, 6K or E3 genes of any variant or in the C gene of TVl. 
The Asp~Asn substitution in TVl gives rise to a 
tripeptide sequence, Asn-Gln-Thr, potentially involved in 
asparagine-linked glycosylation (Chapter 1). We predict that 
TVl E2 may be glycosylated at position 246. 
Sequence studies on TlBl-resistant variants. Both TV51 
and TV52 had identical mutations in the E2 gene at position 
1786 (Figure 2.3). This resulted in an Asp~Asn substitution in 
E2 at residue 246 (Table 2.5). The nucleotide change and amino 
acid substitution in these variants was similar to that found 
in TVl (Table 2.5) and it could be predicted that these 
variants may also be glycosylated at amino acid 246 in E2. 
These variants had no change in their El, 6K or E3 genes or in 
the C gene of TV51. 
In summary, in all mab-resistant variants of RRV T48 
single nucleotide substitutions had taken place in the E2 gene. 
In each case this led to a single predicted amino acid 
substitution in E2. No mutations were found in the El, 6K, E3 
or C genes of any variant except TV35 where a single nucleotide 
mutation was found in El. This, however, did not result in an 
amino acid change. All amino acid substitutions were non-
conservative and were located within a limited stretch of 36 
amino acids (216-251). Interestingly, this stretch lies 
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between the two predicted asparagine-linked glycosylation sites 
in E2 at residues 200 and 262 (Dalgarno et al., 1983). Tl0C9-
resistant variants had an amino acid substitution at residue 
216; NB3C4-resistant variants at residue 234; T1E7-resistant 
variants at residues 246, 248 or 251; and TlBl-resistant 
variants had substitutions at amino acid 246 in E2, as in the 
T1E7 variants. Thus three neutralising epitopes in the primary 
amino acid sequence of E2 have been defined around amino acids 
216 (T10C9 epitope), 234 (NB3C4 epitope) and 246-251 (T1E7 and 
TlBl epitope). 
2.3.4 Attempts to select multi-epitope antigenic variants 
of RRV T48 with two mabs used concurrently 
The question of whether the epitopes identified above 
were in functionally the same or different antigenic areas was 
examined by estimating the isolation frequency of RRV T48 
variants when two mabs were used in combination. Given that 
the isolation frequency of antigenic variants altered in a 
single epitope is -10-5 (Table 2.3), and that these variants 
are point mutants, we reasoned that a variant with mutations in 
two functionally distinct epitopes would be isolated at a 
frequency equal to the product of the two mutation rates, that 
is -10-lO (Yewdell et al., 1979; Portner et al., 1980). 
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No variants could be isolated from -2 x 10 7 PFU of RRV 
T48 when mabs T1E7 and NB3C4, T1E7 and Tl0C9 or NB3C4 and T10C9 
were used concurrently. This indicates that the frequency of 
variants altered in a combination of these two epitopes is 
<2 x 10-7 . However, when mabs T1E7 and TlBl were used 
concurrently, variants could be isolated at a frequency of 
1.8 x 10-S (data not shown). 
We conclude that the epitopes defined by T10C9 and 
NB3C4 are distinct, they will be referred to below as epitopes 
I and II respectively; T1E7 and TlBl define an overlapping, if 
not identical, epitope which will be referred to as epitope 
III. 
2.3.5 Cross-neutralisation of antigenic variants of 
RRV T48 by monoclonal antibodies 
To determine whether a point mutation in one epitope 
grossly affects the neutralisation function of others, cross-
neutralisation of RRV T48 antigenic variants with the non-
selecting mabs was examined. TVS and TV51 (both epitope III 
variants), TV61 (epitope II variant) and TV42 (epitope I 
variant) were chosen as representatives of each group of 
variants. Their neutralisation by mabs T1E7, T10C9, TlBl and 
NB3C4 was examined in PRNTs (Table 2.6). 
All variants were sensitive to neutralisation by non-
selecting mabs except that TVS (resistant to T1E7) was 
resistant to TlBl, and TV51 (resistant to TlBl) was resistant 
Table 2.6 Cross neutralisation of RRV T48 antigenic 
variants by monoclonal antibodies. 
Antibody 
used 
TlE7 
Tl0C9 
NB3C4 
TlBl 
Polyclonal 
RRV T48 antiserum 
Variant 
TVS 
0 
100 
100 
0 
100 
Neutralisation* 
Variant 
TV51 
0 
100 
100 
0 
100 
Variant 
TV42 
100 
0 
100 
100 
100 
Variant 
TV61 
100 
100 
0 
100 
100 
Approximately 200 PFU of virus was incubated with undiluted 
antibody at 37°c for 1 hr and plated on Vero cell monolayers 
for plaque assay. HESS was used in place of antibody in 
controls. 
*Per cent neutralisation of virus infectivity. 
to T1E7. All variants were neutralised by polyclonal RRV T48 
antiserum. 
These results confirmed that epitopes defined by T1E7 
and TlBl were overlapping and demonstrated that using this 
method of analysis, the three epitopes were independent in 
their neutralisation function since a mutation in one epitope 
did not grossly affect the neutralisation of virus by mab 
recognising a different epitope. 
2.3.6 Isolation of RRV T48 antigenic variants resistant 
to neutralisation by two or three mabs using 
sequential selection 
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In an attempt to explore the relationship between the 
epitopes defined above, antigenic variants resistant to two or 
three mabs were sequentially selected with mabs directed to 
different epitopes. It was argued that if the epitopes were 
totally independent (i.e. an amino acid change in one having no 
influence on the conformation of others), an amino acid 
substitution in one epitope should not change the frequency of 
isolation of variants on selection with a second mab, the 
location of the amino acid change or the nature of the 
substitution. 
Precisely the same procedure used for selection of 
variants resistant to a single mab was used. Thus to obtain 
variants resistant to mabs T10C9 and NB3C4, variant TV42 
(resistant to T10C9, Table 2.3) was incubated with NB3C4. From 
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this, variants TV131, TV145 and TV147 were isolated. To obtain 
variants resistant to mab Tl0C9, NB3C4 and TlE7, variant TV147 
was incubated with T1E7 leading to the isolation of TV161 and 
TV162. These variants were resistant to TlBl also. All the 
variants isolated were neutralised by polyclonal anti-RRV 
antiserum. 
For selection of variants resistant to a single mab, 
-5 x 10
6 
PFU of RRV T48 was normally incubated with the mab. 
In this way approximately 50 antibody resistant plaques were 
obtained giving an isolation frequency of -10-5 . To isolate 
variants resistant to two mabs, it was necessary to incubate 
-1.4 x 10
7 
PFU of TV42 with NB3C4 in order to obtain 25 plaques 
giving an isolation frequency of -1.8 x 10- 6 , a five-fold 
reduction in frequency. When -7.6 x 10 7 PFU of TV147 were 
incubated with TlE7 to isolate variants resistant to three 
mabs, 23 plaques appeared giving an isolation frequency of 
-3 x 10-
7
, a 30-fold reduction over the isolation frequency of 
variants resistant to a single mab (Table 2.3). Although the 
. isolation frequencies of variants resistant to two or three 
mabs are based on a single set of observations, we believe that 
they are significantly different from the isolation frequency 
of variants resistant to a single mab. 
Se ence studies on e anti enic variants 
of RRV T48. The segment of the E2 gene of multi-epitope 
antigenic variants coding for the amino acids between the two 
predicted glycosylation sites of E2 was sequenced. Variants 
Figure 2.4 Sequence ladders for multi-epitope 
variants of RRV T48. 
RNA extracted from virus infected BHK cells was 
sequenced using primer E2/1990 (Table 2.1). The 
positions of the changed nucleotides in the cDNA 
sequence ladder are indicated by arrows. 
TV161 TV162 
CTAGCTAG 
TV147 
CTAG 
TV131 TV145 RRVT48 
CTAG CTAGCTAG 
Table 2.7 Mutations in RRV T48 variants resistant to 
neutralisation by two or three monoclonal antibodies. 
Monoclonal 
antibodies 
used for 
selection 
Tl0C9 
and 
NB3C4 
Tl0C9, 
NB3C4 
and 
TlE7 
Variant 
TV131 
TV145 
TV147 
TV161 
TV162 
Mutation 
and positiont 
ACC~AUC (1697) 
AAA~AAU (1752) 
ACC~AUC (1697) 
AAA~AAC (1752) 
ACC~AUC (1697) 
AAA~AAU ( 1752) 
ACC~AUC (1697) 
AAA~AAU (1752) 
GAU~AAU (1786) 
ACC~AUC (1697) 
AAA~AAU ( 1752) 
GAU~AAU (1786) 
Amino acid 
substitution 
and positiontt 
Thr~Ile ( 216) 
Lys~Asn ( 2 3 4) 
Thr~Ile ( 216) 
Lys~Asn ( 2 3 4) 
Thr~Ile ( 216) 
Lys~Asn ( 234) 
Thr~Ile ( 216) 
Lys~Asn (234) 
Asp~Asn ( 2 4 6) 
Thr~Ile ( 216) 
Lys~Asn ( 2 3 4) 
Asp~Asn ( 2 4 6) 
tNumbered from the 5'-end of RRV T48 26S RNA (Dalgarno 
et al., 1983). 
ttNumbered from N-terminus of E2 (Dalgarno et al., 1983). 
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TV131, TV145 and TV147 each had two nucleotide substitutions at 
positions 1697 and 1752 (Figure 2.4) which resulted in 
predicted amino acid changes at residues 216 (Thr~Ile) and 234 
(Lys~Asn) in E2 (Table 2.7). These variants were resistant to 
T10C9 and NB3C4, the nucleotide changes and amino acid 
substitutions were identical to those found in the 
corresponding single step variants of T10C9 (e.g. TV31) and 
NB3C4 (e.g. TV63) (Table 2.5). Variants TV161 and TV162 had 
three nucleotide changes at positions 1697, 1752 and 1786 
(Figure 2.4) leading to predicted amino acid substitutions at 
residues 216 (Thr~Ile), 234 (Lys~Asn) and 246 (Asp~Asn) in E2 
(Table 2.7). The variants were resistant to T10C9, NB3C4 and 
T1E7 and the mutations were identical to those found in single 
step variants selected with T10C9 (e.g. TV31), NB3C4 (e.g. 
TV63) or T1E7 (e.g. TVl) (Table 2.5). The Asp~Asn change in 
these variants gave rise to a potential asparagine-linked 
glycosylation site as in TVl (Section 2.3.3). It could be 
predicted that E2 of TV161 and TV162 has an additional 
potential glycosylation site. 
In summary, multi-epitope antigenic variants were 
isolated at a significantly lower frequency than were the 
single step variants. Variants resistant to two mabs (double 
variants) had two predicted amino acid changes and variants 
resistant to three mabs (triple variants) had three predicted 
changes in E2. There were identical amino acid substitutions 
in all three double variants sequenced. Similarly, in both the 
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triple variants the amino acid substitutions were identical. 
The location and nature of amino acid changes was identical to 
those in the single step variants suggesting that a change in 
one epitope did not significantly affect the conformation of 
another epitope. 
2.3.7 Identification of neutralisation epitopes of 
RRV NB5092 
Boere et al. (1986) showed that the mouse virulent and 
the avirulent strains of SFV could be distinguished by 
neutralising mabs. Further, mouse-virulent RRV T48 and the 
avirulent RRV NB5092 could be distinguished by mab T1E7 which 
reacted to RRV NB5092 with 1000-fold lower neutralising titers 
than with RRV T48 (C. Fernon, personal communication). These 
observations prompted us to investigate the neutralisation 
epitopes of RRV NB5092. The procedures used were as described 
above for RRV T48. 
Isolation of RRV NB5092 antigenic variants. Since mabs 
T1E7, T10C9 and TlBl, all raised against RRV T48, effectively 
neutralised RRV NB5092 infectivity, these together with NB3C4 
were used to isolate neutralisation resistant variants of RRV 
NB5092. Twelve stable variants were isolated (Table 2.8). 
Variants NVlll, NV113, NV115 and NV117 were selected with 
Tl0C9; variants NV101, NV103, NV104 and NV105 with NB3C4; 
variants NV151 and NV152 with T1E7 and variants NV153 and NV154 
Table 2.8 Isolation of neutralisation resistant variants 
of RRV NB5092. 
Monoclonal Frequency of 
antibody used isolation of 
for selection variants* Variants isolatedt 
T1E7 0.4 X 10-5 NV151, NV152 
T10C9 0. 8 X 10-5 NVlll, NV113, NVl 15, NV117 
NB3C4 1.6 X 10-5 NV101, NV103, NV104, NV105 
TlBl 0.5 X 10-5 NV153, NV154 
*An average of three independent determinations for each antibody. 
tNV indicates an RRV NB5092 variant. 
with TlBl. The isolation frequency of RRV NB5092 antigen ic 
variants was 0.4 x 10-5 - 1.6 x 10-5 (Table 2.8), similar to 
that found for RRV T48 variants. 
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Sequence studies on the E2 gene of antigenic variants 
of RRV NB5092. Variants were sequenced in the region of the E2 
gene encoding the amino acids between the two potential 
glycosylation sites at residues 200 and 262 (S.G. Faragher and 
A.D. Meek, unpublished data) using primer E2/1990 (Table 2.1) 
and virus-infected BHK cell RNA as template (Methods). The 
nucleotide substitutions detected and the predicted amino acid 
changes are listed in Table 2.9. 
The four variants selected with Tl0C9 (NVlll, NV113, 
NV115 and NV117) were each changed at nucleotide 1694 (sequence 
ladders not shown) leading to a Thr~Ile substitution at amino 
acid 216 (Table 2.9). Nucleotide 1694 is in the same relative 
position in the coding region of RRV NB5092 26S RNA as is 
nucleotide 1697 in RRV T48 (see Table 2.3) due to a three 
nucleotide deletion in the 5'-untranslated region of the 26S 
RNA sequence of RRV NB5092 by comparison with RRV T48 26S RNA 
(S.G. Faragher and A.D. Meek, unpublished data). Thus the 
changes in T10C9 variants of RRV NB5092 and RRV T48 were 
identical. 
Of the four variants selected with NB3C4 (Table 2.8), 
three (NV101, NV104 and NV105) were changed at nucleotide 1747 
(Figure 2.5) leading to a Lys~Glu substitution at residue 234 
(Table 2.9). This substitution was identical to that detected 
Table 2.9 Mutations in monoclonal antibody resistant 
variants of RRV NB5092. 
Monoclonal 
antibody 
used for 
selection 
T10C9 
NB3C4 
T1E7 
TlBl 
Variant 
NVlll 
NV113 
NV115 
NV117 
NV101 
NV103 
NV104 
NV105 
NV151 
NV152 
NV153 
NV154 
Mutation 
and positiont 
ACC-,AUC (1694) 
ACC-,AUC (1694) 
ACC-,AUC (1694) 
ACC-,AUC (1694) 
AAA-,GAA (1747) 
CAU-,CGU (1742) 
AAA-,GAA (1747) 
AAA-,GAA (1747) 
?:;: 
? 
? 
? 
Amino acid 
substitution 
and positiontt 
Thr-,Ile* ( 216) 
Thr-,Ile* ( 216) 
Thr-,Ile* ( 216) 
Thr-,Ile* ( 216) 
Ly s-,Glu* ( 234) 
His-,Arg* ( 23 2 ) 
Ly s-,Glu* (2 3 4 ) 
Lys-,Glu* ( 2 34) 
? 
? 
? 
? 
tNumbered from the 5'-end of RRV NB5092 26S RNA (S.G. Faragher and A.D. Meek, unpublished data). 
ttNumbered from N-terminus of E2 (S.G. Faragher and A.D. Meek, unpublished data). 
*Non-conservative change (see legend to Table 2.5) 
:;:Mutations that could not be identified (see Text) 
Figure 2.5 Sequence ladders for RRV NB5092 variants 
selected with NB3C4. 
RNA extracted from virus infected BHK cells was 
sequenced using primer E2/1990 (Table 2.1). The 
position of the changed nucleotide in the cDNA sequence 
ladder is indicated by an arrow. 
RRV 
NV101 NV103 NB5092 NV104 NV105 
CTAG CTAG CTAG CTAG CTAG 
't. 
Figure 2.6 Sequence ladders for RRV NB5092 variants 
selected with T1E7 or TlBl. 
RNA extracted from virus infected BHK cells was 
sequenced using primer E2/1990 (Table 2.1). Cross 
bands in all four lanes of the sequence ladders of the 
antigenic variants are indicated by an arrow and are at 
positions 1783-1786 of RRV NB5092 26S RNA (Faragher and 
Meek, unpublished data) 
RRV 
NV151 NV152 NB5092 NV153 NV154 
CTAG CTAG CTAG CTAG CTAG 
in TV61 , an RRV T48 variant selected with mab NB3C4. Variant 
NV103 had a substitution at nucleotide 1742 (Figure 2.5) 
leading to a His~Arg change at residue 232. 
Variants selected with T1E7 (NV151 and NV152) or T1Bl 
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(NV153, NV154) showed cross bands in all four lanes of the 
sequence ladder at nucleotides 1783-1786 (Figure 2.6). As 
these were not seen for RRV NB5092, sequence differences 
between RRV NB5092 and the antigenic variants may have occurred 
at nucleotide(s) 1783-1786. Substitutions at these nucleotides 
would lead to changes at amino acids 246 and 247. 
In summary T10C9-resistant variants of RRV NB5092 had a 
predicted amino acid substitution at residue 216, NB3C4-
resistant variants had predicted substitutions at residues 232 
and 234 and TlE7- or TlBl-resistant variants possibly had 
changes at residues 246 or 247 or both in E2. These were the 
same amino acids as were identified in neutralisation epitopes 
of RRV T48. From these data we conclude that the location of 
the neutralisation epitopes recognised by mabs T10C9, T1E7, 
TlBl and NB3C4 is conserved between the virulent T48 and the 
avirulent NB5092 strains of RRV. 
2.3.8 Location of amino acid change in RRV antigenic variants 
in predicted secondary structure of E2 
To examine whether the domain of E2 containing the 
neutralisation epitopes (the "neutralisation domain") had any 
unique structural features we have generated a predicted 
Figure 2.7 Location of amino acid changes in RRV 
antigenic variants on predicted secondary 
structure map of E2. 
The primary amino acid sequence of RRV T48 E2 is 
shown. Below the sequence, the secondary structure 
predicted by the method of Chou and Fasman (1978, 1979) 
is shown: a, a-helix; b, ~-sheet; C, random coil; T, 
reverse turn. The position of amino acid changes in 
RRV antigenic variants is indicated by~- The 
predicted glycosylation sites are marked with 
asterisks. Amino acids are numbered from N-terminus of 
RRV T48 E2 (Dalgarno et al., 1983). 
SVTEHFNVYKATRPYLAYCADCGDGYFCYSPVAIEKIRDEASDGMLKIQV (50) aaaabbbbbbbbbbbbbbbbbTTTTCCTTTTaaaaaaaaaTTTTbbbbbb I I I I 
SAQIGLDKAGTHAHTKIRYIAGHDVQESKRDSLRVYTSAACSIHGTMGHF (100) bbbbbbTTTTaaaaaaaaaaaaaaaaaTTTTbbbbbaaaaaaaCCbbbbb I I I I 
IVAHCPPGDYLKVSFEDANSHVKACKVQYKHDPLPVGREKFVVRPHFGVE (150) bbbbbTTTTaaaaaaaTTTTbbbbbbbbbbbTTTTaaaaaaaaTTTTaaa I I I I 
~ LPCTSYQLTTAPTDEGIDMHTPPDIPDRTLLSQTAGNVKITAGGRTIRYN (200) aaTTTTbbbbbTTTTaaaaaaTTTTCCbbbbbbTTTTbbbTTTTbbbbbb I I I I 
?V TT CTCGRDNVGTTSTDKTINTCKIDQCHAAVTSHDKWQFTSPFVPRADQTAR (250) TTTTTTTTCCCTTTTCCTTTTCTTTTaaaaaaTTTTbbbbbbaaaaaaaT I I I I 
T ¥ RGKVHVPFPLTNVTCRVPLARAPDVTYGKKEVTLRLHPDHPTLFSYRSLG (300) TTTbbbbbbbbbbbbbbaaaaTTTTTTTTaaaaaaaTTTTCCCCTTTTCC I I I I 
AEPHPYEEWVDKFSERIIPVTEEGIEYQWGNNPPVRLWAQLTTEGKPHGW (350) CCCTTTTaaaTTTTbbbbbbbbbbbbbbTTTTCbbbbbbbbTTTTTTTTT I I I I 
PHEIIQYYYGLYPAATIAAVSGASLMALLTLAATCCMLATARRKCLTPYA (400) TTTbbbbbbbaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaabbbTTTT 
. I I I I 
LTPGAVVSLTLGLLCCAPRANA (422) CTTTTbbbbbbbbbbbbCCCCC 
I I 
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secondary structure map of RRV T48 E2 (Figure 2 . 7) using the 
program of Chou and Fasman (1978, 1979). The percentage of 
residues predicted to be in each conformation is a-helix, 29%; 
P-sheet, 33%; reverse turn, 31%; and random coil, 7%. The 
cytoplasmic domain (residues 392-422) contains residues 
predominantly in predicted P-sheet. The transmembrane domain 
(residues 364-391) is predicted to have an a-helical 
conformation. The external domain (residues 1-364) has 
alternating segments of short a-helix and P-sheet with frequent 
reverse turns, suggesting a globular structure. In the 
external domain, 31% of amino acids are in predicted reverse 
turns. Compared to this, 42% of amino acids in the 
"neutralisation domain" are in reverse turns. We predict 
therefore that the "neutralisation domain" has no unique 
structural features except for a slightly greater occurrence of 
reverse turns, expected for the surface region of a protein. 
2.3.9 Summary 
Antigenic variants of RRV resistant to neutralisation 
by mabs were isolated at a frequency of -10-5 . All the 
variants had point mutations leading to non-conservative amino 
acid changes in E2. No mutations were found in the El gene 
except for a silent mutation in TV35. RRV variants selected 
with mab Tl0C9 had a predicted change at amino acid 216. 
Variants selected with NB3C4 had changed at amino acids 232 or 
234 and variants selected with TlE7 had changed at amino acids 
246, 248 or 251. Variants selected with mab TlBl had changed 
at amino acid 246. Thus three neutralising epitopes were 
defined around amino acids 216 (epitope I), 232-234 (epitope 
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II) and 246-251 (epitope III). In cross-neutralisation tests, 
mab-resistant variants were neutralised by the non-selecting 
mab interacting with a different epitope. Attempts to isolate 
multi-epitope variants from -2xl0 7 PFU of RRV T48 failed using 
two mabs belonging to two different epitopes concurrently. 
However, multi-epitope variants could be isolated using a 
sequential selection with different mabs. The location of the 
three neutralisation epitopes was conserved between the 
virulent T48 and the avirulent NB5092 strains of RRV. 
2.4 DISCUSSION 
2. 4. 1 Neutralising monoclonal antibodies 
A total of six anti-RRV neutralising mabs were used in 
the present study. All interacted with E2 in 
immunoprecipitation or immunoblotting experiments (C. Fernon 
and R.C. Weir, unpublished data), consistent with the report of 
Dalrymple et al. (1976) that antiserum prepared against 
purified SIN E2 neutralises virus infectivity in vitro, while 
anti-El serum is more effective in HI and does not neutralise 
virus. However, more recently El has been implicated in 
neutralisation by the isolation of anti-El mabs which 
neutralise SIN (Chanas et al., 1982) or SFV (Boere et al., 
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1984) infectivity. While the available evidence favours E2 as 
the major neutralisation antigen in alphaviruses, a role f o r El 
must be considered. Since El and E2 are closely associated to 
form heterodimers in the virion (Rice and Strauss, 1982a), 
binding of certain mabs to El may sterically hinder virus 
binding to the cell by blocking sites on E2 resulting in 
neutralisation of infectivity. An alternative explanation is 
that binding of certain mabs to El affects the conformation of 
E2 such that the virus is rendered non-infectious. Up till now 
no anti-El mab that neutralises RRV infectivity has been 
isolated. However, it is likely that the spectrum of mabs 
isolated against RRV is incomplete and that with more fusions 
neutralising anti-El mabs could be obtained. Thus it is not 
clear whether El is involved in RRV neutralisation. 
2. 4. 2 Isolation of RRV antigenic variants 
The frequency of isolation of RRV antigenic variants 
was around 10-5 for each of the four mabs, similar to that 
observed for S IN ( 1 0 - 3 · 5 -1 0 - 5 ; Stec et a 1 . , 1 9 8 6 ) . The 
frequency of mab resistant variants of other RNA viruses is 
reported as 10-3-10-5 for Sendai, 10-5 for influenza and 
vesicular stomatitis virus (Portner et al., 1980) and 10-3-10-5 
for polio virus (Minor et al., 1983). Multi-epitope variants 
of RRV T48 were, however, isolated at a lower frequency than 
the single step variants. This is perhaps connected to the 
observation that only one type of amino acid substitution 
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(Lys~Asn, Table 2.7) was detected in epitope II of the three 
double variants sequenced as compared to four different 
substitutions in each of the four single step variants altered 
in epitope II (Table 2.5). Similarly in both the triple 
variants sequenced, epitope III showed only one type of amino 
acid substitution (Asp-,Asn, Table 2.7), whereas the four single 
step variants (altered in epitope III) selected with TlE7 
showed four different amino acid substitutions (Table 2.5). 
Although we have not sequenced a sufficient number of double 
and triple variants to conclusively demonstrate that there is 
greater restriction on the type of alteration that can be 
accommodated once the antigenic domain is altered, our results 
suggest that this is a possible explanation for the lower 
frequency of isolation of multi-epitope variants. 
In considering the results presented above, an 
important question relates to the "independence" of each of the 
variants obtained using a single mab. All the variants 
selected with mabs TlE7 had different nucleotide substitutions 
indicating that they were derived from separate, independent 
mutations. A similar observation was made for the NB3C4 
variants. However all the Tl0C9-resistant variants of both RRV 
T48 and RRV NB5092 had the same nucleotide change (Tables 2.5 
and 2.9). Similarly, both RRV T48 variants selected with TlBl 
had the same mutation as each other. Since all variants were 
isolated using a similar procedure and the independent origin 
of TlE7 and NB3C4 variants has been demonstrated, it is likely 
that each Tl0C9 and TlBl variant arose independently. This 
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conclusion could be extended to the multi-epitope variants 
also. The independent origin of variants is also supported by 
the presence of a silent mutation in the El gene of one of the 
T10C9 variants (TV33 ), although this may have arisen after 
selection for mab resistance. Since all epitope I variants had 
the same nucleotide change as opposed to the variety of 
substitutions seen in epitope II and epitope III variants, this 
may suggest that the maintenance of a particular conformation 
in epitope I is more important for virus infectivity than in 
epitopes II and III. 
2.4.3 Neutralisation epitopes of RRV 
Sequencing of RRV antigenic variants defined three 
neutralising epitopes around amino acids 216 (epitope I), 232-
234 (epitope II) and 246-251 (epitope III) in E2. These 
epitopes may constitute part of a neutralisation domain in E2. 
It is postulated that interaction of antibodies with the 
neutralisation domain results in neutralisation of virus 
infectivity. Various approaches used to examine the 
relationship of the three epitopes established that they could 
act independently in neutralisation. This conclusion was 
further strengthened by the observation that the mab-resistant 
variants of RRV T48 did not bind to the selecting mab, and the 
substitution in an epitope did not affect the binding of a mab 
which recognised a different epitope (P. Kerr, personal 
communication). These epitopes were, however, conformationally 
connected since multi-epitope antigenic variants were isolated 
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at a significantly lower frequency and with a restricted type 
of amino acid substitution compared to the single step variants 
(above). This is perhaps not surprising as the epitopes are 
located approximately 15 amino acids apart in the primary amino 
acid sequence. No neutralisation epitopes were found in El. 
With the help of more neutralising mabs it is likely that more 
epitopes involved in RRV neutralisation will be identified. 
A crucial question is whether the domain in E2 which 
contains the identified neutralising epitopes ("neutralisation 
domain") represents the immunodominant region in vivo. CBAs 
have shown that all of the presently available anti-RRV 
neutralising mabs compete with each other and therefore cluster 
in a single region in E2 (C. Fernon and R.C. Weir, personal 
communication). Since these mabs were isolated from five 
independent fusions, it is likely that the "neutralisation 
domain" identified is the immunodominant region. The 
observation that polyclonal antiserum raised against RRV T48 is 
significantly less effective in neutralising TV161 (altered in 
all three epitopes) than RRV T48 also suggests that the three 
epitopes represent the immunodominant site (P. Kerr, personal 
communication). However, to establish with certainty whether 
or not this is the case, information regarding the amounts, 
avidity and epitope specificity of different antibodies to RRV 
in sera of infected animals would be required. An approach to 
partially satisfying this goal could be made by the method of 
Vandepol et al. (1986) who identified the immunodominant region 
in the surface protein of vesicular stomatitis virus by 
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passaging it in the presence of polyclonal antibody. After 80 
such passages in BHK cells, Vandepol et al. (1986) selected a 
mutant which had 10 amino acid changes in the surface protein, 
half of which occurred in a 13 amino acid stretch which had 
already been identified using mabs; this region was considered 
as the immunodominant region on the surface protein of the 
. 
virus. 
Using CBAs different workers have reported different 
numbers of neutralisation sites on El and E2 of SIN and SFV 
( Chapter 1) . It is difficult to compare the number of 
neutralising sites for different alphaviruses with that for RRV 
for two reasons. First, the number of sites defined could be 
influenced by the number of mabs used (e.g. Stec et al., 1986; 
see Chapter l); second, there are no reports for SIN or SFV on 
the molecular relationship of the epitopes in an antigenic site 
as defined by CBAs. 
Multiple independent sites for neutralisation have been 
identified by CBA and sequencing studies in the surface 
proteins of rabies (Wiktor and Koprowski, 1980), influenza 
(Wiley et al., 1981; Wiley et al., 1984), parainfluenza 
(Yewdell and Gerhard, 1982), polio (Hogel et al., 1985) and the 
common cold viruses (Rossmann et al., 1985). Thus for influenza 
A, four neutralisation sites have been located in the three 
dimensional structure of the haemagglutinin -the neutralisation 
antigen. Sites A and Bare around residues 140-146 and 187-196 
respectively. Residues 52-54 and 275, 277 and 278 constitute 
site C, while site Dis around residues 201-220. In polio 
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virus and the common cold virus three and four neutralising 
sites, respectively, have been identified. However, their 
structure is more complex since three different coat proteins 
(VPl-3) constitute the neutralisation antigen. Thus in polio 
virus type 3, site 1 comprises amino acids 89-100 of VPl, site 
2 involves amino acids 164-172 of VP2 whereas site 3 consists 
of amino acids 286-290 of VPl and amino acids 58, 59, 77 and 79 
of VP3 (Minor, 1986). In the common cold virus, neutralisation 
site 1 consists of amino acids 91 and 95 of VPl, site 2 
consists of amino acids 83, 85, 138 and 139 of VPl, site 3 
consists of amino acids 136 and 158-162 of VP2 and amino acid 
210 of VPl whereas site 4 consists of amino acids 72-78 and 203 
of VP3 and amino acid 287 of VPl (Rossmann et al., 1985). 
--
Thus 
antigenic sites in these viruses are "discontinuous" such that 
amino acids from distant parts of the linear sequence 
contribute. Similarly, amino acids that are closely linked . in 
the linear sequence can participate in different sites. In all 
these viruses, although the neutralisation sites were widely 
separated in the primary amino acid sequence, they were 
clustered in one region in the three dimensional structure of 
the virus (Wiley et al., 1981; Hogel et al., 1985; Rossmann et 
al., 1985) It is possible that the three neutralising 
epitopes in RRV E2 are "continuous" since (i) in all the mab 
resistant variants amino acid changes in an epitope were 
located within a span of no more than five amino acids in the 
linear sequence, and (ii) mabs bound to denatured and reduced 
E2 in immunoblotting tests. A conclusive picture, however, can 
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only be obtained by examin i ng the l ocat i on o f the 
neutralisation sites in the three dimensiona l structu r e of the 
. 
virus. 
2. 4. 4 Comparison of the primary amino acid sequences of E2 of 
different alphaviruses in the region containing RRV 
neutralisation epitopes 
The domain containing RRV neutralisation epitopes is 
located between the two predicted glycosylation sites in E2 
which are separated by 62 amino acids. To examine the features 
of this domain we have compared the amino acid sequences of E2 
for RRV T48, RRV NB5092, SFV and SIN in this region (Figure 
2.8). In this region there is 74.6% amino acid sequence 
homology between RRV T48 and SFV, and 37.5% between RRV T48 and 
SIN. For E2 as a whole there is 69% amino acid sequence 
homology between RRV T48 and SFV, and 42% between RRV T48 and 
SIN (Dalgarno et al., 1983). Thus at the amino acid sequence 
level, the "neutralisation domain" is conserved no more or less 
than E2 as a whole. All four cysteine residues in the 
"neutralisation domain" are conserved between RRV, SFV and SIN. 
However, this is not unique to this domain since all the 12 
cysteine residues in the external domain of RRV T48 E2 are 
conserved between RRV, SFV and SIN (see Dalgarno et al., 1983). 
The "neutralisation domain" has, within it, short stret ches of 
amino acids which are conserved between RRV and SFV. The sites 
of change in the neutralisation resistant variants are in the 
Figure 2 . 8 Location of amino acid changes in RRV 
antigenic variants. 
The amino acid sequence of glycoprotein E2 of RRV 
T48, RRV NB5092 , SFV and SIN between the two predicted 
glycosylation sites are shown. Data for RRV T48, RRV 
NB5092, SFV and SIN are from Dalgarno et ~l. (1983), 
, 
S . G. Faragher and A.D. Meek (unpubl ished data), Garoff 
et al . (1980b) and Rice and Strauss (198~ 
respectively . The single letter amino acid code is 
used : A=Ala , C=Cys, D=Asp, E=Glu, F=Phe, G=Gly, H=His, 
I=Ile, K=Lys , L=Leu, M=Met, N=Asn, P=Pro, Q=Gln, R=Arg, 
S=Ser, T=Thr , V=Val, W=Trp, Y=Tyr. A gap has been 
introduced to maximise the homology between the 
sequences . Overlined amino acids in RRV NB5092, SFV or 
SIN are identical to corresponding amino acids in the 
RRV T48 sequence. The positions of the predicted 
glycosylation sites are indicated by asterisks. 
Conserved cysteine residues are shaded. The position 
of amino acid changes in RRV variants selected with 
mabs are indicated as follows: . 
, Tl OC9; V, NB3C4; ,TlE7; and (),TlBl. 
RRV T48 
RRV NB5092 
SFV 
SIN 
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non-conserved regions or are immediately adjacent to them. 
This would suggest that the regions which are not conserved 
between RRV and SFV and which change in RRV antigenic variants 
include type specific determinants. Thus the sequence of 
neutralisation epitopes will be different in RRV and SFV, 
consistent with the type specific nature of alphavirus 
neutralisation sites (Strauss and Strauss, 1985). It may be 
useful to compare the amino acid sequence of Getah virus in the 
region of the "neutralisation domain" since RRV is 
serologically more closely related to Getah than to SFV 
(Calisher et al., 1980). 
2.4.5 Comparison of the hydropathy profiles of E2 of 
different alphaviruses 
To examine the hydrophilicity of the "neutralisation 
domain" the hydropathy profiles of E2 for RRV T48, SFV and SIN 
derived by Dalgarno et al. (1983) have been replotted together 
with that for RRV NB5092 and the position of amino acid changes 
in RRV antigenic variants indicated (Figure 2.9). There are 
two major hydrophilic regions conserved between RRV, SFV and 
SIN; both of these lie within the "neutralisation domain". 
Amino acid changes in RRV variants resistant to mabs TlE7 or 
NB3C4 occur in these regions and thus epitopes II and III are 
located in strongly hydrophilic segments of E2. However, 
change in Tl0C9-variants, and thus epitope I, is located in a 
moderately hydrophilic region. Since there are predicted 
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Figure 2.9 Location in hydropathy profile of predicted 
amino acid changes in RRV antigenic 
variants. 
The hydropathy profiles of E2 of RRV T48, SFV and 
SIN derived by Dalgarno et al. (1983) using the program 
of Kyte and Doolittle (1982) have been replotted 
together with that for RRV NB5092 using sequence data 
of Meek (1986). The degree of hydrophobicity increases 
with the distance above the horizontal line, 
hydrophilicity increases with distance below the line. 
The search length was seven amino acids. The positions 
of predicted asparagine-linked glycosylation sites are 
marked with asterisks. The positions of the predicted 
amino acid changes in RRV variants selected with mab 
are as follows:• ,T10C9; • ,NB3C4; 8 ,T1E7; Q,TlBl. 
Numbering of amino acids is from the N-terminus of E2 
(Dalgarno et al., 1983) 
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glycosylation sites around these epitopes (Dalgarno et al., 
1983) this could further increase the hydrophilicity of the 
"neutralisation domain", and contribute to its location on the 
exposed surface of E2 (Chothia, 1976). 
2. 4. 6 Neutralisation epitopes of RRV T48 and RRV NB5092 
Sequencing studies established that the location of the 
three neutralisation epitopes in the primary amino acid 
sequence of E2 is conserved between the virulent T48 and the 
avirulent NB5092 strains of RRV. The primary structure of 
epitopes recognised by Tl0C9 (epitope I) and NB3C4 (epitope II) 
was identical between RRV T48 and RRV NB5092; however a single 
conservative amino acid difference (Arg/Lys at residue 251) was 
found in epitope III recogised by T1E7 and TlBl (Figure 2.8). 
It would appear that the basic conformation of the 
"neutralisation domain" is similar between the T48 and NB5092 
strains of RRV. This is not unexpected since there is -99% 
amino acid sequence homology between the structural proteins of 
the two strains (S.G. Faragher and A.D. Meek, unpublished 
data). However the conformation of epitope III had a slight 
difference since mab TlE7 could discriminate between RRV T48 
and RRV NB5092 in PRNT (see Section 2.3.7). It is possible 
that this was a result of the single amino acid difference in 
epitope III of the two strains although a change elsewhere in 
E2 or even in El could affect the conformation of epitope III. 
CHAPTER 3 
BIOLOGICAL STUDIES ON 
RRV ANTIGENIC VARIANTS 
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3.1 INTRODUCTION 
In the previous Chapter antigenic variants of RRV T48 
were isolated which were resistant to neutralisation by mabs. 
These variants had single amino acid substitutions in E2. 
Similarly selected antigenic variants of many viruses have been 
shown to express altered virulence. Thus antigenic variants of 
reovirus type 3 selected with neutralising mabs were avirulent 
for mice (Spriggs and Fields, 1982). Some of the mab-resistant 
variants of rabies virus were avirulent for mice (Coloun et 
al., 1982; Coloun et al., 1983; Seif et al., 
-- -
1985). Love et 
al. ( 1985) isolated a mab-resistant variant of mumps virus 
which had reduced virulence in suckling · hamsters. Thus changes 
in neutralisation epitopes may affect the virulence of a virus. 
In addition, there are three sets of data which suggest 
that changes in neutralisation epitopes in E2 may lead to 
alterations in the biological properties of an alphavirus. 
First, Meek (1986) showed that when avirulent RRV NB5092 is 
serially passaged in infant mice to enhance virulence, single 
or double amino acid substitutions occur in E2, many of which 
map to the neutralisation epitopes identified in the previous 
Chapter, although the possibility that changes occurred in non-
structural proteins was not excluded. Second, Barie et al. 
(1981) isolated a mutant of SIN which penetrated BHK cells 
rapidly in vitro; the mutant was avirulent for mice and was 
altered in neutralisation epitope(s) in E2 as judged by its 
reactivity with anti-E2 neutralising mabs (Olmsted et al., 
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1986). Third, Stanley et al. (1985) isolated a neurovirulent 
SIN mutant by passaging the virus in mouse brain; the mutant 
was altered in neutralisation epitopes in E2 as demonstrated 
by altered reactivity against anti-E2 neutralising mabs. 
Considered together, these data gave reason to examine 
the effect of mutations in neutralisation epitopes on the 
biological properties of RRV T48 in cultured cells and in mice, 
the results of which are presented in this Chapter. In the 
first set of experiments, the replication of RRV variants was 
examined in BHK cells where the kinetics of growth, and the 
patterns of RNA and protein synthesis were compared with those 
of RRV T48. To compare the biological properties of RRV 
antigenic variants in mice, their virulence for day-old and 
week-old mice was assayed in terms of the viral lethal dose 
(LD 50 ) and the average survival time (AST) of the infected 
mice. Since differences in virulence have been correlated with 
altered tissue tropisms and with altered growth rates in the 
host (Chapter 1), it was of interest to study growth rates and 
tissue distribution of the antigenic variants in mice. 
3.2 MATERIALS AND METHODS 
3.2.1 Virus and cell cultures 
RRV T48 and the antigenic variants have been described 
in Chapter 2. BHK and Vero cells were as described previously 
(Section 2.2.2). 
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3.2.2 Infection of cells and plaque assay 
Cells were infected as described in Section 2.2.3. 
Virus titer was measured by plaque assay on Vero or BHK cell 
monolayers (Section 2.2.4). Titers on Vero cells are expressed 
as PFU whereas titers on BHK cells are expressed as BHK PFU. 
Titers on BHK cells were approximately 10 times higher than on 
Vero cells. 
3.2.3 
3. 2. 4 
Production of anti-RRV immune ascitic fluid 
This has been described in Section 2.2.10. 
Rate of acquisition of resistance by infecting 
virus to neutralisation by added polyclonal 
antibody (Barie et al., 1981) 
To measure the rates of virus "penetration" into the 
cells, BHK cell monolayers in 60 mm dishes were infected with 
-100 BHK PFU of virus and incubated with intermittent shaking 
at 36°c. At various times (see text) the inoculum was removed 
by aspiration and 0.5 ml of polyclonal anti-RRV immune ascitic 
fluid (diluted 1:10 in HBSS) was added. After 10 min at 36°c 
the ascitic fluid was aspirated, the cell monolayers washed 
(x2) with PBS and overlayed for plaque development (Section 
2.2.4). The number of plaques obtained after a 60 min 
adsorption, PBS wash, but no immune ascitic fluid treatment was 
taken as 100%. The number of plaques obtained in this manner 
was equal to that found using the normal plaque assay 
conditions where inoculum is not removed by washing. Each 
assay was performed in triplicate. 
3.2.5 Time-course of viral RNA synthesis in 
infected cells (Newton et al., 1981) 
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At designated times infected BHK cell monolayers in 35 
mm plastic dishes were washed with PBS and incubated for 2 hr 
at 36°c with 0.5 ml of EMEM containing 10 µCi/ml [5- 3HJ-uridine 
(New England Nuclear) and 5 µg/ml actinomycin-D (AMD; Merck 
Sharp & Dohme). After labelling, monolayers were washed twice 
with PBS and dissociated in 200 µl of 1% SDS. Duplicate 
samples from -2 x 10 5 cells were dried on Gelman type AE glass 
fibre discs, and washed with 5% trichloroacetic acid (5 changes 
over 1 hr), followed by ethanol (3 changes over 10 min). Dried 
discs were counted in toluene/PPO scintillation fluid. 
3.2.6 Radiolabelling of viral polypeptides and polyacrylamide 
gel electrophoresis (Short et al., 1982) 
Confluent BHK cell monolayers in 35 mm plastic dishes 
were infected with virus (moi-1) or mock-infected with HESS. 
Cells were labelled at various times post-infection at 36°c for 
2 hr periods in 0.35 ml of EMEM containing one-tenth the normal 
level of amino acids and 100 µCi/ml of [3H]-amino acid mixture 
(New England Nuclear). Monolayers were washed (x2) with PBS 
and dissociated in 200 µl of 1% SDS. Cell extracts were 
electrophoresed on a 10-20% gradient polyacrylamide gel 
(Section 2.2.11). 
3.2.7 Estimation of viral virulence for mice 
73 
The lethal dose (LD50 ) of the virus and the average 
survival time (AST) of infected mice were used to define the 
virulence of RRV T48 and the antigenic variants. Mice of 
either sex from an outbred line (Walter and Eliza Hall 
Institute; WEHI) were used. For LD 50 determinations 30 µl 
samples of ten-fold virus dilutions in HBSS were injected i.p. 
into day- or week-old mice, using 8-10 litter-mates per 
dilution. LD50 s were calculated according to Reed and Muench 
(1938). Clinical signs and mortality were recorded daily for 
two weeks. Subclinical infections were assayed in mice 
surviving to the 14th day by challenging with 10 5 PFU of RRV 
T48 injected i.p. Mice were held for a further two weeks and 
the absence of clinical signs was taken as evidence of prior 
infection. The AST represents the arithmetic mean for all mice 
dying during the course of a titration regardless of dose, 
since for most RRV strains the time of death was independent of 
dose (Taylor and Marshall, 1975). 
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3.2.8 Virus growth in mice 
WEHI mice of either sex were injected i.p. with -1 00 
PFU of virus. Groups of three mice were killed at each time 
point by cervical dislocation; tissues were removed and stored 
at -7o 0 c. Blood was collected from the heart using heparinised 
capillary tubes (Sherwood Medical Industries, USA) and diluted 
1:10 in ice-cold HBSS before freezing at -70°. For virus 
assay, tissues were homogenised as a suspension in ice-cold 
HBSS using a teflon-glass homogeniser attached to a Virtis 
homogeniser. 
3.3.1 
3.3 RESULTS 
Growth kinetics of RRV T48 antigenic variants 
in BHK cells 
The growth of the mab-resistant antigenic variants was 
compared to that of RRV T48 to assess whether a change in 
neutralisation epitope was accompanied by a change in vira l 
replication which could be detected in cultured cells. BHK 
monolayers were infected with the variants or RRV T48 (moi-1) 
and incubated in GMEM at 36°c. Growth samples were removed at 
intervals and the extracellular virus (EV) titer assayed. 
Growth kinetics of Tl0C9-resistant variants. The growth 
of variants TV31, TV33, TV35 and TV42 (epitope I variants) was 
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Figure 3.1 Growth kinetics of Tl0C9-resistant variants 
of RRV T48 in BHK cells. 
BHK cell monolayers were infected with the variant 
or with RRV T48 (moi-1) and incubated at 36°c. At 
intervals samples were removed, diluted into HBSS, and 
stored at -70°c. EV titers were assayed in duplicate. 
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Figure 3.2 Growth kinetics of TlE7-resistant variants 
of RRV T48 in BHK cells. 
BHK cell monolayers were infected with the variant 
or with RRV T48 (moi-1.5) and incubated at 36°c. At 
intervals samples were removed, diluted into HBSS, and 
stored at -70°c. EV titers were assayed in duplicate . 
EV titer of RRV T48, ( 9). 
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compared with that of RRV T48 in BHK cells (Figure 3.1). For 
RRV T48 the first rise in EV titer was between 4 and 6 hr pi. 
The peak titer (-10 7PFU/ml) was at 24 hr pi. The growth 
kinetics of all T10C9 resistant variants were similar to each 
other and were not significantly different from that of RRV 
T48. 
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Growth kinetics of NB3C4-resistant variants. The growth 
of variants TV61, TV62, TV63 and TV64 (epitope II variants) was 
compared with that of RRV T48 in BHK cells. There was no 
significant difference in the growth kinetics of these variants 
and at no stage could the variants be distinguished from RRV 
T48 (data not shown). 
Growth kinetics of T1E7-resistant variants. The growth 
of variants TVl, TV2, TV3 and TVS (epitope III variants) was 
compared with that of RRV T48 in BHK cells (Figure 3.2). For 
both RRV T48 and the variants the first rise in EV titer was 
between 4 and 5 hr pi. Compared to RRV T48, however, the T1E7 
variants reached approximately 10-fold lower titers during the 
early phase of growth (up to 8 hr pi). Between 8 and 24 hr pi 
the differences in titer became less marked and at 24 hr pi, 
variants and RRV T48 had attained similar titers (-10 8 PFU/ml). 
At no stage were the growth kinetics of the variants 
significantly different from each other. Similar results were 
obtained in three separate experiments. 
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Figure 3.3 Growth kinetics of TlBl-resistant variants 
of RRV T48 in BHK cells. 
BHK cell monolayers were infected with the variant 
or with RRV T48 (moi-1) and incubated at 36°c. At 
intervals samples were removed, diluted into HBSS, and 
stored at -70°c. EV titers were assayed in duplicate. 
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Growth kinetics of TlBl-resistant variants. The growth 
of TV51 and TV59 (epitope III variants) was compared with that 
of RRV T48 in BHK cells (Figure 3.3). For both RRV T48 and the 
variants the first rise in titer was at 4-6 hr pi. However, 
the variants grew more slowly than RRV T48 and at 16 hr pi the 
EV titers of the variants were -1 log unit less than that of 
RRV T48. At 24 hr pi the differences in titer were 
insignificant. 
In summary, the experiments described above showed that 
the growth kinetics in BHK cells of variants altered in 
neutralisation epitopes I or II did not differ from that of RRV 
T48. However variants altered in epitope III (i.e. those 
selected with T1E7 or TlBl) showed retarded growth, although no 
clear difference in latent period was observed. 
Growth kinetics of multi-epitope antigenic variants in 
BHK cells. In view of the above result it was of interest to 
compare the growth of TV147 (altered in epitopes I and II) and 
TV161 (altered in epitopes I, II and III) with that of RRV T48. 
Growth was compared in BHK cells at an moi of -1 (Figure 3.4). 
Variant TV147 showed no significant differences from RRV T48 at 
any stage of growth. However TV161 grew far more slowly than 
RRV T48 although the latent periods were apparently similar. 
At 24 hr pi there was no significant difference in titers of 
TV161 and RRV T48. 
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Figure 3.4 Growth kinetics of multi-epitope 
variants of RRV T48 in BHK cells. 
BHK cell monolayers were infected with variant or 
with RRV T48 (moi-1) and incubated at 36°c. At 
intervals samples were removed, diluted into HESS, and 
stored at -70°c. EV titers were assayed in duplicate. 
EV titer of RRV T4 8, ( 8 ) . 
EV titer of TVl 4 7, ( 0 ) . 
EV titer of TV161, (.) . 
5 10 15 20 25 
TIME (hr) POST-INFECTION 
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We conclude that variants with mutation(s) in 
neutralisation epitopes I or II or both I and II showed no 
difference in their growth kinetics in BHK cells when compared 
with RRV T48. However, variants with a mutation in epitope III 
(TVl, TV2, TV3, TV5, TV51, TV59 and TV161) showed retarded 
growth in BHK cells. 
3.3.2 Rate of acquisition of resistance by infecting 
epitope III variants to neutralisation by added 
polyclonal antibody 
The previous experiment showed that the early growth of 
epitope III variants was retarded in BHK cells compared to RRV 
T48. However, at later times the difference in titers of RRV 
T48 and the variants was insignificant. This suggested that 
the defect in epitope III variants was more likely to be in the 
initial events of infection (i.e. virus-cell interaction) than 
in intracellular replication. To determine whether a lesion in 
virus-cell interaction of the epitope III variants existed we 
have compared the rates of "penetration" of the antigenic 
variants and RRV T48 in terms of the rate of acquisition of 
resistance by infecting virus to neutralisation by added 
polyclonal antibody (Barie et al., 1981). 
--
The rate of "penetration" measured in this way was 
compared for RRV T48, TVl, TV3 and TV161 (Figure 3.5). After 
20 min incubation, <5% of RRV T48 had acquired resistance to 
neutralisation although 10-20% of the variants had become 
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Figure 3.5 Rate of acquisition of neutralisation 
resistance by epitope III variants to 
added polyclonal ant i bodies . 
BHK cell monolayers in 60 mm dishes were infected 
with -100 BHK PFU of RRV T48 or the variants . At the 
designated times, the inoculum wa s re~oved and 0 . 5 ml 
of polyclonal anti-RRV T48 immune ascitic fluid 
(diluted 1:10 in HBSS) was added . After 10 min a t 3 6°c 
the antibody was removed, the monolayer washed (x 2 ) 
with PBS and overlayed for plaque development . The 
number of plaques obtained after a 60 min adsorption , 
PBS wash, but no antibody treatment was taken as 100% 
for each virus. Each assay was done in triplicate and 
the average values are plotted with error bars showing 
the standard error of mean. 
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resistant. At 60 min the corresponding figures for RRV T48 and 
variants were 28% and 50-55% respectively. For SIN, Barie et 
al. (1981) reported that by 20 and 60 min respectively -8% and 
40% of virus had acquired resistance to neutralisation. 
These results showed that in infecting BHK cells, the 
epitope III variants acquired resistance to neutralisation by 
polyclonal antibodies (i.e. "penetrated" cells) faster than RRV 
T48. This appears paradoxical in relation to the earlier 
observation that the epitope III variants were slowed in their 
growth kinetics in BHK cells (see Discussion). 
3.3.3 AMO-resistant RNA synthesis in BHK cells 
infected with the multi-epitope antigenic variants 
In Section 3.2.1 it was shown that the growth kinetics 
of TV147 (an epitope I and II variant) in BHK cells was similar 
to that of RRV T48. However, TV161 (altered in epitopes I, II 
and III) showed a retarded production of infectious virus. To 
determine whether slowed virus production correlated with 
delayed viral RNA synthesis, BHK cells infected with RRV T48, 
TV147 or TV161 (moi -1.0) were labelled with [ 3HJ-uridine (with 
or without AMD) at different times and acid precipitable 
radioactivity determined (Figure 3.6). 
For RRV T48 and TV147 a significant increase in the 
rate of viral RNA synthesis took place between 8 and 10 hr pi. 
This was not observed in TV161 infected cells. Peak viral RNA 
synthesis in both RRV T48- and TV147-infected cells was at 12 
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Figure 3.6 AMO-resistant RNA synthesis in BHK cells 
infected with RRV T48 or with multi-
epitope variants. 
BHK cell monolayers were infected with RRV T48 or 
with the variants (moi-1), or mock-infected with HESS, 
and incubated in GMEM + 8% bovine serum. At intervals, 
monolayers were labelled for two hour periods with EMEM 
containing 10 µCi/ml of [5- 3HJ-uridine (times indicated 
in the Figure are the middle of labelling periods) and 
incubated at 36°c. Infected cells were labelled in the 
presence of 5 µg/ml AMD, and mock-infected cells in the 
absence or presence of 5 µg/ml of AMD. Monolayers were 
dissociated in 200 µl of 1% SDS and the acid-
precipitable radioactivity in 20 µl of the resulting 
extracts, representing -2 X 10 5 cell equivalents, 
determined. 
Incorporation of [ 3HJ-uridine in: 
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hr pi. The time of peak viral RNA synthesis in TV161-infected 
cells could not be determined from this experiment. At 24 hr 
pi, cells infected with RRV T48, TV147 and TV161 showed the 
same rates of virus specific RNA synthesis. 
We conclude that the kinetics of virus-specific RNA 
synthesis in TV161-infected BHK cells is slowed compared to 
that in RRV T48- or TV147-infected cells. This is consistent 
with previous data showing a reduced EV titer early in TV161 
infection compared to RRV T48 (Figure 3.4). Whether other 
epitope III variants show a delayed time-course of viral RNA 
synthesis was not examined, although this seems likely on the 
basis of their similar growth kinetics to TV161 in BHK cells. 
3.3.4 Virus specific polypeptide synthesis in 
BHK cells infected with antigenic variants 
In the previous Chapter, certain of the RRV T48 
antigenic variants had amino acid substitutions in E2 which, 
for variants TVl, TV51, TV59, TV161 and TV162 generated an 
additional potential glycosylation site at residue 246. Also, 
in the experiment described above, TV161 made AMD-resistant RNA 
at a significantly lower rate than RRV T48. To determine 
whether these differences resulted in changes in the kinetics 
of viral protein synthesis, in protein processing (e.g. 
cleavage) or in apparent molecular weight, the synthesis of 
viral polypeptides by RRV T48 and the above variants was 
examined in BHK cells. BHK monolayers were infected (moi -1) 
80 
and labelled with [ 3HJ-amino acids for 2 hr periods at 3, 7 and 
23 hr pi. Cell extracts were analysed on 10-20% gradient 
polyacrylamide gels. For RRV T48, eight infection-specific 
proteins were detected: pllO, p95, p80, PE2, El, E2, C and E3 . 
The identity of the structural proteins (El, E2, C) and of p95, 
and PE2 has been established previously (Martin et al., 1979; 
Short and Dalgarno, unpublished results). E3 is described in 
Chapter 4 of this thesis. pllO and p80 have not been 
described. Since these proteins were detected up to 23 hr pi, 
and the synthesis of the non-structural proteins of other 
alphaviruses declines rapidly at 4-5 hr pi (Lachmi and 
Kaariainen, 1977; Schlesinger and Kaariainen, 1980), it is 
probable that pllO and p80 are precursors of structural 
proteins. 
Epitope III variants. Viral polypeptide synthesis by 
variants TVl, TV2, TV3, TVS (selected with TlE7) and TV51 
(selected with TlBl) was compared with that of RRV T48 (Figure 
3.7). At 3-5 hr pi, T48-infected BHK cells synthesised only two 
virus specific polypeptides: p80 and C; none of the variants 
showed virus specific polypeptide synthesis at this time (data 
for TV51 not shown). At 7-9 and 23-25 hr pi, cells infected 
with T48 or with variants showed labelling of pllO, p95, p80, 
PE2, El, E2 and C; with longer exposure E3 was detected (data 
not shown). The mobilities of corresponding viral proteins 
were identical in all instances except in the case of TVl 
(Figure 3.7) and TV51 (data not shown) where PE2 migrated more 
slowly than the corresponding band in RRV T48-infected cells. 
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Figure 3.7 Viral polypeptide synthesis in BHK cells 
infected with T1E7-resistant variants of 
RRV T48 . 
BHK cell monolayers were infected with RRV T48 (T), 
TVl, TV2, TV3 or TVS, or were mock-infected (M) with 
HBSS, and incubated in GMEM+8% bovine serum at 36°c. 
At indicated times monolayers were labelled for 2 hr 
with EMEM containing one-tenth the normal concentration 
of amino acids and 10 µCi/ml [ 3HJ -amino acids. 
Monolayers were washed (x2) with PBS and dissociated in 
200 µl of 1% SDS and the cell extracts were 
electrophoresed on 10-20% gradient polyacrylamide gels. 
The gels were fluorographed and exposed to Kodak X-Ornat 
S X-ray film at -7o 0 c for 6 days. Positions of viral 
polypeptides are indicated. 
TV TV TV 
MT1235 MT1235 MT1235 
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Designated PE2*, it had an apparent mol. wt. of 64K compared to 
62K for RRV T48 PE2. This may be due to additional 
glycosylation since E2 of these variants was predicted to have 
an additional site for asparagine-linked glycosylation (Chapter 
2). Interestingly, no differences were seen in the migration 
of intracellular E2 or E3 (which are produced by cleavage of 
PE2). Whether E2 in purified virions of these variants has 
additional glycosylation is not known. 
No differences in shut-down of host protein synthesis 
were apparent at any time post-infection when cells infected 
with RRV T48 and variants were compared. 
In summary, variants altered in epitope III showed 
delayed protein synthesis in BHK cells compared to RRV T48. 
Variants TVl and TV51 made a slightly higher molecular weight 
form of PE2 than did RRV T48, consistent with the earlier 
prediction of an additional glycosylation site in E2. 
Epitope I and epitope II variants. Viral polypeptide 
synthesis in BHK cells infected with TV31, TV33 , TV35, TV42 
(T10C9-resistant variants altered in epitope I) and TV61, TV62, 
TV63, TV64 (NB3C4-resistant variants altered 
compared with that in RRV T48-infected cells. 
in epitope II) was 
At 3-5 hr pi BHK 
cells infected with the variants or with RRV T48 showed p80 and 
C (data not shown). At 7-9 and 23-25 hr pi eight virus 
specific polypeptides were seen in cells infected with RRV T48 
or with variants. These were pllO, p95, p80, PE2, El, E2, C 
and E3 as observed previously. Thus there were no differences 
in the kinetics of viral protein synthesis by epitope I and 
epitope II variants compared to RRV T48, consistent with 
previous data showing similar growth rates in BHK cells. No 
differences were seen in the mobilities of viral proteins 
between the variants and RRV T48. 
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Multi-epitope variants. Viral polypeptide synthesis was 
compared in BHK cells infected with RRV T48, TV147 (altered in 
epitopes I and II) or TV161 (altered in epitopes I, II and 
III). At 3-5 hr pi cells infected with RRV T48 or with TV147 
showed labelling of p80 and C. At this stage no virus specific 
proteins were detected in TV161-infected cells. At 7-9 and 23-
25 hr pi, both RRV T48- and TV147-infected BHK cells showed the 
same eight virus specific polypeptides as noted above (data not 
shown). TV161-infected cells also showed the same proteins at 
the same relative position with the exception of PE2 which 
migrated more slowly than RRV T48 PE2 (data not shown). The 
slow migration of PE2 may be due to the predicted additional 
glycosylation site in TV161 E2 (Chapter 2) although no 
differences were seen in the migration of E2 or E3. There were 
no apparent differences in shut down of host protein synthesis 
between RRV T48-infected and the variant-infected cells. 
In summary, T10C9 variants (altered in epitope I), 
NB3C4 variants (altered in epitope II) and TV147 (altered in 
epitopes I and II) showed no differences from RRV T48 in the 
kinetics of synthesis or pattern of processing of viral 
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polypeptides in infected BHK cells. However, all variants with 
a mutation in epitope III showed delayed synthesis of viral 
polypeptides in infected BHK cells. This was consistent with 
the delayed time course of viral RNA synthesis and the lower 
initial EV titers in BHK cells infected with epitope III 
variants. TVl, TV51 and TV161 made a higher mol. wt. form of 
PE2 although no differences were seen in migration of E2 or E3 
of these variants compared with RRV T48. 
3.3.5 Virulence of RRV antigenic variants for mice 
It has previously been shown that mab-resistant 
variants of many viruses have altered virulence for their 
experimental host (see Introduction). This together with the 
observation that serial passaging of avirulent RRV NB5092 
generated virulent virus altered around the neutralisation 
epitopes (Meek, 1986) prompted us to examine the virulence of 
RRV T48 antigenic variants in mice. 
Day-old and week-old mice were injected i.p. with 
serial dilutions of the virus stocks. The onset and severity 
of symptoms and the number of deaths were recorded daily. The 
LD 50 of virus stocks and the AST of infected mice were 
calculated to define the virulence of the virus. Several 
determinations were carried out for each variant and 
comparisons were made with results for RRV T48 using one way 
analysis of variance and t-tests. 
Table 3.1 Virulence of RRV T48 antigenic variants 
for day-old mice. 
Virus 
RRV T48 
TV31 
TV33 
TV35 
TV42 
TVl 
TV2 
TV3 
TVS 
Altered 
epitope 
I 
I 
I 
I 
III 
III 
III 
III 
LD50* (Vero PFU) 
0.047 (3) 
0.055 ( 3) 
0.065 ( 3) 
0.056 (3) 
0.057 (3) 
0.022 (3) 
0.058 ( 3) 
0.019 ( 3) 
0.056 (3) 
AST* 
(days) 
4.93 ( 4) 
5.53 ( 3) 
5.20 (3) 
5.12 ( 3) 
5.63 ( 3) 
5.20 ( 4) 
4.20 ( 3) 
4.68 ( 4 ) 
5.43 ( 3) 
*Figures presented are an average of a number of 
separate determinations (shown in brackets). 
The virulence parameters of variants were compared 
with those of RRV T48 using one-way analysis of 
variance and the t-tests. The LD 50 and the AST values 
of variants did not differ significantly from those of 
RRV T48. 
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Virulence in day-old mice. RRV T48 was highly virulent 
for day-old mice with an LD50 of 0.047 PFU (Table 3.1); 
infected mice showed severe hind leg paralysis and had an AST 
of 4.93 days. Variants TV31, TV33, TV35 and TV42 (epitope I 
variants) and TV2 and TVS (epitope III variants) had slightly 
higher LD50 s than RRV T48, although the differences were not 
statistically significant. Compared to RRV T48, variants TVl 
and TV3 had slightly reduced LD50 s, though differences were not 
significant statistically. Thus none of the epitope I or 
epitope III variants showed a significant difference in LD
50 
or 
AST when compared with RRV T48 (Table 3.1). No differences 
were observed in the time of onset or severity of symptoms in 
mice infected with the variants or RRV T48. 
Virulence in week-old mice. For RRV T48 the LD
50 
and 
AST did not differ significantly between day-old and week-old 
mice (Tables 3.1 and 3.2). Further, no differences were 
observed in the time of onset or the severity of symptoms 
between RRV T48 infected day-old and week-old mice. The LD
50
s 
and the AST values for epitope I, II and III variants showed 
slight differences from those for RRV T48 although the 
differences were not statistically significant except for TV2, 
TV5 and TV161 (Table 3.2). TV2 and TV5 were slightly less 
virulent than RRV T48 (p<0.05) with LD 50 s of 0.206 and 0.275 
PFU respectively compared to 0.048 PFU for RRV T48. The ASTs 
of mice infected with TV2 and TVS did not differ significantly 
from those of mice infected with RRV T48. However for TV161-
Table 3.2 Virulence of RRV T48 antigenic variants 
for week-old mice. 
Virus 
Altered 
epitope 
Amino acid 
change and 
position in E2 
LDso* (Vero PFU) 
AST* 
(days) 
RRV T48 0.048 (6) 5.92 TV31 I Thr--,Ile (216) 0.056 ( 3) 6.04 TV33 I Thr--,Ile (216) 0.055 ( 3) 5.38 TV35 I Thr--,Ile (216) 0.068 ( 3) 6.20 TV42 I Thr--,Ile (216) 0.075 ( 4) 5.81 
TV61 II Lys--,Gly ( 234) 0.039 ( 3) 6.12 TV62 II Lys--,Ile (234) 0.045 ( 3) 6.43 TV63 II Lys--,Asn ( 234) 0.043 ( 3) 5.93 TV64 II Lys--,Glu (234) 0.055 ( 3) 6.72 
TVl III Asp--,Asn (24 6) 0.031 ( 3) 7.08 TV2 III Arg--,Ser (251) 0.206 ( 3) 5.96 TV3 III Thr--,Pro (24 8) 0.028 ( 5) 6.60 TVS III Asp--,Val (24 6) 0.275 ( 3) 4.84 TV51 III Asp--,Asn (24 6) 0.050 ( 3) 6.84 TV59 III Asp--,Asn (24 6) 0.050 ( 3) 6.27 
TV131 I and Thr--,Ile (216) 
II Lys--,Asn (234) 0.049 ( 3) 6.00 
TV147 I and Thr--,Ile ( 216) 
II Lys--,Asn (234) 0.053 ( 3) 5.80 
TV161 I, Thr--,Ile ( 216) 
II and Lys--,Asn (234) 
III Asp--,Asn (2 4 6) 0.079 ( 3) 8.64 
*Figures presented are an average of a number of separate determinations (shown in brackets). 
( 4) 
( 4) 
( 3) 
( 6) 
( 6) 
( 3) 
( 3) 
( 3) 
( 3) 
( 5) 
( 5) 
( 3) 
( 3) 
( 3) 
( 3) 
( 3) 
( 3) 
( 3) 
The virulence parameters of variants were compared with those of RRV T48 using one-way analysis of variance and the t-tests. Virulence parameters of variants did not show a significant difference from those of RRV T48 except where shown in bold type. Thus, LD50S of TV2 and TVS and the AST of TV161 showed a significant difference (p<0.05) from the respective virulence parameters of RRV T48. 
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infected mice there was a significant increase in AST (8.64 
days) over that seen for mice infected with RRV T48 (p<0.05). 
No significant difference in LD 50 or in the time of onset and 
severity of symptoms was noted for TV161 compared with RRV T48. 
In summary, none of the epitope I, epitope II or 
epitopes I and II variants showed a significant difference in 
virulence when compared with RRV T48 in day-old or week-old 
mice. Only variants TV2 and TVS (altered in epitope III), and 
TV161 (the only triple variant checked which was altered in 
epitopes I, II and III), showed any change in virulence; these 
variants were slightly attenuated in week-old mice. However, 
the other four epitope III variants showed no significant 
change in virulence compared to RRV T48. 
3.3.6 Growth of antigenic variants in week-old mice 
Since certain epitope III variants showed a small 
reduction in virulence for week-old mice, the growth of these 
variants in week old mice, together with that of other epitope 
I and epitope III variants of unchanged virulence was compared 
with RRV T48. The kinetics of viral growth, the maximum titers 
attained and the tissue distribution of virus was examined. 
The tissues selected for examination were hind leg muscle, 
brain and blood. Hind leg muscle was chosen as it is the major 
site of RRV replication in mice (Chapter 1). Brain was chosen 
as the extent of RRV replication in neuronal tissue may 
determine the severity of symptoms and death. 
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Figure 3.8 Growth of RRV antigenic variants in mice. 
Week-old WEHI mice were injected i.p. with 100 PFU 
of virus. Mice were killed and tissues removed at 24 hr 
intervals. Virus titers were assayed in blood, brain 
and hind leg muscle. Each time point represents the 
average of determinations made in three mice. Error 
bars are shown where the error is greater than 0.2 log 
units. 
The growth of RRV T48, TV3 and TVS was compared in 
one experiment (upper half of the Figure). In another 
experiment the growth of RRV T48 and TV161 was compared 
(lower half of the Figure). 
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The variants examined were TV3 and TVS (altered in 
epitope III), TV31 and TV3S (altered in epitope I) and TV161 
(altered in epitopes I, II and III). Variants TV3, TV31 and 
TV3S had a similar virulence to that of RRV T48 whereas TVS and 
TV161 were of altered virulence compared to RRV T48. Week-old 
mice were injected i.p. with -100 PFU of virus. For each virus 
three mice were killed at 24 hr intervals and blood, brain and 
hind leg muscle tissues removed for virus assay (Figure 3.8). 
Viraemia. RRV T48 could be detected in blood at 1 d pi 
when a titer of -10 9 PFU/ml was attained. After this the virus 
titer was stable but declined rapidly between 3 and 4 d pi when 
the experiment was terminated as most of the mice did not 
survive beyond this. Viraemia levels for TV3, TVS, TV31 and 
TV3S followed the same pattern and similar titers to those of 
RRV T48 were reached in all cases (data for TV31 and TV3S not 
shown). Variant TV161, however, reached only -10 7 PFU/ml 
although the pattern of change in viraemia did not appear to be 
greatly altered. 
Brain. RRV T48 reached a peak titer of -10 8 PFU/g at 1 
d pi and remained almost unchanged until 4 d pi. Variants TV3, 
TV31 and TV3S grew to approximately the same titers as RRV T48 
(data for TV31 and TV3S not shown). Compared to RRV T48, 
variants TVS and TV161 grew to slightly lower titers at each 
time point, although the differences were not statistically 
significant. 
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Hind leg muscle. RRV T48 attained a peak titer of -10 9 
PFU/g at 1 d pi after which the titer did not change 
significantly up to 4 d pi. Variants TV3, TVS, TV31 and TV3S 
attained similar peak titers and showed a similar pattern of 
growth which did not differ significantly from that of RRV T48 
(data for TV31 and TV3S not shown). Compared to RRV T48, TV161 
grew to slightly lower titers; this difference was consistent 
throughout the experiment although not significant 
statistically. 
In summary, none of the antigenic variants could be 
distinguished from RRV T48 in their growth characteristics in 
week-old mice except TV161 which reached -100-fold lower titers 
in blood compared to RRV T48. Variant TVS, which had a -4-fold 
higher LDso than RRV T48, did not show a significant difference 
in viral growth or in peak titers when compared with RRV T48. 
3.4 DISCUSSION 
The aim of the studies described in this Chapter was to 
examine the effect of the previously determined amino acid 
substitution(s) in E2 on the biological properties of RRV T48 
antigenic variants in cultured cells and in mice. The results 
obtained show that variants altered in epitopes I or II could 
not be distinguished from RRV T48 in their kinetics of growth, 
protein synthesis and RNA synthesis in BHK cells. However all 
epitope III variants examined showed retarded growth and 
delayed RNA and protein synthesis in BHK cells. 
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An interesting parallel to the biological properties of 
the variants in BHK cells was seen in mice. Antigenic variants 
altered in epitopes I or II showed no differences in virulence 
or growth in mice. However, three epitope III variants (TV2, 
TVS and TV161) out of seven examined showed slightly reduced 
virulence for week old mice. Further, TV161 produced lower 
levels of viraemia in mice than did RRV T48. 
From the results observed in cultured cells it seems 
likely that the changes seen in mice did not result from 
altered recognition of the variants by the immune system. This 
follows from two considerations. First, the week-old mice used 
in the present studies are considered to be immunologically 
immature (Murgita and Wigzell, 1981); and second, any antibody 
produced in mice would be polyclonal and able to neutralise the 
antigenic variants effectively. Hence, changes in biological 
properties of epitope III variants suggest some important 
function of this epitope besides that of reacting with 
neutralising antibody. 
3. 4. 1 Involvement of the "neutralisation domain" in 
attachment/entry of virus in cultured cells 
Antigenic variants altered in epitopes I or II, . or in 
both I and II had similar kinetics of growth and of RNA and 
protein synthesis to RRV T48 in BHK cells. However variants 
altered in epitope III (TVl, TV2, TV3, TVS, TV51 and TV52) and 
TV161 (altered in epitopes I, II and III) showed retarded 
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growth in BHK cells. Consistent with this, epitope III 
variants showed a delayed synthesis of viral RNA and protein in 
BHK cells. However no obvious defect in RNA replication or in 
protein synthesis was seen. These experiments suggest that 
epitope III variants had a lesion in viral attachment/entry, a 
conclusion somewhat strengthened by the observation that 
epitope III variants showed an altered rate of acquisition of 
resistance to neutralisation by antibody compared to RRV T48. 
It should be noted first however that control experiments with 
epitope I and epitope II variants designed to determine their 
"penetration" rates were not carried out. Secondly, the 
alteration in rate of "penetration" was in the direction of an 
increase rather than a decrease for TVl, TV3 and TV161. 
Further studies are required to clarify these issues. 
Studies with picornaviruses and rotaviruses suggest 
that the neutralisation antigenic sites of these viruses are 
involved in virus-cell interaction. Thus one of the three 
neutralisation sites on VPl, the major outer capsid protein of 
foot-and-mouth disease virus, is involved in virus attachment 
to bovine kidney cells since mabs to this site inhibit virus 
attachment to cells whereas mabs to other sites do not (Baxt et 
al. , 19 8 4) . In similar type of studies Emini et al. (1983) 
suggested that one of the seven neutralising epitopes on polio 
virus type I is involved in virus attachment to cells. More 
recently Sabara et al. (1985) have demonstrated that the 
receptor binding site of simian rotavirus is located in the 
major glycoprotein in a domain which contains the 
neutralisation antigen. 
3. 4. 2 
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Relationship between changes in the "neutralisation 
domain" and changes in virulence of antigenic variants 
for mice 
In order to examine the role of the neutralisation 
epitopes in determining viral virulence, the virulence of the 
antigenic variants was determined in mice. None of the 
antigenic variants showed any differences in virulence from RRV 
T48, except for TV2, TVS and TV161 which were slightly 
attenuated for week-old mice. None of the variants showed 
significantly increased virulence. Interestingly, TV2 and TVS, 
which showed a small increase in LD 50 (-4 fold), did not show a 
significant increase in AST. Variant TV161 showed a small, but 
significant increase in AST, although it did not show a 
significant change in LD 50 . This suggests that these two 
virulence parameters do not inevitably co-vary. 
It is noteworthy that the three variants which showed 
attenuation all had a mutation in epitope III (Table 3.2). 
Variant TV2 had an Arg~Ser substitution at residue 251 while 
TVS had an Asp~Val substitution at residue 246. However an 
Asp~Asn substitution at residue 246 in TVl did not result in a 
significant virulence change. The explanation for this 
possibly lies in the nature of the amino acid changes. Variant 
TV161 had changes in all three epitopes: Thr~Ile at residue 
216, Lys~Asn at residue 234 and Asp~Asn at amino acid 246. 
Variant TVl also had an Asp~Asn substitution at residue 246 in 
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E2; however, its virulence was unchanged. It is possible that 
the attenuation seen for TV161 was a cumulative effect of 
multiple mutations since none of the equivalent single changes 
altered the virulence of the corresponding variants. 
Our results are consistent with the findings of Meek 
(1986) who showed that single amino acid substitutions in RRV 
NB5092 E2 accompanied altered virulence, although the extent of 
change was much greater than that seen in the present study. 
In the present study, single amino acid substitutions in TV2 
and TV5 resulted in approximately four-fold increase in LD 50 
whereas in RRV NB5092 variants the difference was -10 6 times 
(Meek, 1986). This may have resulted from the positive 
selection pressure applied in the studies of Meek (1986) which 
would select for amino acid mutations enhancing viral growth 
and thus virulence. However, in our case the mutants were 
selected for their neutralisation resistance and not for a 
change in virulence. This may also explain why only a 
proportion of epitope III variants showed changes in biological 
properties. It should also be noted that changes leading to 
enhanced virulence may have occurred in the non-structural 
protein genes of RRV NB50 92 variants of Meek ( 198 6) (Chapter 
1) . 
When the titers of the antigenic variants were measured 
in different tissues of infected mice, no significant 
differences were observed except that TV161 produced a lower 
viraemia than RRV T48. This may be related to the longer AST 
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of mice infected with TV161. TVS which had a four-fold h ighe r 
LD50 than RRV T48 showed slightly lower titers in mouse brain 
than RRV T48 although the differences were not statistically 
significant. A change in cell tropism of the variants could 
affect virulence and this may not have been reflected in gross 
titers measured in experiments carried out in this Chapter. 
From these results, it is clear that only changes in 
epitope III altered the virulence of the virus and that even 
within this epitope, only certain amino acid substitutions were 
capable of affecting virulence. Thus TVl and TV3 (altered at 
amino acids 246 and 248 respectively) did not show a change in 
virulence although TVS (altered at amino acid 246) had reduced 
virulence. Similar observations have been made with rabies 
' virus. Seif et al. (1985) isolated 58 mab-neutralisation 
resistant variants of rabies virus using 4 different mabs which 
bound to a single antigenic site. They found that only 
variants altered at amino acid 333 of the glycoprotein were 
attenuated; others changed at amino acids 330, 336 or 338 did 
not show any change in their virulence. They suggested that 
arginine 333 was probably within the region of the glycoprotein 
which interacted with the host cell receptor. Similarly for 
mumps virus only one out of four neutralisation resistant 
variants isolated with a single mab had altered virulence (Love 
et al., 1985); the amino acid changes which took place in the 
different variants were not identified. 
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3. 4. 3 Biological role of the "neutralisation domain" in E2 
Studies with cultured cells and with mice described in 
this Chapter suggest a role for epitope III in some aspect of 
viral attachment/entry. This is consistent with recent studies 
of Meek (1986) who showed that virulent mutants obtained by 
passaging avirulent RRV NB5092 in mice had changes at amino 
acids 212, 232, 234 and 251 which were located in 
neutralisation epitopes in E2. As RRV NB5092 was passaged in 
neonatal mice where the immune system is immature, it is 
unlikely that the mutations were selected as a result of 
antibody pressure. Since the virulent mutants of RRV NB5092 
grew to higher titers in the blood and brain of mice it may be 
that mutants were selected which were better able to interact 
with the cellular receptor. Meek (1986) proposed that ' amino 
acids at which substitutions occurred during passaging were 
involved in receptor binding. In SIN, a region of E2 involved 
in neutralisation is involved in virus attachment and entry in 
BHK cells (Barie et al., 1981; Olmsted et al., 1986). --
Based on these studies we propose that both receptor 
binding site and neutralisation epitopes are in the same domain 
of E2. Thus a change in a neutralisation epitope could alter 
the conformation of the receptor binding site leading to an 
altered recognition of cellular receptor. This could result 
a change in cell/tissue tropism or in an altered rate of 
attachment/entry of virus to the cell which may affect the 
' in 
establishment and spread of the infection. Such changes could 
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affect growth rate and the virulence of the virus (Chapter 1). 
If this model is correct it appears that the three 
epitopes of the "neutralisation domain" are not involved in 
virus-antibody interaction and in virus-cell interaction 
equally since epitopes I, II and III were all involved in 
virus-antibody interaction whereas only epitope III appears to 
be involved in virus-cell interaction. However in RRV NB5092 
variants, virulence-associated changes occurred in all three 
neutralisation epitopes (Meek, 1986). This may suggest that 
the nature of amino acid change, rather than its position in 
the neutralisation epitope, is important in affecting virus-
cell interaction. 
The model described above is similar to the situation 
proposed for influenza virus (Wilson et al., 1981; Wiley et 
al., 1981) and the common cold virus (Rossmann et al., 1985) 
--
where a pocket of conserved amino acids representing the 
receptor binding site is surrounded by neutralisation epitopes. 
Mutants of swine influenza virus which differ in their capacity 
to replicate in chicken embryo cells, Madin-Darby kidney cells 
and the respiratory tract of swine (Kilbourne et al., 1981) can 
be distinguished by neutralising mabs (Kilbourne et al., 
1983). A single amino acid difference at residue 155 is 
responsible for these differences; this amino acid is located 
in the antigenic area immediately adjacent to the proposed 
receptor binding site (Both et al., 1983). 
3.4.4 Mechanism of RRV neutralisation 
No published information exists which explains the 
mechanism of alphavirus neutralisation although different 
mechanisms have been proposed for neutralisation of different 
. 
viruses. Thus neutralising antibodies to foot-and-mouth 
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disease virus (Baxt et al., 1984) and bovine rotavirus (Sabara --
et al., 1985) inhibit virus-cell interaction. However virus 
bound to neutralising antibodies may still bind to host cells. 
Thus neutralised rabbit poxvirus (Joklik, 1964) and poliovirus 
(Mandel, 1967) bind to HeLa cells. Emini et al. (1983) showed 
that binding of mab to six out of seven neutralisation epitopes 
of poliovirus did not inhibit virus interaction with HeLa 
cells, although mab to one epitope did inhibit virus binding to 
the cells. Similarly influenza A virus neutralised with 
polyclonal antibody or with mab binds to a variety of cell 
lines (see Dimmock, 1984). Another mechanism proposes that 
antibody binding to virus induces conformational changes in 
viral structure, thus rendering the virus non-infectious. This 
is based on the observation that binding of neutralising 
antibody to poliovirus (Mandel, 1976) or to bovine rotavirus 
(Carthew, 1976) changes the isoelectric point of the virus, 
indicating a conformational change in the protein structure. 
It would appear that different viruses may have 
different mechanisms of neutralisation and that different 
mechanisms may operate for neutralisation of the same virus 
with different antibodies. Since we have proposed that t h e 
neutralisation epitopes and the receptor binding site are 
the same domain of RRV E2, it is possible that binding of 
neutralising antibodies inhibits virus binding to cellular 
. in 
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receptor, thus neutralising the virus infectivity. This model 
will require a multi-hit mechanism of virus neutralisation 
since a large number of E2 molecules and thus a number of 
receptor binding sites are available on the virion surface 
(Della-Porta and Westaway, 1977). Again, this may be one of 
several mechanisms involved in alphavirus neutralisation. 
CHAPTER 4 
BIOLOGICAL STUDIES ON A MUTANT 
OF RRV T48 CARRYING A DELETION 
IN THE E2 GENE 
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4.1 INTRODUCTION 
In the course of the nucleotide sequence determination 
of the 26S subgenomic RNA of RRV T48, Dalgarno et al. (1983) 
obtained evidence which predicted the existence, in the virus 
stock, of a mutant with a deletion of 21 nucleotides in the E2 
gene. Subsequently a mutant which formed uniformly small 
plaques was detected in the stock. The mutant was plaque 
purified twice (L. Dalgarno, unpublished data) and its genome 
sequenced in the appropriate region (S.G. Faragher, unpublished 
data). This showed that the small plaque mutant had the 
predicted deletion in a region of the E2 gene coding for amino 
acids 55-61. The mutant was referred to as RRV dE2. Comparison 
of TaqI and HaeIII restriction digest profiles of cDNAs to 
virion RNA showed no difference between RRV T48 and RRV dE2 
except for the deletion in E2 of RRV dE2 (Faragher, 1982), 
although a possibility of a point mutation(s) could not be 
ruled out. The existence of this genetically defined mutant 
provided an opportunity to investigate the effect of the 
deletion in E2, the neutralisation antigen, on the biological 
properties of the virus. 
Preliminary studies of Faragher (1982) indicated that 
RRV dE2 could not be distinguished from RRV T48 in single cycle 
growth in BHK cells or in neutralisation tests using polyclonal 
antiserum. The mutant was, however, more thermolabile at 50°c 
and made more RNA in BHK cells than RRV T48. In addition, RRV 
dE2 shut down host protein synthesis in BHK cells faster than 
did RRV T48. 
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These preliminary observations were indicative of 
significant changes in the structure and replication of RRV dE2 
which were worthy of further investigation. In this Chapter we 
examine the structural proteins of RRV dE2 and RRV T48 and 
compare their biological properties in cultured cells. We also 
compare the virulence and growth of RRV dE2 in mice with that 
of RRV T48. 
4.2 MATERIALS AND METHODS 
4. 2. 1 Virus, cells and plaque assay 
These have been described in Sections 2.2.1, 2.2.2 
and 2.2.3. 
4. 2. 2 
4.2.3 
Rate of acquisition of resistance by infecting 
virus to neutralisation by added polyclonal 
antibody (Barie et al., 1981) 
This has been described in Section 3.2.3. 
Preparation of primary mouse cell cultures 
Two to three day-old outbred WEHI mice of either sex 
were killed and rinsed with ethanol and PBS. Skin and thigh 
muscles were removed, chopped and digested with -100 units of 
crude collagenase (Worthington Biochemical Co., USA; diluted in 
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HESS) per g of tissue at 37°c for 30 - 60 min. After standing, 
the supernatant was removed and seived through a fine stainless 
steel mesh into 2 . 5 ml of heat-inactivated foetal calf serum . 
Cells were pelleted by slow centrifugation (400 g) for 5 min 
and resuspended in GMEM supplemented with 8% bovine serum and 
2% foetal calf serum . Cells were seeded in 35 mm plastic 
dishes at a density of 2xl0 6/dish and incubated at 36°c in a 
humidified atmosphe r e of 5% carbon dioxide and 95% air . About 
90% confluent monolayer s were obtained after 24 hr . 
4 . 2 . 4 Labelling of virus specific polypeptides 
Virus specific proteins in infected BHK cells were 
labelled with [ 3HJ - amino acids (Section 3.2 . 6) . 
4 . 2 . 5 Purification of virus 
Virus was purified by polyethylene glycol precipitation 
and sucrose g r adient centrifugation (Section 2 . 2 . 5). 
4 . 2 . 6 Polyacrylamide gel electrophoresis of proteins 
This has been described in Section 3 . 2 . 6 . 
4 . 2 . 7 Estimation of rates of RNA synthesis 
Rates of AMD - resistant RNA synthesis were measured as 
described in Section 3 . 2 . 5 . 
4 . 2 . 8 Extraction of RNA from virus infected BHK cells 
RNA was extracted by the phenol/cresol extraction 
method (Section 2 . 2 . 14) . 
4.2.9 Estimation of viral virulence for mice 
Virulence was estimated in terms of the LD 50 of the 
virus and the AST of infected mice (Section 3.2.7). 
4 . 2 . 10 Growth of virus in mice 
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Virus growth in mice was examined in blood , brain and 
hind leg muscle tissues (Section 3.2.8). 
4 . 3 RESULTS 
4 . 3 . 1 Growth of RRV dE2 and RRV T48 in BHK cells 
Since certain RRV T48 variants with amino acid alterations 
in E2 showed retarded growth in BHK ce s (Chapter 3) it was of 
interest to compare the growth of RRV dE2 and RRV T48 in cell 
culture. Although the preliminary studies of Faragher (1982) 
had shown no significant differences in EV titers for the two 
viruses when BHK cells were infected at a moi-1, a more 
sensitive test would be to infect eels at a lower moi . Under 
these conditions virus would grow in ultiple cycles and any 
difference in growth would be amplified. Therefore growth o f 
RRV dE2 and RRV T48 was examined at moi-1 and 0 . 001 in BHK 
cells. 
At moi-1, the first increase in RRV T48 titer took 
place between 3 and 6 hr pi. A maximum titer of -10 7 PFU/ml 
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was reached at 12 hr pi. The growth kinetics and maximum titer 
of RRV dE2 were similar to those of RRV T48 (data not shown). 
At moi-0.001 the growth kinetics of RRV dE2 and RRV T48 were 
also similar, although both viruses grew more slowly than at a 
moi-1 (data not shown). The first rise in titer of both 
viruses was between 6 and 9 hr pi and both reached the maximum 
titer (-10 8 PFU/ml) at 36 hr pi. Thus RRV dE2 could not be 
distinguished from RRV T48 by growth in BHK cells. Similar 
results were obtained in Vero cells (data not shown). 
4.3.2 Rate of acquisition of resistance by infecting RRV 
T48 and RRV dE2 to neutralisation by added 
polyclonal antibody 
In Chapter 3 it was shown that certain RRV T48 variants 
altered in E2 had an altered rate of "penetration" as judged by 
the rate of acquisition of neutralisation resistance by virus 
to polyclonal antibody in tissue culture cells. It was of 
interest to investigate whether RRV dE2, with a structural 
perturbation in a different region of E2, was affected in the 
same way. 
102 
Vero monolayers were inoculated with -100 PFU of virus 
and incubated at 36°c for 10 , 20, 30, 40 and 60 min followed by 
addition of polyclonal antibody (diluted xlO in HBSS) for 10 
min. After washing to remove excess antibody, overlay medium 
was added and plates incubated for plaque development. Each 
assay was carried out in triplicate. RRV dE2 and RRV T48 gave 
virtually identical profiles of acquisition of neutralisation 
resistance (data not shown). 
4.3.3 Temperature sensitivity of plaque formation 
Since for some alphaviruses small plaque mutants are 
temperature sensitive (Peleg, 1971), plaque formation and 
plaque morphology of RRV dE2 and RRV T48 were compared over a 
range of temperatures (28, 30, 32, 34, 35, 36, 37, 39 and 41 °c) 
( Tab l e 4 . 1 ) . 
For both RRV T48 and RRV dE2 maximum plaque number and 
maximum plaque size was at 36°c; RRV T48 and RRV dE2 made 
plaques of diameter -3-4 mm and -1-2 mm respectively. There was 
a decrease in the efficiency of plaque formation by both 
viruses above 36°c and a more marked decrease below 30°c. No 
differential change in the efficiency of plaque formation or in 
plaque size was observed for the two viruses as the temperature 
was altered. Thus the small plaque morphology of RRV dE2 was 
not due to the temperature sensitivity of plaque formation. 
Table 4 . 1 Temperature sensitivity of plaque formation by 
RRV dE2 and RRV T48. 
RRV T48 RRV dE2 
Temperatu r e 
degrees C 
28 
30 
32 
34 
35 
36 
37 
39 
41 
Number 
o f plaque s * 
0 
122 
13 6 
1 31 
117 
CLt 
65 
33 
0 
Di ameter 
(mm) 
< l 
1 - 2 
2 - 3 
2 - 3 
3 - 4 
2 - 3 
1 - 3 
* per 6- well Linbro plate . 
Number 
of plaques* 
0 
143 
134 
137 
147 
CLt 
77 
24 
0 
t CL , confluent lysis of the rnonolayer . 
Diameter 
(mm) 
<l 
<l - 1 
1- 2 
1- 2 
1- 2 
1 - 2 
1- 2 
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4.3.4 Structural proteins of RRV dE2 
The seven amino acid deletion in E2 predicted from 
nucleotide sequencing (Dalgarno et al., 1983; S.G. Faragher, 
unpublished data) could lead to an altered pattern of 
processing or glycosylation of the structural proteins or to 
changes in the assembly of these proteins in the mature virion. 
Experiments were carried out to test this and to examine 
whether the deletion in E2 resulted in a detectable alteration 
in its electrophoretic mobility. 
To examine the polypeptides in virions, [ 3HJ-amino acid 
labelled RRV T48 and RRV dE2 were purified in parallel, 
dissociated in 1% SDS and electrophoresed on a 10-20% gradient 
polyacrylamide gel (Figure 4.1). In both RRV T48 and RRV dE2 
only three polypeptides (El, E2 and C) were detected. No 
obvious differences were seen in the molar ratios of the three 
proteins in either virus. The E2 of RRV dE2 migrated with a 
slightly greater mobility than did E2 of RRV T48. 
It is not known whether RRV virions contain E3 (Chapter 
1). Further, since in SFV, E3 is found associated with El and 
E2, a deletion in E2 of RRV dE2 may affect its interaction with 
E3 if E3 were present in RRV virions. To determine whether E3 
was present in RRV T48 and in RRV dE2, labelled RRV T48, RRV 
dE2 and SFV were purified in parallel and the viral proteins 
examined on a polyacrylamide gel (Figure 4.2). Both RRV T48 and 
RRV dE2 virions contained trace amounts of a protein of nominal 
mol. wt. 13,000 which had a slightly lower mobility than SFV E3 
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Figure 4.1 Structural proteins of RRV dE2 
and RRV T48. 
[ 3HJ-arnino acid labelled RRV T48 and RRV dE2 were 
purified in parallel. Virus was disrupted in 1% SDS 
and electrophoresed on a 10-20% gradient 
polyacrylarnide gel. The gel was fluorographed and 
exposed to X-ray film for a week at -7o 0 c. The 
positions of El, E2 and Care indicated. 
T, RRV T48; D, RRV dE2. 
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Figure 4.2 Structural proteins of RRV and SFV. 
A. [ 3HJ-amino acid labelled RRV T48, RRV dE2 and 
SFV were prepared and purified in parallel. Virus was 
d isrupted in 1% SDS, electrophoresed on a 10-20% 
gradient polyacrylamide gel and fluorographed. The 
f ilm was overexposed to allow detection of RRV E3 (see 
ar row). The positions of El, E2, C and E3 are 
indicated. T, RRV T48; S, SFV; D, RRV dE2. 
B. Extracellular tissue culture fluid from which 
t he virus had been removed by centrifugation was mixed 
wi th sample buffer containing SDS and electrophoresed 
on a separate polyacrylamide gel as above. The film 
was exposed for six weeks. Tissue culture fluids from 
mock infected cells (M), RRV T48 infected cells (T), 
SFV infected cells (S) and RRV dE2 infected cells (D) 
were examined. The position of E3 is indicated. 
A B 
TSD STDM 
E3 - - - E3 
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(see arrow in Figure 4 . 2A). A prote in of s imilar mo l . wt. wa s 
present in the corresponding extracellular flu i ds (Figure 4 . 2B ) 
and this is presumably RRV E3. SFV virions containe d E3 and no 
E3 was detected in SFV tissue culture fluid. Thus, as for SIN 
(Welch and Sefton, 1979), RRV E3 appears not t o be stable in 
virions and is released into the culture medium. 
To investigate the processing of RRV dE2 viral 
polypeptides, virus-specific proteins in infected BHK cells 
were labelled with [3HJ-amino acids, dissociated in 1% SOS and 
electrophoresed on a 10-20% gradient SDS polyacrylamide gel 
(Figure 4.3). In both RRV T48- and RRV dE2-infected BHK cells 
the following eight virus specific polypeptides were detected: 
pllO, p95, p80, PE2, El, E2, C and E3. No differences were 
observed in the migration of these polypeptides between RRV 
T48- and RRV dE2-infected cells except for PE2 and E2 of RRV 
dE2 which migrated slightly faster than the corresponding 
proteins in RRV T48 infection. 
These experiments provided no indication of differences 
in the processing and assembly of the structural polypeptides 
between RRV T48 and RRV dE2. The altered mobility of E2 from 
RRV dE2 virions and of E2 and PE2 in RRV dE2-infected cell 
extracts could be due to a reduced mol. wt. and changed 
conformation owing to the deletion of the seven amino acids. As 
E3 in RRV dE2-infected cells had the same mobility as E3 of RRV 
T48, it can be concluded that there was no alteration in the 
cleavage of PE2 to yield E2 and E3 in RRV dE2 infection. 
,:-
• l 
t 
,t" 
~· 
' ~ ; 
j.' 
;. ' .. !:;:;· 
~\ 
-.. ·,. 
" .. :· .. ·• . 
.,.._._ .. 
!j: 
J. •.• .. ;..··' 
,1:· .. •• 
t::~:, 
~:::; 
t, :-~ 
..... , 
f.:: 
~~::~. 
; :·. 
;.;:,"":--.· 
;(·~ 
,.._-. 
•"i..''• 
;;~-~. 
~,·..:-{~::: 
,."'-""'-' 
.. --~-..; 
:·.~ 
f:i 
,. .. 
.. ~:·.. . "· 
~ ... 
Figure 4.3 Viral proteins in RRV infected BHK cells. 
BHK cells were infected (moi-3) with RRV T48 (T), 
RRV dE2 (D) or mock infected with HBSS (M) and 
incubated for 2 hr from 23 hr pi in EMEM containing 
one-tenth the normal amino acid concentration and 25 
µCi/ml of [3HJ-amino acids. The cell monolayers were 
dissolved in 1% SDS and electrophoresed on a 10-20% 
gradient polyacrylamide gel. The gel was 
fluorographed and exposed to X-ray film for a week at 
-70°c. The position of viral proteins is indicated. 
M T D 
-p110 
.... -p95 
-p80 
-PE2 
-E1 
~E2 
-E3 
10 5 
4.3.5 Thermal instability of RRV dE2 
Studies on mutants of SIN have shown that many mutants 
which are altered in structural proteins are thermolabile 
(Strauss et al., 1976). Similarly, Faragher (1982) found that 
RRV dE2 is relatively heat sensitive at so 0 c. However 
Faragher (1982) did not investigate the mechanism responsible 
for the loss of virus infectivity. We have made an attempt to 
determine whether heat induced any structural changes in RRV 
dE2 virions which might correlate with the loss of infectivity 
at so 0 c. 
Samples of RRV T48 and RRV dE2 were incubated at 
so 0 c. As described by Faragher (1982) RRV dE2 infectivity 
decreased sharply with time (data not shown). Thus within 40 
min the RRV dE2 titer had been reduced by more than 4 log 
units, whereas the RRV T48 titer was reduced by less than one 
log unit. 
To detect aggregation or dissociation of virions at 
so 0 c, the sedimentation properties of heated and unheated RRV 
T48 and of heated and unheated RRV dE2 were compared. 
amino acid labelled purified RRV T48 and RRV dE2 were 
incubated separately at so 0 c for 40 min followed by 
sedimentation on sucrose gradients (Figure 4.4). For the 
unheated control samples (kept on ice) sharp radioactivity 
peaks of infectious virus were obtained. Only a small fraction 
(-4%) of the radioactivity was recovered from the bottom of the 
gradient. When heated RRV T48 was sedimented, approximately 18% 
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Figure 4.4 Effect of heat on the sedimentation 
properties of RRV T48 and RRV dE2 
virions. 
[ 3HJ-amino acid labelled purified RRV T48 (-88,000 
cpm) or RRV dE2 (-85,000 cpm) were incubated 
separately in HBSS for 40 min at 50°c. Controls were 
kept on ice. The virus was sedimented on a 10-30% 
sucrose gradient (in NTE buffer; 0.12 M NaCl, 0.012 M 
Tris pH 7.5, 0.001 M EDTA, 0.1% bovine serum albumin). 
Fractions were collected and counted for 
radioactivity. The per cent recovery of total 
radioactivity applied to the gradient is indicated. 
Radioactivity which sedimented to the bottom of the 
tube was recovered by dissolving the pellet in 
distilled water. 
a, unheated RRV T48; 
b, heated RRV T48; 
c, unheated RRV dE2; 
d, heated RRV dE2. 
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of the radioactivity pelleted. However, when heated RRV dE2 was 
sedimented, no radioactivity peak corresponding to the 
infectious virus was seen and approximately 38% of the 
radioactivity was recovered from the bottom of the gradient. 
From these results it would appear that when RRV dE2 is 
heated, the virus becomes aggregated and non-infectious. A 
similar process may occur with RRV T48 but to a smaller extent. 
4.3.6 Virus specific RNA synthesis in RRV T48-
or RRV dE2-infected BHK cells 
A striking feature of the preliminary study of RRV dE2 
was the ability of the mutant to induce a higher level of AMD-
resistant RNA synthesis in BHK cells than RRV T48, although EV 
titers were similar for the two viruses (Faragher, 1982). To 
determine if there were any differences in the species of RNA 
synthesised in the cells infected with RRV T48 or RRV dE2, 
infected BHK cells (moi-3) were labelled from 3-5 and 7-9 hr pi 
in medium containing [ 3HJ-uridine+AMD and RNA extracted and 
fractionated on sucrose gradients. Two major peaks representing 
the 49S and the 26S viral RNAs were seen in each case (data not 
shown). There was no significant difference in the ratio of 
26S and 49S RNA synthesis in RRV T48- and RRV dE2-infected BHK 
cells and no species other than the usual 26S and 49S RNAs were 
detected. It is difficult to envisage how a deletion in a 
structural protein could affect the rate of RNA synthesis. 
This may indicate a lesion in a non-structural protein, however 
it was not investigated. 
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4.3.7 Virulence of RRV dE2 and RRV T48 for mice 
Since some of the RRV antigenic variants changed i n E2 
had altered virulence (Chapter 3) it was of interest to 
determine if the deletion in E2 led to a change in the 
virulence of RRV dE2. The virulence of RRV dE2 and RRV T48 
were compared in day-old and week-old mice by measuring the 
LD 50 of the virus and the AST of infected mice (Table 4.2). 
RRV T48 was highly virulent for day-old mice with an 
LD 50 of 0.047 PFU; mice injected with low doses of virus showed 
severe hind leg paralysis and died with an AST of 4.93 days. 
RRV dE2 had a slightly greater LD 50 (0.066 PFU) and the 
infected mice survived significantly longer (AST 7.46 days) 
than those infected with RRV T48. Hind leg paralysis was less 
severe in day-old mice infected with RRV dE2 than in those 
infected with RRV T48. 
The LD 50 of RRV T48 and the AST of infected mice did 
not differ significantly between day-old and week-old mice. In 
contrast, RRV dE2 was completely avirulent in week-old mice. 
The virus did not kill mice even at high doses (-8 X 10 6 PFU 
injected i.p.) and elicited no clinical symptoms. Two weeks 
after RRV dE2 injection, mice were challenged with a high dose 
(-10 6 PFU) of RRV T48. None of the mice showed any disease 
symptoms and all survived the challenge, thus demonstrating 
previous RRV dE2 infection and its protecting power against the 
virulent virus. From these results it was concluded that RRV 
dE2 was slightly less virulent than RRV T48 in day-old mice 
Table 4.2 Virulence of RRV dE2 and RRV T48 for mice. 
Age of mice 
One day 
One week 
Virus 
RRV T48 
RRV dE2 
RRV T48 
RRV dE2 
LDSO * (PFU) 
0.047 
0.066 
( 3) 
( 3) 
0.0486 (6) 
>8xl0 (3) 
AST* (days) 
4.93 (4) 
7.46 (3) 
5.92 
NDRt 
( 4) 
( 3) 
*Figures presented are an average of a number of separate determinations (shown in brackets). 
tNDR = no deaths recorded. 
Virulence parameters for RRV T48 and RRV dE2 were compared using one-way analysis of variance and t-tests. The LD values for RRV dE2 differ significantly from those of ~fv T48 in both day-old and week-old mice (p<0.05). The AST values of day-old mice infected with RRV T48 or RRV dE2 are significantly different (p<0.05). 
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but, unlike RRV T48, was avirulent for week-old mice. 
4. 3. 8 Growth of RRV T48 and RRV dE2 in mice 
To determine whether the differences in RRV T48 and RRV 
dE2 virulence correlated with their growth and tissue 
distribution, virus growth was compared in day-old and week-old 
mice. Virus titers were examined in blood, brain and hind leg 
muscle tissues. Day-old or week-old mice were injected sub-
cutaneously (s.c.) with -100 PFU of RRV T48 or RRV dE2. Three 
mice infected with each virus were killed at 24 hr intervals, 
appropriate tissues removed and assayed individually for virus 
titers (Figure 4.5). 
Growth in day-old mice. In blood, RRV T48 attained a 
peak titer of -10 10 PFU/ml at 2 d pi after which it declined; 
at 4 d pi RRV T48 could not be detected. The peak RRV dE2 
titer in blood was -4 log units lower than for RRV T48 and at 
3 d pi RRV dE2 was not detected. 
In brain, RRV T48 attained a peak titer of -10 11 PFU/g 
at 2 d pi after which the titer declined until 4 d pi. The peak 
RRV dE2 titer of -10 7 PFU/g was at 2 d pi after which it 
declined gradually to about 10 5 PFU/g at 4 d pi. As no RRV 
T48 infected mice survived beyond this time point, the 
experiment was stopped. RRV dE2-infected mice survived at 
least 6 d pi. 
The highest titers for both RRV T48 and RRV dE2 were 
Figure 4.5 Growth of RRV T48 and RRV dE2 in mice. 
WEHI mice were injected s.c. with 100 PFU of 
virus. Mice were killed and tissues removed at 24 hr 
intervals. Virus titers were assayed in blood, brain 
and hind leg muscles. Each time point represents the 
average of separate determinations made in three mice. 
Error bars are shown where the error is greater than 
0.2 log units. Titers of less than 100 PFU/ml are 
indicated by an asterisk. 
RRV T48 titers in day-old mice, (.) ; 
RRV dE2 titers in day-old mice, ( O); 
RRV T4 8 titers in week-old mice, ( B) ; 
RRV dE2 titers in week-old mice, ( D) ; 
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reach ed in musc l e. RRV T48 gre w t o a peak ti t e r of - 10 12 PFU/g 
at 2 d pi. RRV dE2 attain ed a peak t it e r o f only -1 0 8 PFU/g . 
After 2 d pi RRV dE2 titers declined gradually unt i l 4 d pi 
when the experiment was stopped. 
Growth in week-old mice. In blood, RRV T48 attained a 
peak titer of -10 10 PFU/ml at 1 d pi. The titer did not change 
significantly until 3 d pi after which it declined gradually 
until 5 d pi. The peak RRV dE2 titer was -10 5 PFU/ml at 2 d pi 
after which the titer declined; virus was undetectable at 
4 d pi. 
In brain, RRV T48 reached a titer of -10 9 PFU/g which 
was maintained until 5 d pi. RRV dE2 titers were -5 log units 
lower than RRV T48. All RRV T48-infected mice had died at 6 d 
pi when the experiment was terminated. None of the RRV dE2-
infected mice died during the experiment. 
RRV T48 and RRV dE2 attained the highest titers in 
muscle tissue. RRV T48 reached a peak titer of -10 11 PFU/g at 
2 d pi which did not change markedly up to 5 d pi. RRV dE2 
grew to titers which were about 2 log units lower than RRV T48 
titers. 
In summary, for both viruses maximum titers in all 
tissues examined were at 1-2 d pi in mice of both age groups. 
The highest titers were in muscle. RRV dE2 grew to markedly 
lower titers than RRV T48 in all tissues of both one day-old 
and week-old mice. The greatest difference in the titers o f 
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the two viruses (-5 log units) was in the brain tissue of week-
old mice. 
4. 3. 9 Growth of RRV T48 and RRV dE2 in primary mouse cells 
To determine whether the differences in titers of RRV 
T48 and RRV dE2 seen in mice were due to an intrinsic 
difference in ability of the two viruses to replicate in mouse 
cells, their growth was compared in primary mouse muscle and 
skin cell cultures. These were chosen as the hind leg muscle 
is the major site for RRV replication (Chapter 1) and epidermal 
tissue is likely to be the initial site of replication in a 
natural RRV infection. Primary mouse brain cells were 
difficult to culture (R.W. Boulton, personal communication) and 
were not used in these studies. 
In muscle cells infected at an moi -1, RRV T48 grew 
slowly and reached a maximum titer (-10 6 PFU/ml) at 72 hr pi 
(Figure 4.6). RRV dE2 showed similar growth kinetics. At 48 hr 
pi, massive cytopathic effects (cpe) became visible in both RRV 
T48 and RRV dE2 infected cells. 
Both RRV strains grew poorly in skin cells infected at 
an moi -1. The peak titer for each was -10 5 PFU/ml at 48 hr pi 
(Figure 4. 6) . Skin cells infected with RRV T48 showed no cpe 
during the experiment. However, cpe was visible at 48 hr pi in 
cells infected with RRV dE2. 
It can be concluded that RRV T48 and RRV dE2 did not 
differ in their growth in primary mouse muscle cells or skin 
Figure 4.6 Growth of RRV T48 and RRV dE2 in primary 
mouse cells. 
Primary mouse muscle or skin cell monolayers were 
infected (moi-1) with virus and incubated at 36° C in 
GMEM + 10% serum. At intervals samples were removed 
from the culture medium, diluted 10-fold into HBSS and 
stored at -7 0° C. EV titers were assayed by plaque 
formation on Vero cell monolayers. 
RRV T4 8 titers in muscle cells, ( •) ; 
RRV dE2 titers in muscle cells, ( O) ; 
RRV T48 titers in skin cell, 
RRV dE2 titers in skin cells, 
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cell cultures. However, it is possible that cultured mouse 
cells are not fully representative of the tissue in vivo. 
4.3.10 Mixed infection of mice with RRV T48 and RRV d.E2 
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One reason for the reduced RRV dE2 titers seen in mice 
(Figure 4.5) could be that it induced an enhanced host response 
(e.g. interferon production) compared to RRV T48. If this were 
true, RRV T48 might be expected to grow to lower titers in mice 
when injected together with RRV dE2. 
To examine this, day-old mice were injected s.c. with a 
mixture containing -100 PFU each of RRV T48 and RRV dE2. 
Control mice were injected with -100 PFU of RRV T48 or RRV dE2 
separately. Mice were killed daily and blood, brain and hind 
leg muscle tissues removed to assay virus titers. It was 
anticipated that if RRV T48 and RRV dE2 grew to similar levels, 
an estimate of the individual titers could be made on the basis 
of their different plaque morphologies. However, if RRV T48 
grew to higher titers than RRV dE2 (as above), it would not be 
possible to assay RRV dE2 titers as the larger RRV T48 plaques 
would overgrow the smaller plaques of RRV dE2. 
Figure 4.7 shows that in control mice RRV dE2 grew to 
lower titers than RRV T48, as earlier. In mice injected with 
both viruses, RRV T48 grew to high titers as in control mice. 
As RRV dE2 could not be detected by plaque assay in any of the 
samples from mice infected with both viruses simultaneously, it 
would appear that RRV dE2 grew to far lower titers than RRV 
Figure 4.7 Growth of RRV T48 and RRV dE2 in mice 
during mixed infection. 
Week-old WEHI mice were injected s.c. with a 
mixture containing 100 PFU each of RRV T48 and RRV 
dE2. The control mice were injected subcutaneously 
with 100 PFU of RRV T48 or RRV dE2. Virus in blood, 
brain and hindleg muscles was assayed at various time 
intervals. Each time point represents the average of 
determinations made in three mice. Error bars are 
shown where errors are more than 0.2 log units. 
RRV T4 8 titers in control mice, ( O) ; 
RRV dE 2 titers in cont r o 1 mice, ( • ) ; 
RRV T48 titers in mice infected 
with both RRV T48 and RRV dE2, ( 0) . 
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T48. Although it was not possible to come to an unequivocal 
conclusion about the growth of RRV dE2 for this reason, the 
possibility that the low RRV dE2 titers were due to some host 
response that did not affect RRV T48 seems unlikely. 
4.3.11 Stability of RRV T48 and RRV dE2 in mouse serum 
To determine whether the low RRV dE2 titers reached in 
vivo were due to the lability of the mutant in blood, RRV dE2 
and RRV T48 were incubated in non-immune mouse serum at 37°c 
for 2 hr. Samples were removed and assayed for virus 
infectivity. Neither RRV T48 nor RRV dE2 lost any infectivity 
over the 2 hr period (data not shown). This suggested, but did 
not prove, that there were no differences in stability of RRV 
T48 and RRV dE2 in serum which might explain the differences in 
titers reached in the mouse. 
4.4 DISCUSSION 
The studies described in this Chapter were aimed at 
examining the effects of a deletion in E2 on the biological 
properties of RRV T48. There have been previous reports of 
alphavirus mutants with deletions in the major glycoproteins 
(Bracha and Schlesinger, 1978, Leone et al., 1980). However, 
in no case was a precise identification of the deletion made or 
its effect on the biological properties of the virus examined 
in an experimental animal. Bracha and Schlesinger (1978) 
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isolated a SIN variant which had lost approximately 30 amino 
acids from the N-terminus of E2 as a result of an aberrant 
proteolytic cleavage of the precursor PE2. The variant did not 
differ from the parental virus in plaque morphology or single 
step growth kinetics in BHK cells. Leone et al. (1980) isolated 
a SIN mutant in which El had lost approximately 70 amino acids. 
The mutant retained the capacity for haemagglutination and did 
not differ significantly in its structure and growth in 
cultured cells from wild type virus. 
The fact that large deletions in the major alphavirus 
envelope proteins can be tolerated without eliminating viral 
infectivity may seem surprising as there is strong size 
conservation and amino acid sequence homology in E2 between 
RRV, SFV and SIN (Dalgarno et al., 1983). Although RRV dE2 is 
viable under laboratory conditions, the effects of the deletion 
on virus survival in the field are not known . However, the 
data on RRV dE2-viraemia in mice suggests that natural 
transmission of the deletion mutant by mosquito vectors would 
be unlikely. 
4.4.1 Virulence and growth of RRV dE2 in mice 
RRV dE2 was only slightly less virulent than RRV T48 in 
day-old mice, but it grew to far lower titers (-3-4 log units) 
than RRV T48. Significantly, although the virulence of RRV T48 
did not differ between day-old and week-old mice, RRV dE2 was 
avirulent for week-old mice. There was no significant 
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difference in peak RRV T48 titers in the blood or hind leg 
muscle of day-old and week-old mice. A similar conclusion was 
reached for RRV dE2. However, differences between RRV dE2 and 
RRV T48 titers in brain were greater in week-old mice than in 
day-old mice. Although no experiments examining virus 
distribution in different parts of brain were done, it seems 
possible that the avirulence of RRV dE2 for week-old mice was 
due to a changed cell tropism within the brain. Fields and 
Green (1982) have reported that mutants of reovirus type 3 
changed in structural proteins had altered tissue tropism in 
mice. 
The lower RRV dE2 titers in mice were probably not due 
to a defect in intracellular events in viral replication as RRV 
dE2 showed no differences in growth in BHK cells or in primary 
mouse cells when compared with RRV T48. Nor did the poor 
growth of RRV dE2 appear to be the result of enhanced 
interferon induction since when RRV dE2 and RRV T48 were used 
to coinfect mice, the growth of RRV T48 was similar to that 
obtained when it alone was used for infection. The differences 
in titer were probably not the result of different degrees of 
inactivation of the two viruses in mice as there was no 
difference in the rate of loss of infectivity of the two 
viruses after a two hr incubation in mouse serum at 37°c. 
Further, it is unlikely that the low RRV dE2 titers in mice 
resulted from an enhanced specific immune response to RRV dE2 
since this would need to occur shortly after infection and be 
specific for RRV dE2. However polyclonal antibody does not 
distinguish RRV T48 and RRV dE2 in neutralisation t ests 
(Faragher, 1982). 
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It has recently been shown that the E2-specific 
monoclonal antibody NB3C4 neutralises RRV dE2 infectivity 1000 
times less efficiently than RRV T48 infectivity (R.C. Weir, 
personal communication). This indicates that changes have 
occurred in the conformation of the "neutralisation domain" in 
RRV dE2 which may be involved in virus entry (Chapter 3). It 
is possible that the different growth profiles of RRV dE2 and 
RRV T48 in mice are due to alterations in the entry of the 
virus resulting from conformational changes in E2. These 
changes appear to have induced greater effects on replication 
in mice than on patterns of growth in cultured cells. This is 
surprising but consistent with results from Barie et al. (1981) 
and Olmsted et al. (1984). Barie et al. (1981) isolated a 
rapidly growing mutant of SIN by selecting for virus released 
early in infection of BHK cells. The variant had an increased 
rate of "penetration" (see Chapter 1) into BHK cells (but not 
into other cell types), and from neutralisation studies with 
mabs was probably altered in E2. Olmsted et al. (1984) showed 
that virus selected in this way was of reduced virulence for 
mice and that rapid penetration into BHK cells was strongly 
correlated with attenuation in mice. Barie et al. (1981) 
concluded that the class of cellular receptors active in SIN 
uptake by BHK cells is of low specificity compared with that 
involved in penetration in mouse cells . 
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The attenuation of virulence of RRV dE2, together with 
the protection of RRV dE2-immunised mice against lethal 
challenge with RRV T48, suggests that selection or generation 
of deletion variants may provide a useful route to stable (non-
reverting) virus variants suitable for use as safe alphavirus 
vaccines. 
4. 4. 2 RRV pathogenesis in mice 
It has previously been argued that RRV pathogenesis in 
infant mice is not typical of alphaviruses since it does not 
involve early and rapid replication in neural tissues but is 
accompanied by extensive replication in non-neural tissues, 
particularly skeletal (hind leg) muscle (Mims et al., 1973; 
Murphy et al., 1973). By contrast SFV produces widespread 
infection and necrosis in the central nervous system and death 
takes place before there is time for the evolution of the 
pathological changes seen with RRV (Mims et al., 1973). Murphy 
et al. (1973) proposed that the muscle lesions produced by RRV 
in newborn mice explain the paralysis seen in RRV infection 
since the type of involvement of brain and spinal cord which 
could account for this paralysis was not seen. 
Using the same outbred strain of mice as that used by 
Murphy et al. (1973) we have shown in this Chapter that the 
loss of virulence of RRV dE2 in week-old mice is accompanied by 
a sharp reduction in virus replication in brain tissue (Figure 
4.5) by comparison with that seen in day-old mice. In Chapter 
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5 of this thesis we show that an attenuated variant of RRV T48 
obtained by serial passage in BHK cells grows to lower titers 
in mouse brain compared to RRV T48, although no differences 
were seen in the hind leg muscle titers. Recently, Meek (1986) 
showed that virulent variants of RRV NB5092 obtained by serial 
passage in mice, grow to higher titers in brain with little 
change in hind leg muscle of day-old mice. Furthermore, Seay 
and Wolinsky (1982) and Kingston (1983) have reported that RRV-
induced central nervous system demyelination occurs in a way 
which suggests a causal relationship with paralysis. 
Considered together these data suggest that RRV replication 
brain tissue may be a more important determinant of viral 
virulence than the extent of replication in hind leg muscle 
tissue. 
' in 
CHAPTER 5 
STUDIES ON ATTENUATED VARIANTS 
OF RRV T48 
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5.1 INTRODUCTION 
In the previous Chapters it was shown that certain 
point mutations or a deletion in E2 resulted in attenuation of 
RRV virulence for mice. Thus E2 protein is one of the 
determinants of RRV virulence. In this Chapter we examine 
whether attenuation of RRV virulence achieved by virus 
passaging in tissue culture cells is accompanied by change(s) 
in E2. This was prompted by the observation of Barie et al. 
(1981) who isolated a mouse-attenuated variant of SIN by serial 
passage in BHK cells. The variant was changed in neutralisation 
epitope(s) of E2 as judged by its reactivity pattern with anti-
E2 neutralising mabs, although the change(s) in the structural 
protein was not identified by sequencing (Olmsted et al., 
1986). 
We describe here the isolation of attenuated variants 
of RRV T48 by serial passage in BHK cells using the method of 
Barie et al. (1981). The virulence of the resulting passaged 
virus is measured in mice to determine the degree of 
attenuation. Growth of one such attenuated variant in mice is 
investigated to examine whether changes occurred in tissue 
tropism on virulence attenuation. The properties of the 
attenuated variants are examined in BHK cells to identify any 
changes which may be associated with virulence attenuation in 
mice. Finally the nucleotide sequence of the structural 
protein genes of the variants is determined and compared with 
the parental RRV T48 sequence to identify any mutation(s) 
accompanying attenuation. 
5.2.1 
5.2.2 
5.2 MATERIALS AND METHODS 
Virus, cells and plaque assay 
These have been described previously (Chapter 2). 
Serial passage of RRV T48 in BHK cells 
(Barie et al., 1981) 
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A BHK monolayer was infected with RRV T48 (moi -40); 
adsorption was at 36°c for 1 hr. The monolayer was washed (x2) 
with PBS and incubated with GMEM + 8% bovine serum at 36°c. 
Virus was harvested 5.5 hr after the end of the adsorption 
period and used undiluted for the next passage. This process 
was carried out eleven times and virus plaque purified from the 
12th passage. 
5.2.3 Estimation of viral virulence for mice 
LD 50 s and ASTs were determined in week-old mice as in 
Section 3.2.7. The clinical dose (CD 50 ) was the dose required 
to produce clinical symptoms (hind leg paralysis) in 50% of the 
mice inoculated (Reed and Muench, 1938). One-way analysis of 
variance and t-tests were performed to compare the virulence 
parameters of RRV T48 and the passaged variants. 
5. 2. 4 
5.2.5 
5.2.6 
Rate of AMD-resistant RNA synthesis 
Rates were determined as described in Section 3.2. 5 . 
Rate of acquisition of resistance by infecting virus 
to neutralisation by added polyclonal antibody 
The method has been described in Section 3.2.4. 
Extraction of infected cell RNA and sequencing of 
viral RNA 
The procedures were as described in Sections 2.2.14 
and 2.2.15. 
5.3 RESULTS 
5.3.1 Serial passage of RRV T48 in BHK cells 
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In an attempt to generate attenuated variants of RRV 
T48, a BHK monolayer was infected at a multiplicity of -40 and 
progeny virus was harvested at 6.5 hr pi. The harvest was used 
undiluted as inoculum for next passage. Serial passage was 
continued blind in this way for 12 passages. The titers of RRV 
at the different passage levels indicate that from the second 
passage onwards BHK cells were infected at a multiplicity of -1 
(Table 5.1). Six plaque purified isolates (RRV P12/1-6) were 
Table 5.1 Virus titers at different passage levels 
during serial passage of RRV T48 in BHK cells. 
Passage level Titer (PFU/ml)* 
1 2.0 X 10 6 
3 2.8 X 10 6 
5 4. 1 X 10 6 
7 2.0 X 10 6 
9 2.2 X 10 6 
11 1.7 X 10 6 
12 1.0 X 10 6 
*at 6.5 hr pi. 
obtained from the 12th passage material (see Table 5 . 2 for 
nomenclature). 
5.3.2 Virulence of BHK-passaged variants for 
week-old mice 
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In previous Chapters it was observed that virulence 
changes were more pronounced in week-old mice than in day-old 
mice. Therefore virulence of RRV Pl2/2, RRV Pl2/4, RRV P12/5 
and RRV Pl2/6 was determined in week-old mice and compared with 
that of RRV T48. The LD 50 s of the variants and ASTs of 
infected mice are shown in Table 5.2. 
RRV T48 was highly virulent (LD 50 = 0.05 PFU) and 
infected mice showed severe hind leg paralysis at 3-4 d pi. 
All RRV T48-infected mice showing paralysis died eventually 
(LD 50 :cD50 ratio= 1:1) with an AST of 5.9 days. The virulence 
of all the passaged variants was significantly lower than that 
of RRV T48 (p<0.05). The LD50S for RRV Pl2/2, RRV Pl2/4 and 
RRV Pl2/5 were 0.23, 0.63 and 0.83 PFU respectively which did 
not differ significantly from each other. However, the LD 50 of 
RRV Pl2/6 was 1.48 PFU which was significantly different from 
that of the other isolates assayed (p<0.05). 
As for mice infected with RRV T48, mice infected with 
the passaged variants also showed hind leg paralysis at 3-4 d 
pi; however the AST (-10 days) was approximately twice that of 
mice infected with RRV T48 (p<0.05). Thus the passaged 
variants had a wider range of LD 50 values (5-30 times) than of 
AST values. 
Table 5.2 Virulence of BHK passaged RRV variants 
for week-old mice. 
Virust LD 50 (PFU)* AST (days)* 
RRV T48 0.05 ( 6) 5.9 ( 4 ) 
RRV P12/2 0.23 ( 3) 10.2 ( 3) 
RRV P12/4 0.63 ( 3) 9.7 ( 3) 
RRV P12/5 0.83 ( 3) 9.1 ( 3) 
RRV P12/6 1.48 ( 3) 10.1 ( 3) 
t Nomenclature: RRV P12/2 indicates RRV clone 2 
derived from 12th passage material. 
* Figures are the average of a number of separate 
determinations (shown in brackets). The LD 50 s and 
the ASTs of all the passaged variants were 
significantly different from those of RRV T48 
(p<0.05). The LD50S of RRV P12/2, 4 and 5 did not 
differ significantly from each other, although they 
were significantly different from that of RRV P12/6 
(p<0.05). The ASTs of the passaged variants did not 
differ significantly from each other. 
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A significant number of variants infected mice showing 
paralysis recovered within 7-10 days after the symptoms were 
first seen. A rough estimate of LD 50 :cD50 ratio was 10:1 to 
100:1, although a precise estimate of CD50 could not be made 
due to a shortage of mice. 
We conclude that attenuation of virulence occurred on 
serial passage of RRV T48 in BHK cells and that RRV Pl2/6 was 
the most attenuated of the four passaged variants examined. 
5.3.3 Growth of RRV P12/6 in mice 
To determine whether attenuation correlated with 
changes in growth kinetics, titers reached and tissue 
distribution of virus in mice, the growth of RRV Pl2/6 and RRV 
T48 was compared in week-old mice (Figure 5.1). 
The results obtained with RRV T48 were similar to those 
reported previously. In blood, RRV T48 could be detected at 
1 d pi. The peak titer (-10 10 PFU/ml) was reached at 2 d pi. 
The titer declined slightly at 3 d pi and was followed by a 
marked reduction at 4 and 5 d pi. No mice injected with RRV 
T48 survived beyond 5 d when the experiment was stopped. RRV 
Pl2/6 was also found in blood by 1 d pi. However, the peak 
titer (also at 2 d pi) was -2 log units lower than that of RRV 
T48. Subsequently, the RRV Pl2/6 titer declined and was <100 
PFU/ml at 5 d pi. 
In brain, RRV T48 attained a peak titer of -10 8 PFU/g 
at 2 d pi after which it declined slowly. The peak titer of 
I 
,1. 
j; 
.. 
'· 
.. 
· . . 
,. ·.· 
:~>'." 
-··.·· ,.,- .... , 
:.:~ :~ 
-
~:--.: 
£::::; 
;-:--:~ 
,;.··" 
6 • .. •• 
·~:=.·~: . 
... .. . -~ 
~.. . ....
tJ 
t? ;. > ..j,.~-.;~, 
;::·~ 
::~\~: 
;~~} . 
... ,·( 
_,:,.·. 
;.~~!~: 
t:>: 
... 
~>~·. 
r:::~~: 
~;·/ f':.:· 
.1,·/· 
~- . 
ti} 
;::~;:: 
!lfi 
~---·< 
t··-···-
t} 
......... . 
.. ; -~---i. ·• • 
··./·· ~ · .. -~ 
,·. 
' .. · ;,. 
r:::\. 
y .·,,. 
•" r./ 
f:;\: 
.:-·:-- ·' 
:; .:• 
t) 
t~~::~ 
~-,--
f:/ 
~- • . 
. '...,,., 
..... 
\ '· ~- ~ 
tJ 
t}t 
,'·• \.", (} 
f;·.;.: 
:,"',·:··. 
l'Jlf ... 
:~:~ .. \~ 
i-'·'" ~ '~'";:~ {j 
;,''~ 
. - \; :-:.~ 
r:-: .. ~ 
~ .:,.. 
~ .. (:: (~ 
f:~ 
,·,< 
~-·~'\, 
~::;~ 
,.;.,;· 
r .. ~: 
~* \P, ,{• 
t:~ ~:~ 
,,_-"J_,· 
,..~ 
, .. ,_. 
~·· ./ 
•""'j (:~ 
, i-1. ,, ... ,., 
p:~ 
~;:Z;o:, 
r. ,'{(.-ft 
~:-.tz-~~ 
~-:~.-
~··'.Z,(~ 
,:;{~£·. 
, .... ~ ., 
•. :r_.,..'::.,; 
',:~/.-; 
<.r;,:j 
~;;~ 
.' 
..... ~~. ;,,·. ~ 
. ... .-,;-,..,, f.: ..... :-:·:r::.·*-·-.. C. :·.~: ..... , • 
Figure 5.1 Growth of RRV T48 and RRV P12/6 in mice. 
Week-old WEHI mice were injected i.p. with 100 PFU 
of virus. Mice were killed and tissues removed at 24 hr 
intervals. Virus titers were assayed in blood, brain 
and hind leg muscle. Each time point represents an 
average of determinations made in three mice. Error 
bars are shown where the error is greater than 0.2 log 
units. Titer less than 100 PFU/ml is indicated by an 
asterisk . 
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RRV Pl2/6 was -10 6 PFU/g and was reached at 2 d pi after which 
there was a gradual decline. 
In hind leg muscle, RRV T48 reached a peak titer of 
-10 10 PFU/g at 2 d pi which then declined until 5 d pi. RRV 
P12/6 reached roughly the same titer (10 10 PFU/g) at 2 d pi. 
Thus no significant difference was observed in hind leg muscle 
titers of RRV P12/6 and RRV T48. 
In summary, RRV P12/6 reached markedly lower titers in 
the blood and brain tissues of week-old mice than did RRV T48. 
Since the two viruses grew to similar titers in hind leg muscle 
tissue this suggests that a change in tissue tropism of the 
passaged variant had taken place. 
5.3.4 Replication of RRV P12/6 in BHK cells 
Growth kinetics. The growth kinetics of RRV T48, RRV 
Pl2/6 and RRV P6/l (a variant from an intermediate passage 
level) were examined in BHK cells; samples were taken at 2 hr 
intervals. For all three viruses the first increase in EV 
titer was at 2-4 hr pi (data not shown). At 12 hr pi both 
variants and RRV T48 had reached a titer of -10 7 PFU/ml. Thus 
no significant difference was observed between RRV T48 and the 
variants in growth kinetics in BHK cells. 
RNA synthesis. Rates of viral RNA synthesis in RRV 
T48- and RRV Pl2/6-infected BHK cells were compared by 
measuring the incorporation of [3HJ-uridine (Figure 5.2). 
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Figure 5.2 AMD-resistant RNA synthesis in BHK cells 
infected with RRV T48 or with passaged 
variants. 
BHK cell monolayers were infected with RRV T48 or 
with variants (moi-1), or mock-infected with HBSS, and 
incubated in GMEM + 8% bovine serum. At intervals, 
monolayers were labelled for two hour periods with EMEM 
containing 10 µCi/ml of [5- 3HJ-uridine (indicated in 
the Figure are the middle of labelling periods) and 
incubated at 36°c. Infected cells were labelled in the 
presence of 5 µg/ml AMD; mock-infected cells were 
labelled in the absence or presence of 5 µg/ml of AMD. 
Monolayers were dissociated in 200 µl of 1% SDS and the 
acid-precipitable radioactivity in 20 µl of the 
resulting extracts (representing -2 x 10 5 cell 
equivalents) determined. 
Incorporation of [3HJ-uridine in: 
-mock infected cells without AMD, ( •) . 
-mock infected cells with AMD, ( D) . 
-RRV T48 infected cells, 
-RRV P6/1 infected cells, 
-RRV Pl2/2 infected cells, 
-RRV Pl2/4 infected cells, 
-RRV P12/5 infected cells, 
-RRV Pl2/6 infected cells, 
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Viral RNA synthesis was detected at 2 hr pi for both viruses, 
although the rate was higher in RRV P12/6 infected-cells 
compared to that in RRV T48 infected-cells. Peak RNA synthesis 
was at 10 hr pi in both cases, however the rate in RRV P12/6 
infected cells was approximately three times greater than in 
RRV T48 infected cells. A similar result was observed for RRV 
Pl2/1, RRV P12/4, RRV P12/5 and RRV P6/1 (Figure 5.2). There 
was no obvious correlation between the rate of RNA synthesis in 
BHK cells and the virulence of the virus for mice. 
Viral polypeptide synthesis. Viral polypeptide 
synthesis in BHK cells infected with RRV P12/6, RRV Pl2/5 and 
RRV T48 (moi -1) was followed by labelling with [ 3HJ-amino 
acids at 3-5, 10-12 and 23-25 hr pi. Cell extracts were 
electrophoresed on a 10-20% gradient polyacrylamide gel. At 3-
5 hr pi, two virus-specific proteins, p80 and C, were detected 
in RRV T48-infected cells; both were also seen in the cells 
infected with the variants at the same time (data not shown). 
At 10-12 hr pi, eight virus-specific polypeptides, pllO, p95, 
p80, PE2, El, E2, C and E3, were seen in cells infected with 
RRV T48 and with the variants (data not shown). There was no 
difference in shut down of host protein synthesis or in the 
mobilities of virus-specific proteins between RRV T48 and the 
· variants. A similar conclusion was drawn from labelling at 23-
25 hr pi. Thus there was no difference in the time course of 
viral polypeptide synthesis or in shut down of the host protein 
synthesis between cells infected with RRV T48 or with variants 
12 5 
during the time periods examined in this experiment . 
Rate of acquisition of resistance by infect i ng RRV 
P12/6 to neutralisation by added polyclonal antibody . Barie et 
al . (1981) observed that the BHK- passaged variants of SIN 
showed a rapid "penetration " in BHK cells as judged by the 
rate of acquisition of resistance of the infecting virus to 
neutralisation by polyclonal antibody. We have examined the 
rate of "penetration " of RRV P12/6 , RRV Pl2/5 and RRV T48 in 
BHK cells using the method of Barie et al . (1981). BHK 
monolayers were inocul a ted with - 100 BHK PFU of virus and 
incubated at 36°c for 10 , 20 , 30 , 40 and 60 min followed by 
addition of polyclonal antibody for 10 ' min . After washing to 
remove exce s s antibody , ov e rl a y medium wa s added and plates 
incubated for plaque development . Figure 5 . 3 shows the rate of 
acquisition of neutralisation resi s tance by RRV P12/6, RRV 
P12/5 and RRV T48 . By 20 min , -5% of RRV T48 and RRV P12/6 had 
acquired resistance to neutralisation ; by comparison the figure 
was - 20% for RRV Pl2/5 . By 40 min -10% of RRV T48 had acquired 
resistance to neutralisation . Corresponding figures for RRV 
P12/6 and RRV P12/5 were -20% and -35% respectively . At 60 
min , -25% of RRV T48 and -50% of RRV P12/5 and RRV Pl2/6 had 
acquired neutralisation resistance . The results for RRV T48 
were similar to those reported by Barie et al . (1981) for SI 
We conclude that passaged variants "penetrated" BHK cells mo re 
rapidly than did RRV T48 . 
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Figure 5.3 Rate of acquisition of neutralisation 
resistance by passaged variants to added 
polyclonal antibodies. 
BHK cell monolayers in 60 mm dishes were infected 
with -100 BHK PFU of RRV T48 or variants. At the 
designated times, the inoculum was removed and 0.5 ml 
of polyclonal anti-RRV T48 immune ascitic fluid 
(diluted 1:10 in HBSS) was added. After 10 min at 36°c 
the antibody was removed, the monolayer washed (x2) 
with PBS and overlayed for plaque development. The 
number of plaques obtained after a 60 min adsorption, 
PBS wash, but no antibody treatment was taken as 100% 
for each virus. Each assay was done in triplicate and 
the average values are plotted with error bars showing 
the standard error of mean. 
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5.3.5 Sequence studies on the structural protein genes of 
passaged variants 
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The two most striking observations described above are 
(i) that RRV P12/2,4,5 and 6 had significantly higher RNA 
synthetic rates than RRV T48, and (ii) that RRV P12/5 and RRV 
P12/6 acquired resistance to neutralisation by polyclonal 
antibodies more rapidly than RRV T48. This suggests that 
mutants with changes in both the structural and non-structural 
protein genes may have been selected during BHK cell passage. 
However, initial sequence studies (described below) were 
directed at the structural protein genes because of the 
availability of primers (Section 2.2.15). 
The sequence of the genes encoding El, E2, E3, C and 
the 6K proteins of RRV T48 and RRV P12/2, RRV P12/4, RRV P12/5 
and RRV P12/6 was determined by dideoxy sequencing of infected 
cell RNA using synthetic oligodeoxynucleotides as primers. 
None of the four passaged variants showed nucleotide changes 
from the RRV T48 sequence between nucleotides 1 and 4010 of the 
26S RNA (Dalgarno et al., 1983) (data not shown). There were, 
however, 156 positions out of -4000 at which the nucleotide 
could not be identified due to cross bands in all 4 lanes of 
the sequence ladder. These positions were randomly distributed 
throughout the region sequenced. At these positions the RRV 
T48 sequence ladder also showed cross bands suggesting that 
there was no sequence difference at these positions although 
the possibility of mutation/sin these positions could not be 
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ruled out completely. Positions at which mutations occurred in 
the mab-resistant variants of RRV T48 (Chapter 2) were 
sequenced satisfactorily, however. Sequencing of the non-
structural protein genes was not attempted due to time 
limitations. 
5.4 DISCUSSION 
Serial passage of virus in tissue culture cells has 
often been employed to attenuate virulence (Olmsted et al., 
1984). Consistent with this, serial passage of mouse virulent 
RRV T48 in BHK cells resulted in selection of variants which 
had reduced virulence for week-old mice. The LD 50 s of variants 
obtained after 12 BHK passages were 5-30 times greater than RRV 
T48 and the ASTs of mice infected with the passaged variants 
were about twice those of RRV T48 infected mice. Thus the 
change in virulence was greater than that seen in mab-
resistant variants of RRV T48 where only about a four-fold 
change in LD 50 was observed (Chapter 3). Results described in 
this Chapter are consistent with those of Barie et al. ( 1981) 
who reported that the BHK passaged SIN was attenuated in mice, 
although they did not report the extent of attenuation or the 
method of measurement. In this context it is of interest that 
with ten serial passages of mouse-avirulent RRV NB5092 in mice, 
variants were selected in which the Lo50 had changed -10 6-fold 
(Meek, 1986). 
128 
In the present study, all RRV T48 infected mice which 
developed paralysis died eventually, thus giving a LD 50 :cD50 
ratio of one, consistent with levels previously reported for 
virulent virus (Taylor, 1972; Meek, 1986). However a 
significant number of mice infected with the passaged variants 
recovered after showing paralysis. The LD 50 :cD50 ratio was 
between 10:1 and 100:1 indicating an attenuation of virulence. 
The significantly different levels of virulence of passaged 
variants plaque purified from the same passage level (Table 
5.2) indicate that virus obtained after passaging was 
heterogeneous in virulence. Taylor and Marshall (1975) and 
Meek (1986) who passaged RRV NB5092 in mice to enhance 
virulence also observed sub-populations of different virulence 
in passaged virus stock. 
Since the virus was plaque purified before passaging it 
seems likely that attenuated virus appeared spontaneously 
during passaging rather than resulting from the amplification 
of pre-existing mutants in the starting virus stock. As the 
virus was harvested, during passaging, at 6.5 hr pi, soon after 
the end of the latent period (Martin et al., 1979) it is likely 
that the rapid replication in BHK cells was the selection 
pressure for the variants. In fact all the passaged variants 
synthesised RNA at a significantly higher rate than RRV T48, 
although this did not confer any growth advantage on the 
passaged variants in terms of the EV titers. This is analogous 
to the situation in RRV dE2 which synthesised RNA at a 
significantly higher rate than RRV T48 in BHK cells, although 
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the EV titers of the two viruses did not differ (Chapter 4). 
Our results showing increased rates of RNA synthesis by RRV T48 
passaged variants are similar to those reported by Barie et al. 
(1981) where the maximal rate of RNA synthesis by attenuated 
SIN in BHK cells was twice that of the parental virus. 
However, in contrast to our findings, attenuated SIN had a one 
hour shorter latent period and one log unit higher titers than 
the parental virus throughout the growth cycle in BHK cells 
(Barie et al., 1981). A change in the rate of viral RNA 
synthesis may also be expected to affect the kinetics of 
protein synthesis. However, no differences were seen in the 
kinetics of viral protein synthesis between BHK cells infected 
with RRV T48 or with the passaged variants during the limited 
time periods examined in the experiment. A comprehensive study 
of the kinetics of protein synthesis by the passaged variants 
needs to be carried out by labelling the infected cells more 
frequently. 
The growth of RRV Pl2/6, the most attenuated of all the 
passaged variants examined, was compared with that of RRV T48 
in week-old mice. Although the two viruses grew to similar 
titers in hind leg muscle, RRV Pl2/6 grew to peak titers in 
brain and blood which were -2 log units lower than RRV T48, 
suggesting a change in tissue tropism. This is consistent with 
the previous conclusion (Chapter 4) that virus replication in 
the brain is more critical for RRV virulence than its 
replication in hind leg muscle. 
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During infection of BHK cells, passaged variants of RRV 
T48 acquired resistance to neutralisation more rapidly than did 
RRV T48. Thus by 60 min -50% of the RRV Pl2/5 or RRV Pl2/6 had 
acquired resistance to neutralisation compared to -25% for RRV 
T48. This observation is consistent with the findings of Barie 
et al. (1981) although the rates were much faster than seen in 
present case; thus after 60 min -100% of the BHK passaged, 
attenuated SIN had acquired resistance to neutralisation 
whereas corresponding figure for parental SIN was -40%. We 
have not explored the question of whether the change in rate of 
acquisition of neutralisation resistance is due to a faster 
attachment or a faster penetration of virus. Barie et al. 
(1981), however, concluded that the passaged SIN penetrated the 
cells faster since there was no difference in attachment of the 
passaged SIN and the parental virus. 
Barie et al. (1981) and Olmsted et al. (1986) concluded 
that change(s) had occurred in neutralisation epitope(s) of E2 
in the BHK passaged, attenuated SIN. However, mutation(s) in 
the structural protein gene(s) were not identified by 
sequencing. In our case an apparent change in tissue tropism 
and the change in "penetration" rate suggest that change(s) 
have taken place in the envelope proteins of RRV T48 during 
passaging in BHK cells. Surprisingly, no mutations could be 
detected in the genes coding for El, E2, E3, C or the 6K 
proteins of RRV Pl2/2,4,5 and 6, although the possibility could 
not be ruled out rigorously due to the problem of cross bands. 
Mabs could be employed to explore the possibility that changes 
in conformation of envelope proteins of the virus had occurred. 
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Since BHK-passaged variants of RRV T48 synthesised RNA 
at a significantly higher rate than RRV T48, it seems likely 
that mutations have also occurred in the sections of the genome 
controlling viral RNA synthesis. The variants, therefore, 
could be useful in identifying important regions of the non-
structural protein gene(s) involved in viral RNA replication. 
Sequencing of the non-structural protein genes would be a 
necessary step in this direction. 
CHAPTER 6 
SEQUENCE STUDIES ON THE E2 GENE 
OF NATURAL ISOLATES OF RRV 
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6.1 INTRODUCTION 
RNA viruses have high potential for evolution due to 
the high frequency of mutations in their genome (Holland et 
al., 1982). A high rate of evolution has been demonstrated by 
RNA fingerprinting for polio virus which underwent 1-2% 
nucleotide substitution over a period of a one-year epidemic in 
a non-immune population (Nottay et al., 1981). However, there 
is little comparable quantitative information on the evolution 
of an alphavirus. This is due in part to the lack of isolates 
from well-defined epidemics where the temporal spread of the 
virus could clearly be demonstrated. The EPA outbreak in a 
non-immune population in the South Pacific (Chapter 1), 
therefore, provided a unique opportunity to study the evolution 
of an alphavirus. A start on this was made by Faragher et al. 
(1985a) who compared the HaeIII and TaqI restriction digest 
profiles of RRV isolates obtained from the South Pacific during 
the course of the epidemic. The isolates showed essentially 
identical profiles indicating that sequence evolution, if it 
occurred at all, had been extremely limited . 
During the course of the polio virus epidemic (above) 
most of the mutations accumulated in the VPl gene (Nottay et 
al., 1981) which codes for the viral surface protein containing 
neutralisation antigenic sites (Minor et al., 1983). For 
alphaviruses E2 has been implicated in strain differentiation 
and virus evolution (Dalgarno et al., 1983) and a domain in E2 
has been identified which contains neutralisation epitopes 
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( Chapter 2) . In the light of these observations the E2 gene of 
RRV isolates from the South Pacific was sequenced to 
investigate virus evolution at the nucleotide level. 
In previous unpublished studies A.T.H. Burness, I. 
Pardoe and L. Dalgarno determined the sequence of the E2 gene 
of RRV isolates from Fiji (F9073), American Samoa (AS213970) 
and the Cook Islands (CI215398) between nucleotides 1124 and 
1439 which code for the stretch of E2 between amino acids 25 
and 129. They found no difference between the Pacific isolates 
in this region. However, their data covers only one-fourth of 
the E2 gene and does not cover the "neutralisation domain". In 
this Chapter we completely sequence the E2 gene of a number of 
Pacific isolates obtained from human cases at various stages 
during the outbreak in order to determine (i) the rate of 
genetic change in the E2 gene during the spread of RRV in a 
non-immune population, and (ii) whether any detected changes 
mapped to the domain previously identified as having a role in 
attachment/ penetration and in recognition of neutralising 
antibodies (Chapters 2 and 3). 
Another question which arises relates to the 
relationship between virus causing the outbreak in the South 
Pacific and the various RRV genetic types and sub-types 
identified in Australia. The studies of Faragher et al. 
(1985a) showed that the South Pacific isolates of RRV were 
closely related to the Australian RRV isolates NL26301, SC18008 
and BH38006 respectively, which were obtained from mosquitoes 
collected at Narran Lake, Sandy Camp and Barmah Forest, all in 
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New South Wales. In this Chapter we have determined the E2 
sequence of RRV NL26301 and compared it with that of the South 
Pacific RRV isolates to examine their relationship at the 
nucleotide sequence level. 
RRV could not be isolated from human EPA patients in 
Australia until recently when Aaskov et al. (1985) described 
the isolation of RRV CO and RRV MC from two patients in 
Rockhampton in Queensland. These patients showed a similar 
disease pattern to that seen in EPA patients in the South 
Pacific (Aaskov et al., 1985) which were different from that 
seen in the previous EPA cases in Australia (Rosen et al., 
1 9 8 1 ; Aas k o v et al . , 1 9 8 5 ) . 
--
It was therefore of interest to 
determine the genetic relationship between the Rockhampton 
isolates and those from the South Pacific. Also, the 
relationship between the Rockhampton isolates and other 
Australian isolates from non-human sources is investigated. The 
results of these studies are described in this Chapter. 
It has been argued that RRV exists in Australia in a 
number of ecological niches, where, over an extended period of 
time independent strain differentiation has occurred (Faragher 
et al., 1985a). Thus based on similarities and differences in 
HaeIII and TaqI restriction digest profiles of viral RNA 
Faragher et al. (1985a) grouped the different geographical 
isolates of RRV into three genetic types, I, II and III 
(Chapter 1). However, strain specific differences between 
various isolates are not known. This Chapter describes an 
attempt to explore strain related differences in RRV by 
comparing the E2 sequences of a small number of different 
natural isolates of the virus. 
6.2 MATERIALS AND METHODS 
6.2.1 Virus and cells 
13 5 
Virus isolates used in this study are listed in Table 
6.1. Culture supernatants from infected BHK cells served as 
stock virus. BHK cells were grown in GMEM (Section 2.2.2). 
6.2.2 Extraction of high molecular weight RNA from virus 
infected BHK cells and sequencing the E2 gene of 
RRV isolates 
High molecular weight RNA extracted from virus infected 
BHK cells (Section 2.2.14) was the template for dideoxy 
sequencing using primers 6K/2350, E2/1990, E2/1635 and E2/1455 
(Table 2.1). Virus was not plaque purified and the sequence 
obtained, therefore, represents that of the majority of virus 
population present in the stock. When sequencing RRV isolates, 
RRV T48 RNA was sequenced in parallel. Approximately 50 cross 
bands were seen which were evenly distributed throughout the 
1266 nucleotides long E2 gene. In most instances the cross 
band was present in the same position in the RRV T48 sequence 
ladder also, in which case the nucleotide was considered to be 
the same as that in RRV T48 (Dalgarno et al., 1983), otherwise 
it was recorded as an unidentified nucleotide (N). 
Isolate Area of isolation 
T48 Townsville, Qld. 
PB629 Lake Poomah, Vic. 
GG2227 Gol Gol, N.S.W. 
NL26301 Narran Lake, N.S.W. 
Table 6.1 RRV isolates used in this study. 
Year Source 
1959 Aedes vigilax 
1974 Culex annulirostris 
1974 Culex annulirostris 
1981 AnoEheles amictus 
Genetic 
type* Passage history 
I -10 passages in 
L ] 
mice, 
plaque purified 
1-2 suckling 
mouse brain 
passages 
Supplier 
Dr. R.A. Shope 
Yale Arbovirus 
Research Unit 
Dr. I.D. Marshall 
JCSMR, ANU 
BH38091 Barmah Forest, Vic. 1983 Aedes sag_ax ND C6-36 cells/mice Dr. I.D. Marshall 
F213978 Fiji 
AS213970 American Samoa 
CI215398 Cook Islands 
co 
MC 
Rockhampton, Qld. 
Rockhampton, Qld. 
1979 
1979 
1980 
1983 
1983 
Human serum 
Human serum 
Human Serum 
Human serum 
Human serum 
*From Faragher et al. (1985a); ND=Not determined. 
II 
II 
II 
ND 
ND 
2 passages in 
Toxorhynchites 
amboinensis 
mosquitoes 
C6-36 cells 
C6-36 cells J 
Virus was not plaque purified unless indicated in Table or Text. 
Dr. L. Rosen 
University 
of Hawaii 
Dr. I.D. Marshall 
Reference 
Doherty 
et al., 
(1963) 
Marshall 
et al., 
(1982) 
Aaskov et al., 
(1981) 
Tesh et al., 
(1981) 
Rosen et al., 
(1981) 
Aaskov et al., 
(1985) 
6.3.1 
6.3 RESULTS 
Sequence of the E2 gene of RRV isolates from 
human EPA cases in the South Pacific 
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During 1979-80 RRV spread sequentially in the non-
immune population of Fiji, American Samoa and the Cook Islands 
in the South Pacific. To examine the evolution of the RRV E2 
gene during this spread, the E2 gene sequence of virus isolated 
from human patients in different islands was determined. The 
isolates sequenced were RRV F213978, isolated in Fiji in 1979; 
RRV AS213970, isolated in American Samoa in 1979; and RRV 
CI215398, isolated in the Cook Islands in 1980. 
Figure 6.1 shows the nucleotide sequence of the E2 gene 
of RRV F213978 and the deduced amino acid sequence colisted 
with that of RRV T48 (see below). The E2 sequences of RRV 
AS213970 and RRV CI215398 were identical to each other and are 
shown as a single sequence in Figure 6.2. 
The RRV AS213970/RRV CI215398 sequence showed a single 
nucleotide difference from that of RRV F213978. At position 
1705 an A in RRV F213978 RNA was replaced by a Gin RRV 
AS213970 and RRV CI215398 RNAs (Figure 6.3, Table 6.2). This 
change led to a predicted non-conservative amino acid change 
(Thr~Ala) at position 219 in E2 (Table 6.3). Interestingly 
this change was in epitope I of E2 (Chapter 2). 
Compared to RRV T48 there were 37 nucleotide 
differences in the E2 gene of RRV F213978 (Figure 6.1, Table 
, 
Figure 6.1 Nucleotide sequence of RRV F213978 E2 gene 
and the deduced amino acid sequence of E2. 
Nucleotides are numbered from the 5'-end of RRV T48 
26S RNA and amino acids from the N-terminus of E2 
(Dalgarno et al., 1983). Identical nucleotides and 
amino acids to the top sequence are shown by a broken 
line. 
N=unidentified nucleotide 
X=unidentified amino acid 
Nucleotides between position 1099-1102 could not be 
identified due to compression. 
RRV T48 
RRV FIJI 
serValThrGluHisPheAsnValTyrLysAlaThrArqProTyrLeuAlaTyrCysAlaAspCysGlyAspGlyTyrPheCysTyrSerProValAlaileGluLysileArqAspGlu (40) 
AGUGUAACAGAGCACUUCAAUGUGUAUAAGGCUACUAGACCGUACUUAGCGUAUUGCGCUGACUGUGGGGACGGGUACUUCUGCUAUAGCCCAGUUGCUAUCGAGAAGAUCCGAGAUGAG (1170) 
I I I I I I I I I I I 
--------------------------------------------------------------------
-----------------------------------------A------NNNN----------u--c------------------------------------------------------
AlaSerAspGlyMetLeuLysileGlnValSerAlaGlnileGlyLeuAspLysAlaGlyThrHisAlaHisThrLysileArqTyrMetAlaGlyHisAspValGlnGluSerLysArg (BO) 
GCGUCUGACGGCAUGCUCAAGAUCCAAGUCUCCGCCCAAAUAGGUCUGGACAAGGCAGGUACCCACGCCCACACGAAGAUCCGAUAUAUGGCUGGUCAUGAUGUUCAGGAAUCUAAGAGA (1290) 
I I I I I I I I I I I 
------------------------------------------------------------------------------Leu---------------------------------------
--------u--------u------------------------------------------------------------c-----------------------------------------
AspSerLeuArgValTyrThrSerAlaAlaCysSerileHisGlyThrMetGlyHisPheileValAlaHisCysProProGlyAspTyrLeuLysValSerPheGluAspAlaAspSer (120) 
GAUUCCUUGAGGGUGUACACGUCCGCAGCGUGCUCUAUACAUGGGACGAUGGGACACUUCAUCGUCGCACAUUGUCCGCCAGGCGACUACCUCAAGGUUUCGUUCGAGGACGCAGAUUCA (1410) 
I I I I I I I I I I I 
----------------------------------------------------------------------
-----------------------------------c--------------------u--------------c-----A--------------------------u--------------G 
HisValLysAlaCysLysValGlnTyrLysHisAspProLeuProValGlyArgGluLysPheValValArgProHisPheGlyValGluLeuProCysThrSerTyrGlnLeuThrThr (160) 
CACGUGAAGGCAUGUAAGGUCCAAUACAAGCACGACCCAUUGCCGGUGGGUAGAGAGAAGUUCGUGGUUAGACCCCACUUUGGCGUAGAGCUGCCAUGCACCUCAUACCAGCUGACAACA (1530) 
I I I I I I I I I I I 
---------------------------------Asn------------------------------------------------------------------------------------
---------------------------------A-U--------------------------------------A-----------u--------------------------------G 
AlaProThrAspGluGlylleAspMetHisThrProProAsplleProAspArgThrLeuLeuSerGlnThrAlaGlyAsnValLyslleThrAlaGlyGlyArgThrlleArgTyrAsn (200) 
GCUCCCACCGACGAGGGGAUCGACAUGCACACACCGCCAGAUAUACCGGAUCGCACCCUGCUAUCACAGACGGCGGGCAACGUCAAAAUAACAGCAGGCGGCAGGACUAUCAGGUACAAU (1650) 
I I I I I I I I I I I 
---------------Glu------------------------------------------------------------------------------------------------------
----------------A---U--------U------------------------------------------------------------------------------------------
CysThrCysGlyArgAspAsnValGlyThrThrSerThrAspLysThrileAsnThrCysLysileAspGlnCysHisAlaAlaValThrSerHisAspLysTrpGlnPheThrSerPro (240) 
UGUACCUGUGGCCGUGACAACGUAGGCACUACCAGUACUGACAAGACCAUCAACACAUGCAAGAUUGACCAAUGCCAUGCUGCCGUUACCAGCCAUGACAAAUGGCAAUUUACCUCUCCA (1770) 
I I I I I I I I I I I 
---------------------------------------------------Tyr------------------------------------------------------------------
---------------------------------------------------U-------U------------------------------------------------------------
PheValProArgAlaAspGlnThrAlaArgArgGlyLysValHisValProPheProLeuThrAsnValThrCysArgValProLeuAlaArgAlaProAspValThrTyrGlyLysLys (280) 
UUUGUUCCCAGGGCUGAUCAGACAGCUAGGAGGGGCAAAGUGCAUGUUCCAUUCCCUUUGACUAACGUCACCUGCCGAGUGCCGUUGGCUCGAGCGCCGGAUGUCACCUAUGGUAAGAAG (1890) 
I I I I I I I I I I I 
------------------------------Lys---------------------------------------------------------------------------------------
-------------------------------AA--------A--------G------c--------------------------------------------------------------
GluValThrLeuArgLeuHisProAspHisProThrLeuPheSerTyrArgSerLeuGlyAlaGluProHisProTyrGluGluTrpValAspLysPheSerGluArgilelleProVal (320) 
GAGGUGACCCUGAGAUUACACCCAGAUCAUCCGACGCUCUUCUCCUAUAGGAGUUUAGGAGCCGAACCGCACCCGUACGAGGAGUGGGUUGACAAGUUCUCUGAGCGCAUCAUCCCAGUG (2010) 
I I I I I I I I I I I 
----------------------------------------------------------------------------
--------------------------------------------------------------U--------------------A------------------------------------
ThrGluGluGlyileGluTyrGlnTrpGlyAsnAsnProProValArgLeuTrpAlaGlnLeuThrThrGluGlyLysProHisGlyTrpProHisGluileileGlnTyrTyrTyrGly (360) 
ACGGAAGAAGGGAUUGAGUACCAGUGGGGCAACAACCCGCCGGUCCGCCUAUGGGCGCAACUGACGACCGAGGGCAAACCCCAUGGCUGGCCACAUGAAAUCAUUCAGUACUAUUAUGGA (2130) 
I I I I I I I I I I I 
-------------------------------------------------------------------------------------
--------------------------------------------------G---------------------------------------------------------------------
LeuTyrProAlaAlaThrlleAlaAlaValSerGlyAlaSerLeuMetAlaLeuLeuThrLeuAlaAlaThrCysCysMetLeuAlaThrAlaArgArgLysCysLeuThrProTyrAla (400) 
CUAUACCCCGCCGCCACCAUUGCCGCAGUAUCCGGGGCGAGUCUGAUGGCCCUCCUAACUCUAGCGGCCACAUGCUGCAUGCUGGCCACCGCGAGGAGAAAGUGCCUAACACCAUACGCC (2250) 
I I I I I I I I I I I 
-----------------------------------------------------------------------------------
-----------------U--------------------------------------------G------------------------------------------------- -G------
LeuThrProGlyAlaValValSerLeuThrLeuGlyLeuLeuCysCysAlaProArgAlaAsnAla 
UUGACGCCAGGAGCGGUGGUAUCGUUGACACUGGGGCUGCUUUGCUGCGCACCGAGGGCGAACGCA 
I I I I I I 
---------------------Pro------------------------------------------
c--------------------C-A--------------------------------------u---
( 42 2) 
(2316) 
Figure 6 . 2 Nucleotide sequence of RRV AS213970 and 
RRV CI215398 E2 genes and the deduced 
amino acid sequences of E2. 
Nucleotides are numbered from the 5'-end of RRV T48 
26S RNA and amino acids from the N-terminus of E2 
(Dalgarno et al., 1983). Identical nucleotides and 
amino acids to the top sequence are shown by a broken 
line. 
N=unidentified nucleotide 
Nucleotides between position 1099-1102 could not be 
identified due to compression. 
RRV T48 SerValThrGluHisPheAsnValTyrLysAlaThrArgProTyrLeuAlaTyrCysAlaAspCysGlyAspGlyTyrPheCysTyrSerProValAlalleGluLysileArgAspGlu 
AGUGUAACAGAGCACUUCAAUGUGUAUAAGGCUACUAGACCGUACUUAGCGUAUUGCGCUGACUGUGGGGACGGGUACUUCUGCUAUAGCCCAGUUGCUAUCGAGAAGAUCCGAGAUGAG 
I I I I I I I I I I I 
RRV AS/ RRV CI ------------------------------------------------------------------------------------------------------------------------
-----------------------------------------A------NNNN----------U--C------------------------------------------------------
AlaSerAspGlyMetLeuLyslleGlnVa1SerAlaGlnlleGlyLeuAspLysAlaGlyThrHisAlaHisThrLyslleArgTyrMetAlaGlyHisAspVa1GlnGluSerLysArg 
GCGUCUGACGGCAUGCUCAAGAUCCAAGUCUCCGCCCAAAUAGGUCUGGACAAGGCAGGUACCCACGCCCACACGAAGAUCCGAUAUAUGGCUGGUCAUGAUGUUCAGGAAUCUAAGAGA 
I I I I I I I I I I I 
------------------------------------------------------------------------------Leu---------------------------------------
--------u--------u------------------------------------------------------------c-----------------------------------------
AspSerLeuArgVa1TyrThrSerAlaAlaCysSerlleHisGlyThrMetGlyHisPhelleValAlaHisCysProProGlyAspTyrLeuLysVa1SerPheGluAspA1aAspSer 
GAUUCCUUGAGGGUGUACACGUCCGCAGCGUGCUCUAUACAUGGGACGAUGGGACACUUCAUCGUCGCACAUUGUCCGCCAGGCGACUACCUCAAGGUUUCGUUCGAGGACGCAGAUUCA 
I I I I I I I I I I I 
------------------------------------------------
-----------------------------------c--------------------u--------------c-----A--------------------------u--------------G 
HisValLysAlaCysLysValGlnTyrLysHisAspProLeuProValGlyArgGluLysPheValValArgProHisPheGlyValGluLeuProCysThrSerTyrGlnLeuThrThr 
CACGUGAAGGCAUGUAAGGUCCAAUACAAGCACGACCCAUUGCCGGUGGGUAGAGAGAAGUUCGUGGUUAGACCCCACUUUGGCGUAGAGCUGCCAUGCACCUCAUACCAGCUGACAACA 
I I I I I I I I I I I 
---------------------------------Asn------------------------------------------------------------------------------------
---------------------------------A-U--------------------------------------A-----------u--------------------------------G 
AlaProThrAspGluGlylleAspMetHisThrProProAsplleProAspArgThrLeuLeuSerGlnThrAlaGlyAsnValLysileThrAlaGlyGlyArgThrlleArgTyrAsn 
GCUCCCACCGACGAGGGGAUCGACAUGCACACACCGCCAGAUAUACCGGAUCGCACCCUGCUAUCACAGACGGCGGGCAACGUCAAAAUAACAGCAGGCGGCAGGACUAUCAGGUACAAU 
I I I I I I I I I I I 
---------------Glu------------------------------------------------------------------------------------------------------
----------------A---U--------U------------------------------------------------------------------------------------------
CysThrCysGlyArgAspAsnValGlyThrThrSerThrAspLysThrlleAsnThrCysLyslleAspGlnCysHisAlaAlaValThrSerHisAspLysTrpGlnPheThrSerPro 
UGUACCUGUGGCCGUGACAACGUAGGCACUACCAGUACUGACAAGACCAUCAACACAUGCAAGAUUGACCAAUGCCAUGCUGCCGUUACCAGCCAUGACAAAUGGCAAUUUACCUCUCCA 
I I I I I I I I I I I 
---------------------------------------------------TyrAla---------------------------------------------------------------
---------------------------------------------------U--G----u------------------------------------------------------------
PheValProArgAlaAspGlnThrAlaArgArgGlyLysValHisValProPheProLeuThrAsnValThrCysArgValProLeuAlaArgAlaProAspValThrTyrGlyLysLys 
UUUGUUCCCAGGGCUGAUCAGACAGCUAGGAGGGGCAAAGUGCAUGUUCCAUUCCCUUUGACUAACGUCACCUGCCGAGUGCCGUUGGCUCGAGCGCCGGAUGUCACCUAUGGUAAGAAG 
I I I I I I I I I I I 
------------------------------Lys---------------------------------------------------------------------------------------
-------------------------------AA--------A--------G------C--------------------------------------------------------------
GluValThrLeuArgLeuHisProAspHisProThrLeuPheSerTyrArgSerLeuGlyAlaGluProHisProTyrGluGluTrpValAspLysPheSerGluArgllelleProVal 
GAGGUGACCCUGAGAUUACACCCAGAUCAUCCGACGCUCUUCUCCUAUAGGAGUUUAGGAGCCGAACCGCACCCGUACGAGGAGUGGGUUGACAAGUUCUCUGAGCGCAUCAUCCCAGUG 
I I I I I I I I I I I 
- - --- --- -- --------------------------------------------------
--------------------------------------------------------------U--------------------A------------------------------------
ThrGluGluGlylleGluTyrGlnTrpGlyAsnAsnProProValArgLeuTrpAlaGlnLeuThrThrGluGlyLysProHisGlyTrpProHisGlullelleGlnTyrTyrTyrGly 
ACGGAAGAAGGGAUUGAGUACCAGUGGGGCAACAACCCGCCGGUCCGCCUAUGGGCGCAACUGACGACCGAGGGCAAACCCCAUGGCUGGCCACAUGAAAUCAUUCAGUACUAUUAUGGA 
I I I I I I I I I I I 
-------------------------------------------
--------------------------------------------------G---------------------------------------------------------------------
LeuTyrProAlaAlaThrileAlaAlaValSerGlyAlaSerLeuMetAlaLeuLeuThrLeuAlaAlaThrCysCysMetLeuAlaThrAlaArgArgLysCysLeuThrProTyrAla 
CUAUACCCCGCCGCCACCAUUGCCGCAGUAUCCGGGGCGAGUCUGAUGGCCCUCCUAACUCUAGCGGCCACAUGCUGCAUGCUGGCCACCGCGAGGAGAAAGUGCCUAACACCAUACGCC 
I I I I I I I I I I I 
- -------------------- -------------------------------------------
-----------------U--------------------------------------------G--------------------------------------------------G------
LeuThrProGlyAlaVa1Va1SerLeuThrLeuG1yLeuLeuCysCysAlaProArgAlaAsnA1a 
UUGACGCCAGGAGCGGUGGUAUCGUUGACACUGGGGCUGCUUUGCUGCGCACCGAGGGCGAACGCA 
I I I I I I 
---------------------Pro------------------------------------------
C--------------------C-A----------------------------- ---------u---
(40) 
(1170) 
(80) 
(1290) 
(120) 
(1410) 
(160) 
(1530) 
(200) 
(1650) 
(240) 
(1 770) 
(280) 
(1890) 
(320) 
(2010) 
(360) 
(2130) 
(400) 
(2250) 
( 4 22) 
(2316) 
Figure 6.3 Sequence ladders for RRV T48, RRV F213978, 
RRV AS213970 and RRV CI215398. 
RNA extracted from virus infected BHK cells was 
sequenced using primer E2/1990 (Table 2.1). The 
changed nucleotide in cDNA sequence ladder is indicated 
by an arrow. 
RRV RRV RRV RRV 
T 48 F213978 AS213970 Cl215398 
CTAG CTAG CTAG CTAG 
Table 6. 2 Sequence differences between E2 gene of 
RRV natural isolates and RRV T48. 
Nucleotide 
positiont 
1092 
1113 
1116 
1170 
1179 
1188 
1221 
1249 
1326 
1347 
1353 
1362 
1368 
1371 
1395 
1410 
1444 
1446 
1485 
1497 
1501 
1527 
1530 
1547 
1551 
1560 
1702 
1705 
1710 
1794 
1802 
1803 
1808 
1812 
1821 
1828 
1953 
1974 
2061 
2106 
2148 
2193 
2244 
2251 
2272 
2274 
2313 
RRV 
T48 NL F 
G A A 
C u u 
u C C 
G 
C u u 
C u u 
C 
A C C 
u C C 
C u u 
C 
u C C 
G N A 
A 
C u u 
A G G 
G N A 
C u u 
C A A 
A u u 
C 
A 
A G G 
G A A 
C u u 
C u u 
A u u 
A N 
C u u 
A 
G A A 
G A A 
A 
G A A 
A G G 
u C C 
C u 
G A A 
A G G 
u 
C u u 
A G G 
A G G 
u C C 
u C C 
G A A 
C u u 
RRV isolate* 
AS CI MC co PB BH 
A A A A 
u u u u 
C C C C 
A 
u u u u 
u u u u 
u u 
C C C C C C 
C C C C 
u u u u 
u u 
C C C C 
A A A A 
G G 
u u u u 
G G G G 
A A A A 
u u u u 
A A A A 
u u u u 
u 
G G 
G G G G 
A A A A A A 
u u u u 
u u u u 
u u 
G G N N 
u u u u 
G G 
A A A A 
A A A A 
G 
A A A A 
G G G G 
C C C C 
u u 
A A A A 
G G G G 
C C 
u u u u 
G G G G 
G G G G 
C C C C 
C C C C 
A A A A 
u u u u 
GG 
A 
u 
C 
u 
G 
u 
G 
A 
G 
G 
C 
t Numbered from 5'-end of RRV T48 26S RNA (Dalgarno et al., 1983). 
* RRV isolates are indicated as follows: NL, RRV NL26301; 
F, RRV F213978; AS, RRV AS213970; CI, RRV CI215398; MC, RRV MC; 
CO, RRV CO; PB, RRV PB629; BH, RRV BH38091; GG, RRV GG2227. 
N=unidentified nucleotide, not considered when comparing the 
isolates; 
blank space=same nucleotide as in RRV T48. 
Table 6.3 Predicted amino acid differences between E2 of 
RRV natural isolates and RRV T48. 
RRV isolate* 
Position 
of RRV 
amino acidt T48 NL F AS CI MC co PB BH 
67 Ile Leu Leu Leu Leu Leu Leu Leu Leu 
132 Asp X Asn Asn Asn Asn Asn 
166 Gly Glu Glu Glu Glu Glu Glu Glu Glu 
218 Asn Tyr Tyr Tyr Tyr 
219 Thr X Ala Ala X X 
251 Arg Lys Lys Lys Lys Lys Lys 
253 Lys Arg 
408 Ser Pro Pro Pro Pro Pro Pro 
t Numbered from N-terminus of E2 (Dalgarno et al., 1983). 
* RRV isolates are as in Table 6.2. 
Nature 
of amino 
acid 
GG changett 
Leu C 
NC 
Glu NC 
NC 
NC 
C 
Arg C 
NC 
X=uncertain amino acid, not considered for comparing the isolates; 
blank space=same amino acid as in RRV T48. 
tt C=conservative, NC=non-conservative; see legend to Table 2.5. 
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6.2) which did not cluster in any specific region. They 
resulted in 6 predicted amino acid differences between RRV T48 
and RRV F213978 at positions 67 (Ile/Leu), 132 (Asp/Asn), 166 
(Gly/Glu), 218 (Asn/Tyr), 251 (Arg/Lys) and 408 (Ser/Pro) in E2 
(Table 6.3). For RRV AS213970 and RRV CI215398 the same 
differences were detected but there was an additional pred icted 
amino acid change at position 219 (Thr/Ala) (Table 6.3). Thus 
differences at amino acids 218 and 219, and at 251 between any 
of the Pacific isolates and RRV T48 were in the neutralisation 
epitopes I and III respectively. 
6.3.2 Sequence of the E2 gene of RRV obtained from 
mosquitoes collected at Narran Lake in 1981 
On the basis of HaeIII restriction digest profiles of 
cDNA to viral RNA Faragher et al. (1985a) showed that RRV 
NL26301 isolated from mosquitoes collected at Narran Lake in 
1981, was closely related, if not identical, to the South 
Pacific isolates of RRV. To examine the relationship between 
these isolates more closely, the E2 gene of RRV NL26301 was 
sequenced. 
Figure 6.4 shows the E2 sequence of RRV NL26301. There 
was a single nucleotide difference between RRV NL26301 and any 
of the South Pacific RRV isolates (Table 6.2). This was a 
silent change at position 1953. We conclude that the Pacific 
isolates are not identical to RRV NL26301 although they are 
closely related in their E2 gene sequence. 
Figure 6.4 Nucleotide sequence of RRV NL26301 E2 gene 
and the deduced amino acid sequence of E2. 
Nucleotides are numbered from the 5'-end of RRV T48 
26S RNA and amino acids from the N-terminus of E2 
(Dalgarno et al., 1983). Identical nucleotides and 
amino acids to the top sequence are shown by a broken 
line. 
N=unidentified nucleotide 
X=unidentified amino acid 
Nucleotides between position 1099-1102 could not be 
identified due to compression. 
RRV T48 
RRV NL 
l 
SerValThrGluHisPheAsnValTyrLysAlaThrArgProTyrLeuAlaTyrCysAlaAspCysGlyAspGlyTyrPheCysTyrSerProValAlalleGluLyslleArgAspGlu (40) 
AGUGUAACAGAGCACUUCAAUGUGUAUAAGGCUACUAGACCGUACUUAGCGUAUUGCGCUGACUGUGGGGACGGGUACUUCUGCUAUAGCCCAGUUGCUAUCGAGAAGAUCCGAGAUGAG (117 0 ) 
I I I I I I I I I I I 
------------------------------------------------------------- - -------------------------------------
-----------------------------------------A------NNNN----------u--c------------------------------------------------------
AlaSerAspGlyMetLeuLyslleGlnValSerAlaGlnlleGlyLeuAspLysAlaGlyThrHisAlaHisThrLyslleArgTyrMetAlaGlyHisAspValGlnGluSerLysArg 
GCGUCUGACGGCAUGCUCAAGAUCCAAGUCUCCGCCCAAAUAGGUCUGGACAAGGCAGGUACCCACGCCCACACGAAGAUCCGAUAUAUGGCUGGUCAUGAUGUUCAGGAAUCUAAGAGA 
I I I I I I I I I I I 
------------------------------------------------------------------------------Leu---------------------------------------
--------u--------U------------------- 1----------------------------------------c-----------------------------------------
AspSerLeuArgValTyrThrSerAlaAlaCysSerlleHisGlyThrMetGlyHisPhelleValAlaHisCysProProGlyAspTyrLeuLysValSerPheGluAspAlaAspSer 
GAUUCCUUGAGGGUGUACACGUCCGCAGCGUGCUCUAUACAUGGGACGAUGGGACACUUCAUCGUCGCACAUUGUCCGCCAGGCGACUACCOCAAGGUUUCGUUCGAGGACGCAGAUUCA 
I I ·I I I I I I I I I 
--------------------------------------------------- ---------------------------------------
------------------------------ -----c--------------------u--------------c-----N--------------------------u--------------G 
HisValLysAlaCysLysValGlnTyrLysHisAspProLeuProValGlyArgGluLysPheValValArgProHisPheGlyValGluLeuProCysThrSerTyrGlnLeuThrThr 
CACGUGAAGGCAUGUAAGGUCCAAUACAAGCACGACCCAUUGCCGGUGGGUAGAGAGAAGUUCGUGGUUAGACCCCACUUUGGCGUAGAGCUGCCAUGCACCUCAUACCAGCUGACAACA 
I I I I I I I I I I I 
- - ------------------------------- X ----------------------------- - ------------------------------------------------------
---------------------------------N-U---- ----------------------------------A-----------U--------------------------------G 
AlaProThrAspGluGlylleAspMetHisThrProProAsplleProAspArgThrLeuLeuSerGlnThrAlaGlyAsnValLyslleThrAlaGlyGlyArgThrlleArgTyrAsn 
GCUCCCACCGACGAGGGGAUCGACAUGCACACACCGCCAGAUAUACCGGAUCGCACCCUGCUAUCACAGACGGCGGGCAACGUCAAAAUAACAGCAGGCGGCAGGACUAUCAGGUACAAU 
I I I I I I I I I I I 
---------------Glu------------------------ - -----------------------------------------------------------------------------
----------------A---U--------U----------------------------------------------------------------- -------------------------
CysThrCysGlyArgAspAsnValGlyThrThrSerThrAspLysThrlleAsnThrCysLyslleAspGlnCysHisAlaAlaValThrSerHisAspLysTrpGlnPheThrSerPro 
UGUACCUGUGGCCGUGACAACGUAGGCACUACCAGUACUGACAAGACCAUCAACACAUGCAAGAUUGACCAAUGCCAUGCUGCCGUUACCAGCCAUGACAAAUGGCAAUUUACCUCUCCA 
( I I I I I I I , I I I 
---------------------------------------------------Tyr X ---------------------------------------------------------------
---------------------------------------------------0--N----U------------------------------------------------------------
PheValProArgAlaAspGlnThrAlaArgArgGlyLysValHisValProPheProLeuThrAsnValThrCysArgValProLeuAlaArgAlaProAspValThrTyrGlyLysLys 
UUUGUUCCCAGGGCUGAUCAGACAGCUAGGAGGGGCAAAGUGCAUGUUCCAUUCCCUUUGACUAACGUCACCUGCCGAGUGCCGUUGGCUCGAGCGCCGGAUGUCACCUAUGGUAAGAAG 
I I I I I I I I I I I 
------------------------------Lys---------------------------------------------------------------------------------------
-------------------------------AA--------A--------G------c--------------------------------------------------------------
GluValThrLeuArgLeuHisProAspHisProThrLeuPheSerTyrArgSerLeuGlyAlaGluProHisProTyrGluGluTrpValAspLysPheSerGluArgllelleProVal 
GAGGUGACCCUGAGAUUACACCCAGAUCAUCCGACGCUCUUC UCCUAUAGGAGUUUAGGAGCCGAACCGCACCCGUACGAGGAGUGGGUUGACAAGUUCUCUGAGCGCAUCAUCCCAGUG 
I I I I I I I I I I I 
-------------------------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------A------------------------------------
ThrGluGluGlylleGluTyrGlnTrpGlyAsnAsnProProValArgLeuTrpAlaGlnLeuThrThrGluGlyLysProHisGlyTrpProHisGlullelleGlnTyrTyrTyrGly 
ACGGAAGAAGGGAUUGAGUACCAGUGGGGCAACAACCCGCCGGUCCGCCUAUGGGCGCAACUGACGACCGAGGGCAAACCCCAUGGCUGGCCACAUGAAAUCAUUCAGUACUAUUAOGGA 
I I I I I I I I I I I 
---------------------------------------------------------------------------------------------------------------------
--------------------------------------------------G---------------------------------------------------------------------
LeuTyrProAlaA1aThrlleAlaAlaVa1SerGlyAlaSerLeuMetAlaLeuLeuThrLeuAlaAlaThrCysCysMetLeuAlaThrAlaArgArgLysCysLeuThrProTyrA1a 
CUAUACCCCGCCGCCACCAUUGCCGCAGUAUCCGGGGCGAGUCUGAUGGCCCUCCUAACUCUAGCGGCCACAUGCUGCAUGCUGGCCACCGCGAGGAGAAAGUGCCUAACACCAUACGCC 
I I I I I I I I I I I 
------------------------------------------------------------------------------------------------------------------------
-----------------U--------------------------------------------G--------------------------------------------------G------
LeuThrProGlyA1aVa1Va1SerLeuThrLeuGlyLeuLeuCysCysAlaProArgAlaAsnA1a 
UUGACGCCAGGAGCGGUGGUAUCGUUGACACUGGGGCUGCUUUGCUGCGCACCGAGGGCGAACGCA 
I I I I I I 
--------~-----------Pro------------------------------------------
C--------------------C-A--------------------------------------0---
(80) 
(1290) 
(12 0) 
(141 0) 
(160) 
(1530) 
(200) 
(1650) 
(240) 
(1 770) 
(280) 
(18 90) 
(320) 
(2010) 
(360) 
(2130) 
( 400) 
(2250) 
(422) 
(2316) 
138 
There were 37 nucleotide differences between RRV 
NL26301 and RRV T48 E2 genes (Figure 6.4, Table 6.2). These 
resulted in amino acid differences at positions 67 (Ile/ Leu), 
166 (Gly/Glu), 218 (Asn/Tyr), 251 (Arg/Lys) and 408 (Ser /Pro) 
(Table 6.3). The amino acids at positions 132 and 219 could 
not be identified due to cross bands in the sequence ladder at 
the first codon nucleotide for these amino acids. However, the 
absence of cross bands in the RRV T48 sequence ladder at 
corresponding positions suggested nucleotide differences and 
hence amino acid differences. 
6.3.3 Sequence of the E2 gene of RRV isolates obtained 
from mosquitoes collected in the Murray valley 
in 1974 and 1983 
As part of a preliminary examination of the genetic 
relationship between different RRV isolates we have sequenced 
the E2 genes of three isolates obtained from mosquitoes 
collected during RRV epidemics in the Murray valley: RRV PB629 
(from Lake Poomah near Swan Hill) and RRV GG2227 (from Gol Gol 
near Mildura), both isolated in 1974; and RRV BH38091 (from 
Barmah Forest near Echuca) isolated in 1983 (Table 6.1). 
Figure 6.5 presents the E2 sequence of RRV PB629. The 
E2 sequences of RRV GG2227 and RRV BH38091 were identical to 
each other and are listed as a single sequence in Figure 6.6. 
The E2 sequences of RRV GG2227/RRV BH38091 differed from that 
of RRV PB629 at nucleotides 1170, 1501 and 1808 (Table 6.2) one 
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Figure 6.5 Nucleotide sequence of RRV PB629 E2 gene 
and the deduced amino acid sequence of E2. 
Nucleotides are numbered frvm the 5'-end of RRV T48 
26 S RNA and amino acids from the N-terminus of E2 
(Dalgarno et al., 1983). Identical nucleotides and 
a mino acids to the top sequence are shown by a broken 
line . 
N=un identified nucleotide 
Nuc leotides between position 1099-1102 could not be 
identi f ied due to compression. 
RRV T48 
RRV PB 
SerValThrGluHisPheAsnValTyrLysAlaThrArqProTyrLeuAlaTyrCysAlaAspCysGlyAspGlyTyrPheCysTyrSerProValAlaileGluLysileArqAspGlu (40) 
AGUGUAACAGAGCACUUCAAUGUGUAUAAGGCUACUAGACCGUACUUAGCGUAUUGCGCUGACUGUGGGGACGGGUACUUCUGCUAUAGCCCAGUUGCUAUCGAGAAGAUCCGAGAUGAG (1170) 
I I I I I I I I I I I 
----------------------------------------------------------------------
-------------------------------------------------NNNN-------------------------------------------------------------------
AlaSerAspGlyMetLeuLysileGlnVa1SerAlaGlnileGlyLeuAspLysAlaGlyThrHisAlaHisThrLysileArqTyrMetAlaGlyHisAspVa1GlnG1uSerLysArq (80) 
GCGUCUGACGGCAUGCUCAAGAUCCAAGUCUCCGCCCAAAUAGGUCUGGACAAGGCAGGUACCCACGCCCACACGAAGAUCCGAUAUAUGGCUGGUCAUGAUGUUCAGGAAUCUAAGAGA (1290) 
I I I I I I I I I I I 
------------------------------------------------------
------------------------Leu---------------------------------------
--------------------------------------------------0---------------------------c-----------------------------------------
AspSerLeuArqVa1TyrThrSerAlaAlaCysSerileHisGlyThrMetGlyHisPheileVa1AlaHisCysProProGlyAspTyrLeuLysVa1SerPheGluAspAlaAspSer (120) 
GAUUCCUUGAGGGUGUACACGUCCGCAGCGUGCUCUAUACAUGGGACGAUGGGACACUUCAUCGUCGCACAUUGUCCGCCAGGCGACUACCUCAAGGUUUCGUUCGAGGACGCAGAUUCA (1410) 
I I I I I I I I I I I 
--------- --------------------------------------------------------------
------------
--------- - --------------------------------------------
--------U-----------------G---------------------------------------
HisValLysAl aCysLysValGlnTyrLysHisAspProLeuProValGlyArqGluLysPheValValArqProHisPheGlyValGluLeuProCysThrSerTyrGlnLeuThrThr (160) 
CACGUGAAGGCAUGUAAGGUCCAAUACAAGCACGACCCAUUGCCGGUGGGUAGAGAGAAGUUCGUGGUUAGACCCCACUUUGGCGUAGAGCUGCCAUGCACCUCAUACCAGCUGACAACA (1530) 
I I I I I I I I I I I 
----------------------------------------------------------------------------
-------------------------------------------G---
AlaProThrAspG1uGlyileAspMetHisThrProProAspileProAspArqThrLeuLeuSerGlnThrAlaGlyAsnVa1LysileThrAlaGlyGlyArqThrI1eArgTyrAsn (200) 
GCUCCCACCGACGAGGGGAUCGACAUGCACACACCGCCAGAUAUACCGGAUCGCACCCUGCUAUCACAGACGGCGGGCAACGUCAAAAUAACAGCAGGCGGCAGGACUAUCAGGUACAAU (1650) 
I I I I I I I I I I I 
---------------Glu------------------------------------------------------------------------------------------------------
----------------A-------------------------------------------------------------------------------------------------------
CysThrCysGlyArqAspAsnValGlyThrThrSerThrAspLysThrileAsnThrCysLysileAspGlnCysHisAlaAlaValThrSerHisAspLysTrpGlnPheThrSerPro (240) 
UGUACCUGUGGCCGUGACAACGUAGGCACUACCAGUACUGACAAGACCAUCAACACAUGCAAGAUUGACCAAUGCCAUGCUGCCGUUACCAGCCAUGACAAAUGGCAAUUUACCUCUCCA (1770) 
I I I I I I I I I I I 
----------------------------------------------------------------------------
----------------------------------------------------------------------------
PheValProArqAlaAspGlnThrAlaArqArqGlyLysValHisValProPheProLeuThrAsnValThrCysArqValProLeuAlaArqAlaProAspValThrTyrGlyLysLys (280) 
UUUGUUCCCAGGGCUGAUCAGACAGCUAGGAGGGGCAAAGUGCAUGUUCCAUUCCCUUUGACUAACGUCACCUGCCGAGUGCCGUUGGCUCGAGCGCCGGAUGUCACCUAUGGUAAGAAG (1890) 
I I I I I I I I I I I 
-----------------------------------------------------------------------------
-----------------------G------------------------------------------------------------------------------------------------
GluValThrLeuArgLeuHisProAspHisProThrLeuPheSerTyrArqSerLeuGlyAlaGluProHisProTyrGluGluTrpValAspLysPheSerGluArqileileProVal (320) 
GAGGUGACCCUGAGAUUACACCCAGAUCAUCCGACGCUCUUCUCCUAUAGGAGUUUAGGAGCCGAACCGCACCCGUACGAGGAGUGGGUUGACAAGUUCUCUGAGC GCAUCAUCCCAGUG (2010) 
I I I I I I I I I I I 
------------------------------------------------------------------------------
------------------------------------------------------------------------------
ThrGluGluGlyileGluTyrGlnTrpGlyAsnAsnProProVa1ArqLeuTrpAlaGlnLeuThrThrGluGlyLysProHisGlyTrpProHisGluileI1eGlnTyrTyrTyrG1y (360) 
ACGGAAGAAGGGAUUGAGUACCAGUGGGGCAACAACCCGCCGGUCCGCCUAUGGGCGCAACUGACGACCGAGGGCAAACCCCAUGGCUGGCCACAUGAAAUCAUUCAGUACUAUUAUGGA (2130) 
I I I I I I I I I I I 
-------------------------------------------------------------------------------
-----------------------------------------------------------------------c------------------------
LeuTyrProAlaAlaThrileAlaAlaVa1SerGlyAlaSerLeuMetAlaLeuLeuThrLeuAlaAlaThrCysCysMetLeuAlaThrA1aArqArgLysCysLeuThrProTyrA1a (400) 
CUAUACCCCGCCGCCACCAUUGCCGCAGUAUCCGGGGCGAGUCUGAUGGCCCUCCUAACUCUAGCGGCCACAUGCUGCAUGCUGGCCACCGCGAGGAGAAAGUGCCUAACACCAUACGCC (2250) 
I I I I I I I I I I I 
- ----------------------------------------------------------------------
-------
-------- -------------------------------------------------------------------------
------
LeuThrProGlyAlaVa1Va1SerLeuThrLeuGlyLeuLeuCysCysA1aProArqAlaAsnA1a 
UUGACGCCAGGAGCGGUGGUAUCGUUGACACUGGGGCUGCUUUGCUGCGCACCGAGGGCGAACGCA 
I I I I I I 
----------------------------------- --
--------------------------------------
( 4 2 2) 
(2316) 
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Figure 6 . 6 Nucleotide sequence of RRV BH38091 and 
RRV GG2227 E2 genes and the deduced amino 
, 
acid sequences of E2. 
Nucleotide s are numbered from the 5'-end of RRV T48 
26S RNA and ami no a c ids from the N-terminus of E2 
(Dalgarno et al ., 1983) . Identical nucleotides and 
amino acids t o the t op sequence are shown by a broken 
line . 
N=unidentified nucleotide 
Nucleotides between position 1099-1102 could not be 
identified due t o compression. 
RRV T48 
RRV BH/ RRV GG 
SerValThrGluHisPheAsnValTyrLysAlaThrArgProTyrLeuAlaTyrCysAlaAspCysGlyAspGlyTyrPheCysTyrSerProValAlaileGluLysileArgAspGlu (40) 
AGUGUAACAGAGCACUUCAAUGUGUAUAAGGCUACUAGACCGUACUUAGCGUAUUGCGCUGACUGUGGGGACGGGUACUUCUGCUAUAGCCCAGUUGCUAUCGAGAAGAUCCGAGAUGAG (1170) 
I I I I I I I I I I I 
------ -----------------------------------------------------------------
----------------
------------------------------------------------NNNN-------------------------------------------------------------------A 
AlaSerAspGlyMetLeuLysileGlnVa1SerAlaGlnileGlyLeuAspLysAlaGlyThrHisAlaHisThrLysileArgTyrMetAlaGlyHisAspVa1GlnG1uSerLysArg (80) 
GCGUCUGACGGCAUGCUCAAGAUCCAAGUCUCCGCCCAAAUAGGUCUGGACAAGGCAGGUACCCACGCCCACACGAAGAUCCGAUAUAUGGCUGGUCAUGAUGUUCAGGAAUCUAAGAGA (1290) 
I I I I I I I I I I I 
------------------------------------------------------
------------------------Leu---------------------------------------
----------------------------------- ·--------------0---------------------------c-----------------------------------------
AspSerLeuArgVa1TyrThrSerAlaAlaCysSerileHisGlyThrMetGlyHisPheileVa1AlaHisCysProProGlyAspTyrLeuLysVa1SerPheGluAspA1aAspSer (120) 
GAUUCCUUGAGGGUGUACACGUCCGCAGCGUGCUCUAUACAUGGGACGAUGGGACACUUCAUCGUCGCACAUUGUCCGCCAGGCGACUACCUCAAGGUUUCGUUCGAGGACGCAGAUUCA (1410) 
I I I I I I I I I I I 
--------------------------------------------------------------------------------
--------------------------------------------------------------0-----------------G---------------------------------------
HisValLysAlaCysLysValGlnTyrLysHisAspProLeuProValGlyArgGluLysPheValValArgProHisPheGlyValGluLeuProCysThrSerTyrGlnLeuThrThr (160) 
CACGUGAAGGCAUGUAAGGUCCAAUACAAGCACGACCCAUUGCCGGUGGGUAGAGAGAAGUUCGUGGUUAGACCCCACUUUGGCGUAGAGCUGCCAUGCACCUCAUACCAGCUGACAACA (1530) 
I I I I I I I I I I I 
-----------------------------------------------------------------------------------
------------------------------------------------------------------------------------------
0-------------------------G---
AlaProThrAspGluGlyileAspMetHisThrProProAspileProAspArgThrLeuLeuSerGlnThrAlaGlyAsnValLysileThrAlaGlyGlyArgThrileArgTyrAsn (200) 
GCUCCCACCGACGAGGGGAUCGACAUGCACACACCGCCAGAUAUACCGGAUCGCACCCUGCUAUCACAGACGGCGGGCAACGUCAAAAUAACAGCAGGCGGCAGGACUAUCAGGUACAAU (1650) 
I I I I I I I I I I I 
---------------Glu------------------------------------------------------------------------------------------------------
----------------A-------------------------------------------------------------------------------------------------------
CysThrCysGlyArgAspAsnValGlyThrThrSerThrAspLysThrileAsnThrCysLysileAspGlnCysHisAlaAlaValThrSerHisAspLysTrpGlnPheThrSerPro (240) 
UGUACCUGUGGCCGUGACAACGUAGGCACUACCAGUACUGACAAGACCAUCAACACAUGCAAGAUUGACCAAUGCCAUGCUGCCGUUACCAGCCAUGACAAAUGGCAAUUUACCUCUCCA (1770) 
I I I I I I I I I I I 
-----------------------------------------------------------------------------------
----------------------------------------------------------------------------------
PheValProArgAlaAspGlnThrAlaArgArgGlyLysValHisValProPheProLeuThrAsnValThrCysArgValProLeuAlaArgAlaProAspValThrTyrGlyLysLys (280) 
UUUGUUCCCAGGGCUGAUCAGACAGCUAGGAGGGGCAAAGUGCAUGUUCCAUUCCCUUUGACUAACGUCACCUGCCGAGUGCCGUUGGCUCGAGCGCCGGAUGUCACCUAUGGUAAGAAG (1890) 
I I I I I I I I I I I 
------------------------------------Arg---------------------------------------------------------------------------------
-----------------------G-------------G----------------------------------------------------------------------------------
GluValThrLeuArgLeuHisProAspHisProThrLeuPheSerTyrArgSerLeuGlyAlaGluProHisProTyrGluGluTrpValAspLysPheSerGluArgileileProVal (320) 
GAGGUGACCCUGAGAUUACACCCAGAUCAUCCGACGCUCUUCUCCUAUAGGAGUUUAGGAGCCGAACCGCACCCGUACGAGGAGUGGGUUGACAAGUUCUCUGAGCGCAUCAUCCCAGUG (2010) 
I I I I I I I I I I I 
------------------------------------------------------------------------------------
------------------------------------------------------------------------------------
ThrGluGluGlyileGluTyrGlnTrpGlyAsnAsnProProVa1ArgLeuTrpAlaGlnLeuThrThrGluGlyLysProHisGlyTrpProHisGluileI1eGlnTyrTyrTyrG1y (360) 
ACGGAAGAAGGGAUUGAGUACCAGUGGGGCAACAACCCGCCGGUCCGCCUAUGGGCGCAACUGACGACCGAGGGCAAACCCCAU GGCUGG CCACAUGAAAUCAUUCAGUACUAUUAUGGA (2130) 
I I I I I I I I I I I 
--------------------------------------------------------------------------------------
------------------------------------------------------------------------------c------------------------
LeuTyrProAlaAlaThrileAlaAlaValSerGlyAlaSerLeuMetAlaLeuLeuThrLeuAlaAlaThrCysCysMetLeuAlaThrAlaArgArgLysCysLeuThrProTyrAla (400) 
CUAUACCCCGCCGCCACCAUUGCCGCAGUAUCCGGGGCGAGUCUGAUGGCCCUCCUAACUCUAGCGGCCACAUGCUGCAUGCUGGCCACCGCGAGGAGAAAGUGCCUAACACCAUACGCC (2250) 
I I I I I I I I I I I 
--------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------
LeuThrProGlyAlaVa1Va1SerLeuThrLeuG1yLeuLeuCysCysAlaProArgAlaAsnA1a 
UUGACGCCAGGAGCGGUGGUAUCGUUGACACUGGGGCUGCUUUGCUGCGCACCGAGGGCGAACGCA 
I I I I I I 
-------------------------------------------
----------------------------------------
( 422) 
(2316 ) 
139 
of which resulted in a single conservative amino acid 
difference (Lys/Arg) at residue 219 (Table 6 . 3). It can be 
concluded that the two 1974 strains were not identical and that 
RRV GG2227 or a close relative was present in the region (as 
RRV BH38091) in 1983. 
When the RRV PB629 E2 gene sequence was compared with 
that of RRV T48, seven nucleotide differences were found 
(Figure 6.5, Table 6.2) two of which resulted in amino acid 
differences at positions 67 (Ile/Leu) and 166 (Gly/Glu) in E2 
(Table 6.3). Compared to RRV T48, RRV BH38091 and RRV GG2227 
had 10 nucleotide differences in the E2 gene (Figure 6.7, Table 
6.2). These resulted in amino acid differences at positions 67 
(Ile/Leu), 166 (Gly/Glu) and 253 (Lys/Arg) in E2 (Table 6.3). 
From comparing the E2 nucleotide sequences we conclude that the 
three Murray valley isolates of RRV are closely related to the 
prototype T48 strain with< 1% nucleotide sequence divergence 
and hence are of the same genetic type (Faragher et al., 
1985a), provided the genetic divergence is no greatly different 
in other parts of the genome. 
6.3.4 Sequence of the E2 gene of RRV isolates obtained from 
human EPA cases in Rockhampton in 1983 
To examine the relationship between RRV isolated from 
human EPA patients in Australia and the South Pacific, the E2 
genes of RRV CO and RRV MC were sequenced (Figure 6.7). 
The two isolates were identical to each other in their 
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Figure 6.7 Nucleotide sequence of RRV CO and RRV MC 
E2 genes and the deduced amino acid 
sequences of E2. 
Nucleotides are numbered from the 5'-end of RRV T48 
26S RNA and amino acids from the N-terminus of E2 
(Dalgarno et al., 1983) . Identical nucleotides and 
amino acids to the top sequence are shown by a broken 
line. 
N=unidentified nucleotide 
X=unidentified amino acid 
Nucleotides between position 1099-1102 could not be 
identified due to compression . 
RRV T48 
RRV CO/ RRV MC 
l 
SerVa1ThrGluHisPheAsnVa1TyrLysAlaThrArgProTyrLeuAlaTyrCysAlaAspCysGlyAspGlyTyrPheCysTyrSerProValAlaileGluLysI1eArgAspGlu (40) 
AGUGUAACAGAGCACUUCAAUGUGUAUAAGGCUACUAGACCGUACUUAGCGUAUUGCGCUGACUGUGGGGACGGGUACUUCUGCUAUAGCCCAGUUGCUAUCGAGAAGAUCCGAGAUGAG (1170) 
I I I I I I I I I I I 
----------------------------------------------------------------------------------
-----------------------------------------A------NNNN----------u--c------------------------------------------------------
AlaSerAspGlyMetLeuLysileGlnVa1SerAlaGlnileGlyLeuAspLysAlaGlyThrHisAlaHisThrLysileArgTyrMetAlaGlyHisAspVa1GlnGluSerLysArq (80) 
GCGUCUGACGGCAUGCUCAAGAUCCAAGUCUCCGCCCAAAUAGGUCUGGACAAGGCAGGUACCCACGCCCACACGAAGAUCCGAUAUAUGGCUGGUCAUGAUGUUCAGGAAUCUAAGAGA (1290) 
I I I I I I I I I I I 
------------------------------------------------------------------------------Leu---------------------------------------
--------u--------u------------------------------------------------------------c-----------------------------------------
AspSerLeuAr9ValTyrThrSerAlaAlaCysSerileHisGlyThrMetGlyHisPheileValAlaHisCysPr0Pr0GlyAspTyrLeuLysVa1SerPheGluAspA1aAspSer (120) 
GAUUCCUUGAGGGUGUACACGUCCGCAGCGUGCUCUAUACAUGGGACGAUGGGACACUUCAUCGUCGCACAUUGUCCGCCAGGCGACUACCUCAAGGUUUCGUUCGAGGACGCAGAUUCA (1410) 
I I I I I I I I I I I 
------------------------------------------------------------------------------------
-----------------------------------c--------------------u--------------c-----A--------------------------u--------------G 
HisValLysAlaCysLysValGlnTyrLysHisAspProLeuProValGlyArgGluLysPheValValArqProHisPheGlyValGluLeuProCysThrSerTyrGlnLeuThrThr (160) 
CACGUGAAGGCAUGUAAGGUCCAAUACAAGCACGACCCAUUGCCGGUGGGUAGAGAGAAGUUCGUGGUUAGACCCCACUUUGGCGUAGAGCUGCCAUGCACCUCAUACCAGCUGACAACA (1530) 
I I I I I I I I I I I 
---------------------------------Asn------------------------------------------------------------------------------------
---------------------------------A-U--------------------------------------A-----------0--------------------------------G 
AlaProThrAspGluGlyileAspMetHisThrProProAspileProAspArgThrLeuLeuSerGlnThrAlaGlyAsnValLysileThrAlaGlyGlyArgThrileArgTyrAsn (200) 
GCUCCCACCGACGAGGGGAUCGACAUGCACACACCGCCAGAUAUACCGGAUCGCACCCUGCUAUCACAGACGGCGGGCAACGUCAAAAUAACAGCAGGCGGCAGGACUAUCAGGUACAAU (1650) 
I I I I I I I I I I I 
---------------Glu------------------------------------------------------------------------------------------------------
----------------A---U--------U------------------------------------------------------------------------------------------
CysThrCysGlyArgAspAsnValGlyThrThrSerThrAspLysThrileAsnThrCysLysileAspGlnCysHisAlaAlaValThrSerHisAspLysTrpGlnPheThrSerPro (240) 
UGUACCUGUGGCCGUGACAACGUAGGCACUACCAGUACUGACAAGACCAUCAACACAUGCAAGAUUGACCAAUGCCAUGCUGCCGUUACCAGCCAUGACAAAUGGCAAUUUACCUCUCCA (1770) 
I I I I I I I I I I I 
------------------------------------------------------ X ---------------------------------------------------------------
------------------------------------------------------N----0------------------------------------------------------------
PheValProAr9AlaAspGlnThrAlaAr9ArqGlyLysValHisValProPheProLeuThrAsnValThrCysArqValProLeuAlaArgAlaProAspValThrTyrGlyLysLys (280) 
UUUGUUCCCAGGGCUGAUCAGACAGCUAGGAGGGGCAAAGUGCAUGUUCCAUUCCCUUUGACUAACGUCACCUGCCGAGUGCCGUUGGCUCGAGCGCCGGAUGUCACCUAUGGUAAGAAG (1890) 
I I I I I I I I I I I 
------------------------------Lys---------------------------------------------------------------------------------------
-------------------------------AA--------A--------G------c--------------------------------------------------------------
GluValThrLeuAr9LeuHisPr0AspHisPr0ThrLeuPheSerTyrAr9SerLeuGlyAlaGluPr0HisPr0TyrGluGluTrpValAspLysPheSerGluArqileilePr0Val (320) 
GAGGUGACCCUGAGAUUACACCCAGAUCAUCCGACGCUCUUCUCCUAUAGGAGUUUAGGAGCCGAACCGCACCCGUACGAGGAGUGGGUUGACAAGUUCUCUGAGCGCAUCAUCCCAGUG (2010) 
I I I I I I I I I I I 
-------- ----------------------------------------------------------------------------------------
---------------------------------------------------------------------A------------------------------------
ThrGluGluGlyileGluTyrGlnTrpGlyAsnAsnProProValArqLeuTrpAlaGlnLeuThrThrGluGlyLysProHisGlyTrpProHisGluileileGlnTyrTyrTyrGly (360) 
ACGGAAGAAGGGAUUGAGUACCAGUGGGGCAACAACCCGCCGGUCCGCCUAUGGGCGCAACUGACGACCGAGGGCAAACCCCAUGGCUGGCCACAUGAAAUCAUUCAGUACUAUUAUGGA (2130) 
I I I I I I I I I I I 
-----------------------------------------------------------------------------------------
- --------------------------------------G---------------------------------------------------------------------
LeuTyrProAlaAlaThrileAlaAlaValSerGlyAlaSerLeuMe tAl aLe uLeuThrLeuAlaAlaThrCysCysMe tLeuAlaThrAlaArgArqLysCys Le uThrProTyrAla (400) 
CUAUACCCCGCCGCCACCAUUGCCGCAGUAUCCGGGGCGAGUCUGAUGGCCCUCCUAACUCUAGCGGCCACAUGCUGCAUGCUGGCCACCGCGAGGAGAAAGUGCCUAACACCAUACGCC (2250) 
I I I I I I I I I I I 
-----------------------------------------------------------------------------------------
-----------------U--------------------------------------------G------------------------------------------- -------G------
LeuThrProGlyAlaVa1Va1SerLeuThrLeuGlyLeuLeuCysCysAlaProArgA1aAsnA1a 
UUGACGCCAGGAGCGGUGGUAUCGUUGACACUGGGGCUGCUUUGCUGCGCACCGAGGG CGAACGCA 
I I I I I I 
---------------------Pro------------------ -------- ----------------
C--------------------C-A---------------------------- - ---------u---
(422) 
(2316) 
140 
E2 sequences and were closely related, but not identical, to 
the South Pacific isolates of RRV (Table 6.2). There were two 
nucleotide differences between RRV CO/RRV MC and the South 
Pacific RRV isolates at positions 1702 and 1953 (Table 6.2). 
One of these resulted in a predicted amino acid difference 
(Tyr/Asn) at position 218 (Table 6.3). Interestingly this 
amino acid is part of the epitope I (Chapter 2). 
RRV CO and RRV MC were closely related to RRV NL26301. 
There was a single nucleotide difference between the two at 
position 1702 of the E2 gene (Table 6.2). This resulted in an 
amino acid difference (Tyr/Asn) at position 218 in E2 (Table 
6. 3) . 
RRV MC/RRV CO had 36 nucleotide differences from RRV 
T48 in the E2 gene (Table 6.2). These resulted in amino acid 
differences in E2 at positions 67 (Ile/Leu), 132 (Asp/Asn), 166 
(Gly/Glu), 251 (Arg/Lys) and 408 (Ser/Pro) (Table 6.3). The 
amino acid at position 219 may also be changed, however, an 
identification could not be made for reason described in 
Section 6.3.2. 
6.4.1 
6.4 DISCUSSION 
Evolution of RRV during epidemic spread in a non-
immune population 
RRV induced EPA was first reported in Fiji in 1979. In 
August 1979 the virus spread to American Samoa and then in 
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February 1980 the EPA cases were reported from the Co ok I slands 
(Chapter 1). We have examined the evolution of RRV du ring this 
well defined spread of virus in a non-immune population. 
is the first study of its kind for any alphavirus. 
Thi s 
Comparison of the E2 gene sequences of the early (RRV 
F213978) and late (RRV CI215398) isolates in the epidemic 
showed that only a single nucleotide change had been selected 
over the period of a little more than a year. These results 
are consistent with the findings of Faragher et al. (1985a) 
which indicated that during the South Pacific epidemic of RRV 
only limited nucleotide evolution had occurred. 
Since E2 is the most divergent of the structural 
protein genes in terms of amino acid sequence conservation 
between RRV, SFV and SIN (Dalgarno et al., 1983), it is perhaps 
surprising that only a single nucleotide substitution was 
selected during virus spread in the South Pacific epidemic 
involving hundreds of thousands of people (Chapter 1). This 
single nucleotide change in 1266 nucleotides long E2 gene 
represents 0.078% nucleotide sequence evolution. These 
findings are in contrast to those of Nottay et al. (1981) who 
studied the evolution of polio virus during an epidemic which 
spread through a few hundred people belonging to an 
unvaccinated religious community between April 1978 and June 
1979. Using the RNA fingerprinting technique they estimate d 
that during the epidemic 1-2% nucleotide changes were selected 
in the polio virus genome. Most of these changes were in the 
gene coding for the neutralisation antigen VPl (Nottay e t al ., 
1981). 
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This marked difference i n e vo lution r ate s fo r R~V and 
polio virus cannot be attributed to t h e intrinsic g e netic 
stability of RRV since, as an example, the E2 gene o f RRV 
NL26301 is -3% divergent from that of RRV T48 (Tab l e 6 . 4) . 
Further, as judged by the frequency of isolation of t h e mab-
resistant variants (Chapter 2) the rate of mutation in RRV 
genome is similar to that for other RNA viruses. A li ke l y 
reason for the remarkable stability of RRV genome relates to 
the transmission cycle which involves alternate repl i cation in 
vertebrates and invertebrates. Thus a mutation which ma y be 
selected in one host is unlikely to confer an advantage in the 
other host. Hence an alternate replication of RRV in d i fferent 
hosts may provide a negative selection pressure. In cont rast, 
polio virus is passed directly from human to human with out an 
intermediate host. Thus a mutation could be selected 
positively. Consistent with this explanation, when mouse-
avirulent RRV NB5092 was passaged ten times serially in mice to 
enhance its virulence, it accumulated a small number of 
mutations in the E2 gene (Meek, 1986). By contrast, alternate 
passages in mice and mosquitoes keep the viral virulence 
unchanged (Taylor and Marshall, 1975a,b). 
Since RRV genome is so stable under epidemic 
conditions, the question arises as to how the genetic diversi t y 
which exists between RRV isolates arose. Faragher et al. 
(1985a) have proposed that it resulted from the interaction 
between virus, mosquito vector and the mammalian host in 
ecological isolation over long periods of time. 
Table 6.4 Per cent sequence divergence in the E2 gene 
between various RRV isolates. 
PB BH GG NL F AS CI co MC 
T48 0.63 0.86 0.86 2.68 2.92 3.00 3.00 2.76 2.76 
PB 0.23 0.23 3.00 3.39 3.55 3.55 3.31 3.31 
BH 0.00 3.23 3.55 3.39 3.39 3.31 3.31 
GG 3.23 3.55 3.39 3.39 3.31 3.31 
. NL 0.70 0.70 0.70 0.70 0.70 
F 0.70 0.70 0.15 0.15 
AS 0.00 0.15 0.15 
CI 0.15 0.15 
MC 
0.00 
RRV isolates are as in Table 6.2. 
Nucleotide sequence divergence was calculated using the 
number of nucleotide differences between the two isolates 
(Table 6.2) in 1266 nucleotides long E2 gene. 
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When amino acid sequences of RRV F213978 and RRV 
AS213970/RRV CI215398 were compared, a single non-conservative 
change (Thr--"7Ala) was found at residue 219 in neutralisation 
epitope I of E2. This change was probably not selected as a 
result of antibody selection pressure for the following 
reasons. First, the pre-epidemic population in the South 
Pacific had no previous antibodies against RRV (Marshall and 
Miles , 1 9 8 4 ) . Second, because the blood meal taken by a 
mosquito will contain a titer high enough to ensure virus 
transmission only at the time of peak viraemia when antibody 
levels are relatively low, and at this stage antigenic variants 
selected for the resistance to antibody would not represent a 
significant proportion of the injested virus. And, third, any 
antigenic variant which may arise during virus replication will 
be neutralised by the polyclonal antibody made in the 
vertebrate host. 
A possible selective pressure may be exerted by any of 
the hosts in the transmission cycle. The most common 
invertebrate vector of RRV in inland Australia is 
Cx. annulirostris and in coastal Australia Ae. vigilax. The 
later was present in unusually large numbers in Fiji during the 
epidemic and could have played a crucial role in establishing 
RRV infection in Fiji (Marshall and Miles, 1984). Although 
there were many species of mosquitoes active in the Cook 
Islands during the epidemic, only Ae. polynesiensis was shown 
to be transmitting RRV (Rosen et al., 1981). No information 
exists on the species of mosquito involved in RRV spread in 
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American Samoa. Thus it is possible that the amino acid change 
in RRV, as it moved from Fiji to American Samoa and the Co ok 
Islands, was selected as a result of a change in mosquito 
vector. On the other hand, since the virus is proposed to have 
moved from Australia to the South Pacific (Marshall and Miles, 
1984), it can be speculated that the amino acid change was 
selected during the process of the virus adaptation to a 
different human race in the Pacific and thus the difference was 
not seen in the Fijian RRV isolate which was isolated early . in 
the course of the virus spread, but was observed in the later 
RRV isolates from American Samoa and the Cook Islands. 
6.4.2 Relationship between RRV isolates obtained from 
human EPA patients 
RRV was isolated from a human patient for the first 
time in Fiji during the 1979-80 epidemic (Aaskov et al., 
1981b). Efforts to isolate RRV from human EPA patients in 
Australia had failed until 1983 when RRV (MC and CO strains) 
was isolated from the human serum in Rockhampton (Aaskov et 
al . , 19 8 5) • In both the South Pacific and the recent 
Australian EPA cases the first blood sample taken soon after 
the appearance of disease symptoms contained no detectable 
anti-RRV antibodies (Rosen et al., 1981; Aaskov et al., 1985) 
whereas in previous Australian cases such blood samples 
contained RRV antibodies (Clarke et al., 1973). This 
similarity in the pattern of pathogenesis in EPA patients . in 
the Pacific and Rockhampton suggested an involvement of the 
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same or closely related RRV strains in the two epidemics. 
Sequencing studies showed that RRV CO and RRV MC isolated from 
two patients in Rockhampton were identical to each other in 
their E2 and were closely related to the South Pacific isolat e s 
of RRV. Thus there was only a single amino acid difference 
between RRV CO/RRV MC and the South Pacific RRV isolates. 
Since RRV CO and RRV MC were closely related to the 
South Pacific RRV isolates which belonged to genetic type II of 
RRV (Faragher et al., 1985a) it appears that the only viruses 
isolated from human EPA cases so far belong to genetic type II. 
An obvious question is whether only genetic type II virus is 
pathogenic in humans . The answer is almost certainly no, since 
RRV belonging to genetic type III has frequently been isolated 
from mosquitoes in Nelson Bay area during several epidemics 
(Gard et al. , 1973). Also, RRV PB629 and RRV GG2227 which 
belong to type I were isolated in the Murray valley region 
during epidemic years. Although the virus was isolated from 
mosquitoes and could not be isolated from humans (Clarke et 
al ., 1973) it seems probable that it was involved in human 
pathogenesis. 
Since there was a marked difference in the RRV 
pathogenesis in Australia (before the Rockhampton cases) and 
the South Pacific (see above) Rosen et al. (1981) raised the 
question of whether the virus isolated in the Pacific was 
different in its biology from that previously involved in EPA 
in Australia. Conceivably the virus grew faster, with symptoms 
146 
appearing before antibody was produced. Al t e r n ativ el y , the 
virus was less imrnunogenic thus inducing ant i body poorly . 
Compared to all non-human RRV isolates examined in the present 
studies, the South Pacific isolates had differences in the 
"neutralisation domain" in E2. Such differences could affect 
viral immunogenicity and growth since this domain has been 
implicated in virus attachment/entry and virulence (Chapter 3). 
In this context it is of interest that RRV isolates obtained 
from different geographical locations in Australia induce host 
responses to different degrees as judged by relative antibody 
titers in mice (I.D. Marshall, personal communication). 
6.4.3 Strain differentiation in RRV 
There are several enzootic strains of RRV which, it is 
believed, have evolved in isolation over a long period of time 
These strains in ecological niches (Faragher et al., 1985a). 
cannot be distinguished by polyclonal antibody in 
neutralisation tests, although kinetic haemagglutination tests 
can distinguish some of them, e.g. RRV T48 and RRV NB5092 
(Woodroofe et al., 1977). However, certain mabs can 
distinguish many RRV strains in neutralisation tests. Thus mab 
TlE7 neutralised RRV T48 with 100-fold greater titer compared 
to the South Pacific isolates (C. Fernan, personal 
communication) . This indicated that the small differences . in 
neutralisation epitope(s) between different RRV strains were 
significant. The interesting question, therefore, is whether 
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Figure 6.8 Location of amino acid differences in E2 of 
various natural isolates of RRV. 
Figure is a co-listing of amino acid sequences of 
E2 of RRV T48, SFV and SIN (from Dalgarno et al., 
1983). Gaps have been introduced to maximise homology 
between sequences. Asparagine-linked potential 
glycosylation sites are shaded. Overlined amino acids 
in the SFV or SIN sequence are identical to 
corresponding amino acids in RRV T48 sequence. Sites 
of amino acid differences in various natural isolates 
of RRV used in the studies in this Chapter are 
indicated by Y . These were at amino acids 67, 132, 
166, 218, 219, 251, 253 or 408 in various RRV isolates 
(Table 6.3). The putative hydrophobic transmembrane 
domain is underlined by dots. Amino acid sequence data 
for SFV and SIN are from Garoff et al. (1980b) and Rice 
--
and Strauss (1981) respectively. 
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the small amino acid sequence differences seen in various RRV 
isolates are responsible for the strain specific antigenic and 
biological differences. We have plotted the locations of amino 
acid differences in E2 between the various RRV isolates (Figure 
6. 8) . RRV neutralisation epitopes are located in, or 
immediately adjacent to, the stretches of amino acids not 
conserved between RRV and SFV (Chapter 2). In the natural RRV 
isolates five out of eight differences occurred in stretches 
which were conserved between RRV T48 and SFV, three were in 
non-conserved stretches. It would appear that while RRV and 
SFV may be distinguished by a markedly different amino acid 
sequence in their neutralising epitopes, RRV strains may have 
minor conformational differences brought about by small 
change(s) within the epitope or outside in the conserved 
sequence in E2. This is supported by the observation that mab 
TlE7, raised against RRV T48, did not neutralise SFV, however, 
it neutralised different RRV strains, but to a different extent 
( see above) . 
Four out of eight RRV strain specific amino acid 
differences were found in the "neutralisation domain" which 
represents -15% of E2, suggesting that the domain is 
particularly prone to vary in different RRV strains. Earlier 
we have suggested that the changes in the "neutralisation 
domain" may not be selected due to the antibody pressure. 
However, in Chapter 3 evidence was presented for the importance 
of this domain in virus-cell interaction. Therefore such a 
domain should be capable of accomodating changes necessary for 
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virus adaptation to a new host. It can be speculated that the 
changes in the "neutralisation domain" may h ave bee n s elected 
due to host selection pressure and thus the strain spec i f i c 
differences may give the virus an advantage in a particular 
host. 
6.4.4 Nucleotide sequence divergence and genetic typing 
Based on similarities and differences in HaeIII and 
TaqI restriction digest profiles Faragher et al. (1985a) placed 
RRV T48, RRV GG2227, RRV PB629 in genetic type I and RRV 
NL26301, RRV F213978, RRV AS213970, RRV CI215398 and RRV 
BH38091 in genetic type II. 
The sequencing studies reported here show< 1% 
nucleotide sequence divergence between the E2 genes of RRV T48, 
RRV GG2227, RRV PB629 and RRV BH38091 on the one hand and 
between the E2 genes of RRV F213978, RRV AS213970, RRV 
CI215398, RRV CO and RRV MC on the other (Table 6.4). There 
was, however, 2.6-3.3% sequence divergence between the two 
groups (Table 6.4). Thus, the genetic typing of Faragher et 
al. (1985a) is consistent with the results based on E2 
sequences. Since RRV BH38091 showed only 0.86% sequence 
divergence from RRV T48 (genetic type I) and was identical to 
RRV GG2227 (genetic type I) in E2 we propose that it belongs to 
the genetic type I of Faragher et al. ( 1985a) . 
From HaeIII restriction digest profiles of virus 
infe cted BHK cell RNA, S.G. Faragher (personal communication ) 
calculated a 5.6% nucleotide sequence divergence between RRV 
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T48 and the South Pacific RRV isolates. However, based on the 
E2 gene sequence both RRV CO/RRV MC and the South Pacific RRV 
isolates had -3% sequence divergence from RRV T48. Since E2 is 
the most variable structural gene in alphaviruses (Dalgarno et 
al., 1983) this figure should be the maximum extent of sequence 
divergence assuming that the non-structural protein gene 
sequences are highly conserved due to their functional 
requirements. HaeIII restriction profiles "look at" the whole 
genome which in addition to E2 contains less divergent genes 
such as El and the non-structural genes. The ]'-untranslated 
region is very low in GC and thus will not "register" many 
bands in the restriction profile. Therefore HaeIII restriction 
digest analysis will be expected to give an estimate of 
divergence which is perhaps less than that indicated by 
sequencing E2 gene. However estimates of Faragher (1982) based 
on HaeIII restriction profiles gave figures which were 
significantly greater than those obtained from the E2 
sequences. Meek (1986) using the purified virion RNA and the 
method of Faragher et al. ( 1985a) estimated a 2. 2% nucleotide 
sequence divergence between RRV T48 and RRV NB5092. This was 
close to the 2.38% nucleotide sequence divergence as calculated 
by direct comparison of the 26S RNA sequences of the two 
strains (Meek, 1986). Thus a reason for the big difference 
between the estimates of S.G. Faragher (see above) and those 
reported in this Chapter is not clear but it may be related to 
the problems associated with the reproducibility of the 
restriction digestion analysis method when used with the 
infected cell RNA (Faragher et al., 1985b). 
--
CHAPTER 7 
CONCLUSION 
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A maJor aim of the studies described in this thes is was 
to determine the location of RRV neutralisation epitopes in the 
primary amino acid sequence of the relevant structural protein. 
Using neutralising mabs, three neutralisation epitopes were 
identified around amino acids 216 (epitope I), 232-234 (epitope 
II) and 246-251 (epitope III) in E2. The three epitopes were 
each located about 15 amino acids apart in a 35 amino acid long 
stretch between the two predicted glycosylation sites in E2. 
Hydropathy analysis of RRV E2 showed that while epitope I was 
located in a moderately hydrophilic region of E2, epitopes II 
and III were in the two most hydrophilic regions. These two 
regions were conserved as to position and hydrophilicity 
between RRV, SFV and SIN. The neutralisation epitopes were 
located in stretches of amino acids which were not conserved 
between RRV, SFV and SIN or were immediately adjacent to them. 
This indicates that the fine structure of the neutralisation 
epitopes is different between different alphaviruses although 
the conservation of all cysteine residues in RRV, SFV and SIN 
E2 proteins predicts that the basic structural features of the 
neutralisation antigen will be similar between the three 
alphaviruses. The location of these epitopes was the same in 
mouse-virulent RRV T48 and in avirulent RRV NB5092. 
The relationship between the three epitopes was 
examined by cross-neutralisation tests which showed that the 
variants altered in one epitope were neutralised by mabs 
interacting with a different epitope thus suggesting that the 
three epitopes can act independently in neutralisation. 
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However sequencing of two multi-epitope variants, obtained by 
sequential selection with different mabs, showed that a change 
in epitope I led to a restriction on the type of changes that 
could be introduced in epitopes II and III indicating that the 
three epitopes may be conformationally connected. To 
conclusively establish this point, different multi-epitope 
variants obtained using different mabs in various combinations 
need to be sequenced. 
For SFV and SIN, neutralisation epitopes have been 
found in El as well as in E2 (Chapter 1). In the present study 
no neutralisation epitopes were found in RRV El. This may be 
due to the small number of mabs used in these studies. 
However, it appears that the three epitopes defined in RRV E2 
represent the immunodominant neutralisation domain. This is 
reflected in the observation that all six neutralising mabs 
obtained from five independent fusions interact with this 
domain and that polyclonal antiserum raised against RRV T48 
neutralises a variant altered in all three epitopes with lower 
efficiency compared to RRV T48 (P. Kerr, personal 
communication). If these three epitopes do represent the 
imrnunodominant site a synthetic peptide or fusion protein 
harbouring them could be used to examine its potential as a 
synthetic vaccine. A similar approach may be useful in 
developing control measures against more life threatening 
alphaviruses. 
Another aim of the work described in this thesis was to 
examine aspects of the role of E2 in the process of RRV 
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infection. To this end the biological properties of RRV 
mutants were examined. RRV T48 antigenic variants which had 
single amino acid changes in epitopes I or II showed no 
significant differences in growth, or in RNA or protein 
synthesis in BHK cells compared to RRV T48; none of these 
variants showed a change in virulence or tissue tropism in 
mice. However, single amino acid changes in epitope III 
resulted in a slight retardation of growth and of RNA and 
protein synthesis in BHK cells. These variants "penetrated" 
BHK cells more rapidly than did RRV T48. Certain of the 
epitope III variants had a slight, but significant, increase in 
LD50 or AST for week-old mice; none of these variants showed 
any significant difference in growth in week-old mice when 
compared with RRV T48 except one variant which produced lower 
levels of viraemia. 
Compared to the effect of the point mutations in E2 on 
the biological properties of RRV, a seven amino acid deletion 
in E2 of RRV dE2 resulted in a major alteration in virulence 
and tissue tropism in mice. The deletion mutant was only 
slightly attenuated in day-old mice but was totally avirulent 
for week-old mice. In week-old mice the mutant grew to titers 
which were significantly lower than those for RRV T48; in hind 
leg muscle the difference was approximately 2 log units whereas 
in brain the difference was -5 log units thus indicating a 
change in tissue tropism. 
BHK cells infected with RRV dE2 had a significantly 
increased rate of viral RNA synthesis than in RRV T48-infected 
.... 
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cells. It is difficult to envisage a mechanism which could 
explain how a deletion in a structural protein could affect the 
rate of RNA synthesis. The possibility that change(s) in the 
non-structural protein genes of RRV dE2 have taken place must 
be considered, although comparison of HaeIII and TaqI 
restriction profiles of cDNA to RRV dE2 and RRV T48 RNA showed 
no evidence of a difference other than the deletion in the E2 
gene of RRV dE2 (S.G. Faragher, unpublished data). 
Although the deletion in RRV dE2 was between amino 
acids 55-61 of E2 and was approximately 150 amino acids distant 
from the "neutralisation domain" in the primary amino acid 
sequence, this seems to have affected the conformation of this 
domain since mab NB3C4 gave a significantly lower 
neutralisation titer with RRV dE2 than with RRV T48. 
Results of studies with mab-resistant variants and with 
the deletion mutant suggest that part or all of the domain of 
E2 containing the neutralisation epitopes is involved in virus-
cell interaction and may be part of a receptor binding site. 
If this is so a change in conformation of a neutralisation 
epitope could alter the conformation of the receptor binding 
site leading to an altered recognition of the cellular 
receptor. This, in turn, could result in a change in 
cell/tissue tropism in mice or in an altered rate of attachment 
and penetration of virus into cells. This hypothesis is 
supported by the recent observation of Meek (1986) that seven 
out of the eight mouse-passaged virulence variants of RRV 
NB5092 examined had one or two amino acid changes in the 
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"neutralisation domain". Compared to RRV NB5092 these v a r iant s 
had lower LD 50 s in mice and reached higher titers in blood and 
brain with little difference in hind leg muscle titers thus 
indicating a change in tissue tropism. However, the virulence 
of RRV can apparently be affected by changes elsewhere in the 
genome other than in the E2 gene. This was indicated by the 
studies reported in Chapter 5 on BHK-passaged variants of RRV 
T48 which had reduced virulence and altered tissue tropisms 
mice although no mutations were found in the E2 gene or any 
other structural protein genes. Since these mutants had an 
' in 
increased rate of AMD-resistant RNA synthesis in BHK cells it 
appears likely that mutations had occurred in the non-
structural protein genes although attempts to identify them by 
sequencing were not made. Consistent with this view virulent 
variants have been isolated from mouse-passaged RRV NB5092 
which have no alterations in E2 but differ from parental virus 
in their non-structural protein genes as detected by 
restriction analysis of double-stranded cDNA to virion RNA 
(S.G. Faragher, personal communication). The site of these 
mutation(s) in the non-structural protein genes has not yet 
been identified by sequencing. 
Another point which emerges from our studies on growth 
of RRV dE2 and BHK-passaged RRV T48 variants in mice is that a 
decreased replication of virus in brain correlates directly 
with reduced virulence. This suggests that viral replication 
in brain is an important determinant of RRV virulence in mice. 
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In the last section of this thesis the evolution of RRV 
E2, the neutralisation antigen, during epidemic was examined b y 
comparing the E2 gene sequences of RRV isolates obtained during 
the virus spread in a non-immune population in the South 
Pacific. The advantage of this system was that the 
introduction and spread of the virus in the population has been 
well documented and RRV isolates obtained at different stages 
of the progress of the epidemic were available. These studies 
showed that during virus spread RRV evolved far more slowly 
than did polio virus during a similar spread in an unvaccinated 
religious community. The slower rate of RRV evolution may be 
attributable to a difference in the transmission cycle of the 
two viruses. During the RRV spread in the South Pacific a 
single amino acid change in E2 was the only change selected; 
this was in epitope I and may be related to a change in the 
host(s) involved in virus spread. This is consistent with our 
hypothesis that the "neutralisation domain" or a part of it is 
involved in virus-cell interaction. 
During recent EPA cases in Rockhampton patients showed 
a pattern of disease symptoms similar to that seen during the 
South Pacific outbreak. Comparison of the E2 gene sequences of 
the Rockhampton RRV isolates with those from the South Pacific 
showed that the two were closely related although they were not 
identical. 
In an attempt to explore strain related differences in 
RRV E2 the positions of amino acid changes were examined in a 
small number of RRV natural isolates. It was observed that 
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while the type specific sites (i.e. neutralisation epitopes) 
were located in stretches of amino acids which were not 
conserved between RRV, SFV and SIN or immediately adjacent to 
them, the strain related amino acid differences may frequently 
appear in sequences which were conserved between the three 
alphaviruses. Thus various strains of RRV may still be 
neutralised by the type specific antibodies but to a different 
extent owing to small differences in conformation of the 
epitope(s) brought about by the small change(s) in the amino 
acid sequence. 
In summary this thesis is the first report on the 
location of the neutralisation epitopes of an alphavirus and on 
the evolution of an alphavirus neutralisation antigen during an 
epidemic at the nucleotide sequence level. Studies on RRV 
mutants were carried out to understand aspects of the 
biological role of E2, the neutralisation antigen. These 
studies suggested a role for E2 in virus-cell interaction and 
in determining tissue tropism and virulence although further 
work is required in these later areas. 
..... 
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Ross River Virus Mutant with a Deletion in the E2 Gene: Properties of 
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A mutant of RRV T48 the prototype strain of Ross River virus has been isolated with 
a 21-nucleotide deletion in the gene coding for the envelope glycoprotein E2. Direct se-
quencing of the 26 S subgenomic RNA, together with HaeIII and TaqI restriction digest 
analysis of cDNA to RN As from cells infected with the mutant virus (RRV dE2) and with 
RRV T48, were consistent with the deletion being the only major alteration in the mutant 
genome. The E2 protein of RRV dE2 virions had a higher electrophoretic mobility than 
that of RRV T48 E2 protein. Neither RRV dE2 nor RRV T48 virions contained more than 
trace amounts of E3, the small envelope glycoprotein found in Semliki Forest virus. RRV 
dE2 generated small plaques on Vero cell monolayers; plaque formation was not temper-
ature-sensitive between 32 and 41 °. By comparison with RRV T48 the infectivity of RRV 
dE2 virions was thermolabile at 50°. 
In BHK cells RRV dE2 grew with similar kinetics to RRV T48. Rates of synthesis of 26 
S RNA and 49 S RNA were higher in cells infected with RRV dE2 than in cells infected 
with RRV T48. Virus-specific protein synthesis and shut-down of host protein synthesis 
occurred 2-3 hr earlier in RRV dE2-infected cells than in cells infected with RRV T48. 
Minor differences between the two viruses were observed in the profiles of virus-specific 
proteins generated in infected cells. In day-old mice RRV dE2 induced less severe symptoms 
of hind leg paralysis than did RRV T48. A small increase in LD50 and average survival 
time was observed in RRV dE2-infected mice by comparison with RRV T48 infected mice. 
Peak titers reached by RRV dE2 in the hind leg muscle, brain, and blood of day-old mice 
were 3-4 log units less than the titers reached during infection with RRV T48. In week-
old mice the differences in virulence between the two strains were magnified: RRV dE2 
induced no detectable symptoms even when injected at high doses (8 X 106 PFU) whereas 
the LD50 and average survival time for RRV T48 were unchanged from those in day-old 
mice. Peak RRV dE2 titers in hind leg muscle, brain, and blood, respectively, were 2, 5, 
and 5 log units less than the corresponding titers for RRV T48. Peak muscle titers reached 
by RRV dE2 were similar (-108 PFU/g tissue) in day-old mice where lethality was high 
and in week-old mice where the virus was avirulent. In brain tissue, peak RRV dE2 titers 
were 107 and 104 PFU/g, respectively, in day-old and week-old mice. Since the corresponding 
figures for RRV T48 were 1011 and 109 PFU/g, the outcome of RRV infection was probably 
determined more by the extent of replication in neural tissues than in muscle tissues. 
© 1986 Academic Press, Inc. 
INTRODUCTION 
The alphavirus virion contains a single-
stranded RNA molecule (49 S RNA), ap-
proximately 240 capsid protein subunits 
and equimolar amounts of two or three en-
1 To whom requests for reprints should be ad-
dressed. 
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velope glycoproteins [El, E2, and, in the 
case of Semliki Forest virus (SFV), E3] 
which comprise the surface "spikes" of the 
virion (Simons et al., 1980). The envelope 
proteins either individually or together, are 
required for the infectivity of the virus 
particle (Bose et al., 1970; Igarashi et al., 
1970). The El protein is a group-specific 
antigenic determinant (Porterfield, 1980) 
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and is responsible for hemagglutination 
(Dalrymple et al., 1976; Helenius et al., 
1976), hemolysis (Yamamoto et al., 1981) 
and probably plays a role in mediating vi-
rus fusion with intracellular membranes 
during penetration (Garoff et al., 1980; Rice 
and Strauss, 
1
1981a). The E2 protein carries 
antigenic determinants which recognize 
neutralizing antibody (Dalrymple et al., 
1976) and may also play a role in the early 
events in infection by the recognition of 
cell surface receptors (Barie et al., 1981). 
The role if any of E3 is unknown. 
In the course of determining the nucleo-
tide sequence of the 26 S subgenomic RNA 
of the alphavirus Ross River virus (RRV), 
Dalgarno et al. (1983) obtained evidence 
which predicted the existence, in the virus 
stock, of a mutant with a deletion of 21 
nucleotides in the E2 gene. For these se-
quence studies, viral RNA was reverse 
transcribed into single-stranded cDNA, 5' 
end-labeled, digested with enzymes capable 
of cleaving single-stranded DNA (e.g., 
TaqI, HaeIII) and sequenced by the chem-
ical method of Maxam and Gilbert. Two 
TaqI fragments, 243 and 222 nucleotides in 
length, had identical 5' and 3' termini but 
differed in the presence or absence of 21 
internal nucleotides. Since such a deletion 
mutant could provide valuable further data 
on the role of E2, attempts were made to 
characterize it further. 
In the present communication we de-
scribe the isolation of the predicted mu-
tant, report on some of the physical prop-
erties of the virion, examine the replication 
of the virus in tissue culture cells, and de-
scribe the growth and virulence of the virus 
m mice. 
MATERIALS AND METHODS 
Virus. The T48 strain of RRV (Berge, 
1975) was obtained from the Yale Arbovi-
rus Research Unit. The virus had been pas-
saged approximately 10 times in mice when 
received. Virus was assayed by plaque for-
mation on Vero cell monolayers (Newton 
et al., 1981). Cell associated virus was as-
sayed after sonication of cell pellets at 0° 
for 15 sec. 
Cell cultures. BHK-21 cells were grown 
in Eagle-BHK medium and Vero cells were 
grown in M199-LAH medium (Newton et 
al., 1981). Primary mouse cells were ob-
tained by collagenase treatment of skin or 
muscle tissues obtained from an outbred 
strain of Walter and Eliza Hall Institute 
(WEHI) mice. 
Labeling of cells. Cell- and virus-specific 
proteins were labeled and cell extracts 
prepared and electrophoresed as described 
by Dalgarno et al. (1984). Rates of viral 
RNA synthesis were estimated by incu-
bation of cell monolayers with [5-3H]-
uridine (10 µCi/ml) for 2 hr in Eagle's min-
imum essential medium. When required 
actinomycin D was added to 5 µg/ml 10 min 
before isotope addition (Newton et al., 
1981). After labeling, monolayers were 
dissociated, precipitated on glass fiber 
disks, and counted for radioactivity (New-
ton et al., 1981). 
Purification of virus and viral RNA. RRV 
T48 and RRV dE2 were purified from clar-
ified BHK tissue culture supernatant fluids 
(adjusted to 2.3 % w/v, NaCl) by precipi-
tation with polyethylene glycol (7 % w/v; 
Martin et al., 1979). Virion RNA was ex-
tracted from pelleted peak fractions as 
previously described (Ou et al., 1981). In-
tracellular 26 S RNA was isolated from 
RRV dE2-infected BHK cells as described 
by Dalgarno et al. (1983). 
cDNA synthesis, restriction enzyme 
digestion, and polyacrylamide gel electro-
phoresis. cDNA to virion RNA was synthe-
sized using reverse transcriptase in the 
presence of short calf thymus DNA prim-
ers as previously described (Faragher et al., 
1985). Radiolabeled, single-stranded cDNA 
was digested with HaeIII or TaqI and elec-
trophoresed on polyacrylamide gels as de-
scribed by Faragher et al. (1985). 
Sequencing of viral RNA. Virion RNAs 
were sequenced by the dideoxy-nucleotide 
method using as primer a synthetic 17-res-
idue oligodeoxynucleotide (5' ACTTCT-
CTCTACCCACC 3') complementary to nu-
cleotides 1455-1471 of RRV T48 26 S RNA 
(Dalgarno et al., 1983). Reaction mixtures 
contained, in a final volume of 10 µl, 50 mM 
Tris (pH 8.3), 8 mMMgCb, 50 mMKCl, 0.4 
mM dithiothreitol, 50 µM dATP, TTP, and 
dGTP, 2.5 µM dCTP, 10 µCi of [a-32P]dCTP 
(3000 Ci/mmol), 10 µM ddATP, 5 µM 
ddTTP, 2 µM ddGTP, or 0.25 µM ddCTP, 
0.8 µg virion RNA, ~o.001 µg primer, and 
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12 units of AMV reverse transcriptase. Be-
fore addition, mixtures of template RNA 
and primer were heated at 56° for 5 min 
and quick-chilled on ice-water, and KCl 
was added to 80 mM. Incubation of reaction 
mixtures was at 0° for 20 min, followed by 
60 min at 42.5°. One microliter of a solution 
which was 0.5 mM in all dNTPs was then 
added and incubation continued at 42.5° for 
20 min. Reactions were stopped by addition 
of 4 vol of formamide-dye mix (96 % deion-
ized formamide; 25 mM Tris-borate; 0.5 
mM Na2 EDTA; xylene cyanol and bro-
mophenol blue dyes), followed by heating 
at 90° for 2 min. Reaction products were 
separated on 80-cm-long, 0.4-mm-thick 5% 
polyacrylamide gels (acrylamide:bisacry-
lamide, 19:1). Gels were exposed at - 20° to 
Fuji RX medical X-ray film. 
Monoclonal antibodies. Neutralizing 
monoclonal antibodies to RRV T48 were 
obtained from hybridoma cells generated 
by fusion of spleen cells from hyperim-
munized BALB/c mice with X63 myeloma 
cells according to the method of Fazekas 
de St. Groth and Scheidegger (1981). 
Estimation of virulence in mice. WEHI 
mice of either sex were used. For LD50 de-
terminations 30-µl samples of 10-fold virus 
dilutions in Hanks' balanced salt solution 
(HESS) were inoculated intraperitoneally 
(ip) into 1- or 7-day-old mice, using 8-10 
litter-mates per dilution. LD50s were cal-
culated according to Reed and Muench 
(1938). Clinical signs and mortality were 
recorded daily for 2 weeks. Subclinical in-
fections were assayed in mice surviving to 
the 14th day by challenging with 105 Vero 
PFU of virulent RRV T48 inoculated ip. 
Mice were held for a further 2 weeks. The 
absence of clinical signs was taken as ev-
idence of prior infection. Average survival 
times (AST) represent the arithmetic mean 
for all mice dying during the course of a 
titration regardless of dose, since for most 
RRV strains the time of death is indepen-
dent of the dose (Taylor and Marshall, 
1975). 
Virus growth in mice. WEHI mice of ei-
ther sex were injected subcutaneously with 
100 Vero PFU of virus. Groups of three 
mice were killed at 24-hr intervals by cer-
vical dislocation; tissues were removed and 
stored at - 70°. Blood was collected from 
the heart using heparinized capillary tubes 
and diluted 1:10 in ice-cold HESS before 
freezing at -70°. For virus assay, tissues 
were homogenized as a suspension in ice-
cold HESS using a Teflon-glass homoge-
nizer. 
RESULTS 
Isolation of a Mutant of Ross River Virus 
with a 21-Nucleotide Deletion in the E 2 
Gene 
In the course of plaque assays on the vi-
rus stock used in sequencing RRV T48 26 
S RNA (Dalgarno et al., 1983), uniformly 
small plaques C:::::'.1.5 mm diameter) were 
detected on Vero cell monolayers incubated 
for 4 days. The small plaque former was 
plaque-purified twice and examined for re-
version to wild-type plaque size (~4 mm 
diameter). No revertants were observed in 
several thousand small plaques. To deter-
mine whether the small plaque former was 
the E2 deletion mutant predicted from 
previous sequencing studies (Dalgarno et 
al., 1983), intracellular 26 S RNA from 
BHK cells infected with the small plaque 
variant and 49 S virion RNA isolated 
from plaque-purified RRV T48 were se-
quenced in the appropriate region of the 
E2 gene using the dideoxynucleotide 
method. Twenty-one nucleotides (5'GG-
UCUGGACAAGGCAGG U ACC-3'), rep-
resenting nucleotides 1213 to 1233 of RRV 
T48 26 S RNA were absent from the cor-
responding region of the small plaque virus 
genome (Fig. 1). These nucleotides code for 
amino acids 55-61 of E2. RRV E2 is 422 
amino acids long; since the predicted hy-
drophobic domain which anchors E2 in the 
membrane includes residues 354-391 and 
the predicted cytoplasmic "tail" is repre-
sented by residues 395-418 (Dalgarno et al., 
1983) it is likely that the deleted region is 
in the external portion of E2. It can also 
be noted that neither of the glycosylation 
sites in E2 (see below) are removed by the 
deletion. Since no other sequence hetero-
geneity was observed in RRV T48 26 S RNA 
(Dalgarno et al., 1983) we conclude that the 
21-nucleotide deletion is the only difference 
between RRV T48 and the mutant virus in 
the 26 S region of the genome, i.e., that 
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FIG. 1. Sequence of RRV dE2 cDNA in the region 
of the deletion. Virion RNA from purified RRV T48 
or intracellular 26S RNA purified from RRV dE2-in-
fected BHK cells was sequenced by the dideoxynu-
cleotide method using as primer a synthetic oligo-
deoxynucleotide complementary to nucleotides 1455-
1471 of RRV T48 26 S RNA (Dalgarno et al., 1983). 
The 21 nucleotides enclosed between the arrows on 
the RRV T48 sequence are missing from the RRV dE2 
sequence at the indicated position (arrow). Three nu-
cleotides on either side of the deleted sequence are 
indicated. N, ambiguous nucleotide; dE2, sequence of 
RRV dE2 cDNA; T48, sequence of RRV T48 cDNA. 
coding for the structural proteins. The 
mutant virus is referred to below as RRV 
dE2. 
To determine whether RRV dE2 was al-
tered in the non-26 S region of the genome, 
high molecular weight RNA was isolated 
from BHK cells infected with RRV T48 or 
with RRV dE2 or was isolated from mock-
infected cells (Faragher et al., 1985). RNA 
was transcribed into single-stranded cDNA 
using random calf thymus DNA primers, 
digested with Taql or HaeIII, and the di-
gests were electrophoresed on a polyacryl-
amide gel (Faragher et al., 1985). 
In the Taql restriction digests (Fig. 2), a 
cDNA fragment of approximately 243 nu-
cleotides in the RRV T48 profiles was re-
placed by one of 222 nucleotides in the RRV 
dE2 profiles. This would be expected from 
the positions of the established Taql re-
Hae Ill 
MTD MTD 
.... 
--
-
60 cm 20 cm 
Taq I 
M T D M T D 
-243 
-2 22 
243- -
222-
60 cm 20 cm 
FIG. 2. HaeIII and Taql restriction digest profiles 
of cDNA synthesized against total RNA isolated from 
RRV T48-infected cells, RRV dE2-infected cells, and 
mock-infected cells. BHK cell monolayers were mock 
infected (M) or infected with wild-type RRV strain 
T48 (T) or deletion variant (D) (m.o.i. = 3.0). Infected-
cell RNA or mock-infected cell RNA was extracted 16 
hr p.i. Single-stranded cDNA, labeled with [a-
32P]dCTP was synthesized using random primers, and 
digested with HaeIII or Taql. Restriction fragments 
were separated on a 40-cm long 5% polyacrylamide 
gel on which the xylene cyanol marker was run for 
60 or 20 cm, as indicated. Lengths (in nucleotides) of 
deletion-containing and the corresponding wild-type 
fragments, predicted from HaeIII and Taql restriction 
maps of RRV 26 S cDNA (Dalgarno et al., 1983), are 
indicated. Estimates of fragment lengths from the 
known sizes of sequenced HaeIII fragments of RRV 
26 S cDNA (Dalgarno et al, 1983) closely approximated 
the predicted lengths. Partial digestion products are 
denoted by "p." 
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striction sites in RRV T48 26 S cDNA (Dal-
garno et al., 1983). The fragments of 399 
and 378 nucleotides (Fig. 2) probably rep-
resent partial Taql digestion products re-
sulting from occasional failure to cleave at 
a TaqI site (position 1394) in RRV 26 S 
cDNA (see Dalgarno et al., 1983; Figs. 2, 4). 
Restriction nucleases such as Taql and 
HaeIII give rise to a number of partial re-
striction digest fragments when incubated 
with single stranded DNA (Rice and 
Strauss, 1981b; Dalgarno et al., 1983). 
The HaeIII restriction digest profiles of 
RRV T48 cDNA show that a cDNA frag-
ment of 892 nucleotides (Dalgarno et al., 
1983; Fig. 2) was replaced by a more rapidly 
migrating band in the RRV dE2 profile 
(Fig. 2). Within the limits of the method 
used the size of the new band is that pre-
dicted for the proposed mutant. 
No other fragments with altered mobil-
ities were observed and we conclude that 
no large deletion or insertions have taken 
place in the non-26 S region of the RRV 
dE2 genome. However the existence of 
small deletions or point mutations cannot 
be excluded without direct sequencing. 
Structural Proteins of RRV T48 and RRV 
dE2 
A B 
D T D T 
- p97 
- PE2 
- El 
- E2 
-----c 
FIG. 3. RRV proteins in virions and infected cell 
extracts. (A) RRV T48 and RRV dE2 were purified in 
parallel (see under Methods). For labeling virus, cells 
were grown in Eagle's minimum essential medium 
(EMEM) containing one-tenth the normal amino acid 
concentration and 10 µCi / ml of 3H-amino acids. Pu-
rified virus was disrupted in 1 % sodium dodecyl sulfate 
(SDS) and electrophoresed on 10-20% gradient ac-
rylamide gel and fluorographed. (B) BHK cells were 
RRV contains two envelope glycopro- '.nfected (~.o.i. ~ 3) with ~R:V T;8 or ~RV d~2 and 
teins of nominal mol wt 52 000 (gp52) and mcubated m EMEM contammg H-ammo acids (25 
49 000 ( 49) t th ·th ' ·d t · µCi / ml). At 24 hr p.i. the cell monolayer was dissolved gp oge er w1 a caps1 pro em . . . 
' . . m 1 % SDS and electrophoresed as above. The pos1t10n (p32) (Martm et al., 1979). To determme of viral proteins p97, PE2, El, E2, and Care indicated. 
which of the two RRV envelope glycopro- D, RRV dE2; T, RRV T48. 
teins is E2 we have carried out pulse-chase -
experiments and shown that [35S]methi-
onine from a protein of approximate mol 
wt 62,000 (PE2) can be "chased" into gp49 
(N. J. Short and L. Dalgarno, unpublished 
data). We conclude that gp49 is E2. 
E2 from RRV dE2 virions migrated with 
a slightly greater electrophoretic mobility 
than did E2 from RRV T48 virions (Fig. 
3A). E2 and PE2 from RRV dE2-infected 
cells also showed slightly greater mobili-
ties than the corresponding proteins from 
RRV T48-infected cells (Fig. 3B). The al-
tered mobilities of E2 and PE2 could be 
due to conformational changes brought 
about by the deletion of seven amino acids 
or by an altered pattern of glycosylation. 
There are two potential asparagine-linked 
glycosylation sites in RRV E2 at amino ac-
ids 200 and 262 (Dalgarno et al., 1983). 
To determine whether E3 is present in 
RRV T48 and in RRV dE2, H 3-amino acid-
labeled RRV T48, RRV dE2, and Semliki 
Forest virus were purified in parallel and 
the viral proteins examined on a poly-
acrylamide gel under reducing conditions. 
RRV T48 and RRV dE2 virions contained 
no more than trace amounts of E3; a pro-
tein of nominal molecular mass 13,000 Da 
was present in the corresponding extra-
cellular fluids (data not shown). SFV vi-
rions contained E3 and no E3 was detected 
in SFV tissue culture fluids (data not 
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FIG. 4. Thermolability of RRV dE2, RRV dE2, or 
RRV T48 were incubated separately in BHK cell 
growth medium at 50°. At intervals samples were re-
moved and immediately diluted 10-fold into ice-cold 
HESS before assay for infectivity by plaque formation 
on Vero cell monolayers. e, Titer of RRV T48; 0 , titer 
of RRV dE2. 
shown). Our results for SFV confirm pre-
vious reports (Garoff et al., 1974). 
Thermal Instability of RRV dE2 
RRV dE2 showed a marked sensitivity 
to heat inactivation by comparison with 
RRV T48. After 30 min at 50° the titer of 
RRV dE2 was lowered by more than 3 log 
units whereas that of RRV T48 was unaf-
fected (Fig. 4). At 37° no difference in sta-
bility between RRV T48 and RRV dE2 was 
detected. 
Temperature Sensitivity of Plaque For-
mation 
Plaque formation by RRV dE2 and RRV 
T48 was compared at 28, 30, 32, 34, 36, 37, 
39, and 41 °. For both RRV T48 and RRV 
dE2 maximum titers were recorded at 36°. 
' There was a rapid decrease in the efficiency 
of plaque formation for both viruses above 
36° and a more gradual decrease below 36°. 
No differential changes in efficiency of 
plaque formation or in plaque size were 
observed for the two viruses as the tem-
perature was altered (data not shown). 
Growth in BHK Cells and Primary Mouse 
Cells 
The growth kinetics of RRV dE2 and 
RRV T48 were compared in BHK cells and 
in primary mouse muscle and skin cells. 
No significant differences were observed in 
the levels of extracellular virus produced 
in three experiments in which BHK cells 
were infected (m.o.i. ~ 0.001 or 1) and pri-
mary mouse cells were infected (m.o.i. 
~ 3.5) (data not shown). In infected BHK 
cells there was no difference in the ratio of 
cell associated virus to extracellular virus 
for the two viruses (data not shown). 
Rates of Penetration of RRV dE2 and RRV 
T48 in Vero Cell Monolayers 
To compare the rates of penetration of 
RRV dE2 and RRV T48, Vero cell mono-
layers in 60-mm dishes were inoculated 
with approximately 100 PFU of virus and 
incubated at 37° for 10, 20, 30, 40, 50, and 
60 min followed by the addition of poly-
clonal RRV immune ascitic fluid for 10 min 
(Barie et al., 1981). After washing to remove 
unattached antibody, overlay was added 
and plates incubated for plaque develop-
ment. Experiments were carried out in 
triplicate. RRV dE2 and RRV T48 gave vir-
tually identical profiles of virus uptake 
(data not shown). In control experiments, 
certain mutants of RRV selected on the 
basis of their resistance to neutralization 
by monoclonal antibody, were slow in their 
penetration of Vero cells (S. Vrati, unpub-
lished data). 
Virus-Specific RNA Synthesis in Infected 
BHK Cells 
Virus-specific RNA synthesis was higher 
in RRV dE2-infected BHK cells than in 
cells infected with RRV T48 (m.o.i. ~ 3). 
For RRV T48 and RRV dE2, virus-specific 
(actinomycin-resistant) RNA synthesis at 
the time of maximal RNA synthetic rate 
(8-10 hr postinfection) was 30-35% and 50-
60 % ,respectively, of rates in mock-infected 
control cells in the absence of actinomycin 
(data not shown). Virion RNA and 26 S 
RNA were synthesized in the same pro-
portions in RRV T48- and RRV dE2-in-
fected cells (data not shown). 
Polypeptide Synthesis in Infected BHK 
Cells 
BHK cells infected with RRV dE2 or 
RRV T48 were labeled with 3H-amino acids 
at various times after infection (m.o.i. ~ 2) 
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FIG. 5. Time course of polypeptide synthesis in BHK cells infected with RRV dE2 and RRV T48. 
BHK cell monolayers in 35-mm dishes were infected with RRV dE2 or RRV T48 (m.o.i. c::= 2) or mock infected and incubated in cell growth medium. At intervals monolayers were labeled for 2 hr with 1 ml EMEM containing 100 µCi / ml of 3H-amino acids and one-tenth the normal concentration of 
amino acids. Monlayers were disrupted in 200 µl of 1 % SDS and aliquots electrophoresed on 10-20 % gradient polyacrylamide slab gels followed by fluorography. Figures at tracks heads indicate extracts from mock-infected cells (M), RRV dE2-infected cells (D), and RRV T48-infected cells (T). Figures 
a t right indicate the infection-specific polypeptides. 
and cell extracts electrophoresed on 10-
20 % gradient acrylamide gels (Fig. 5). The 
following virus-specific polypeptides were 
identified in cells infected with RRV T48 
and RRV dE2: p95, p80, p70, p62, El, E2, 
C, and E3. Viral structural proteins and 
their precursors were labeled 2-3 hr earlier 
in RRV dE2-infected cells than in RRV 
T48-infected cells, possibly reflecting the 
different rates of virus-specific RNA syn-
thesis (above). Shutdown of host protein 
synthesis occurred earlier in cells infected 
with RRV dE2 than in cells infected with 
RRV T48. There was no change in the pat-
tern of processing of RRV structural pro-
teins in cells infected with RRV dE2. How-
ever, labeling of p80 and p70, two proteins 
of unknown origin and function in RRV in-
fection , was more prominent in RRV dE2-
infected cells than in RRV T48-infected 
cells. 
Discrimination between RRV dE2 and RRV 
T 48 Using N eutralizing Monoclonal 
A ntibodies 
Five neutralizing anti-E2 monoclonal 
antibodies generated against RRV T48, 
were tested for their ability to neutralize 
RRV dE2 and RRV T48 in 50 % plaque re-
duction neutralization tests. Four of them (E7, lDll, 10C9, and 4D2) showed similar 
neutralizing activities (i.e., titers differed 
by 10-fold or less) against RRV T48 and 
RRV dE2. However, the antibody, 3C4, was 
approximately three orders of magnitude 
less effective against RRV dE2 than 
against RRV T48 (Table 1). This indicates 
that an epitope in E2 to which 3C4 binds 
TABLE 1 
PLAQUE NEUTRALIZATION OF RRV T48 AND RRV dE2 
BY MONOCLONAL ANTIBODIES 
Neutralization titer 
of monoclonal antibodies a 
Virus E7 lDll 10C9 4D2 3C4 
RRV T48 4.2 4.8 3.6 4.9 4.1 
RRV dE2 4.7 3.8 3.8 5.1 1.3 
a Titer is the log10 dilution of monoclonal antibody 
resulting in 50 % neutralization of virus plaque for-
mation. 
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TABLE 2 
VIRULENCE OF RRV T48 AND RRV dE2 FOR MICE 
RRV dE2 RRV T48 
Day-old mice Week-old mice Day-old mice Week-old mice 
LD50 (Vero PFU) 
Average survival 
time (days) 
0.066 
7.46 
>8 X 106 
N.D.R.a 
0.046 
4.94 
0.051 
5.92 
Note. Estimates of LD50 and average survival times, obtained as described under Materials and Methods, 
were assessed for statistical significance using one-way analysis of variance and t tests. LD50 values for RRV 
dE2 differ significantly from those of RRV T48 in both day-old mice and week-old mice (P < 0.005). AST 
values in day-old mice are significantly different (P < 0.025). 
a N.D.R.: no deaths recorded. 
is modified in the deletion mutant. No dif-
ferences could be detected between RRV 
T48 and RRV dE2 in their neutralization 
by polyclonal immune ascitic fluid (data not 
shown). 
Virulence of RRV dE2 and RRV T48 for 
Mice 
RRV T48 is highly virulent for young 
mice (Taylor, 1972). Injection of day-old 
mice with low doses of virus by intracra-
nial, intraperitoneal, or subcutaneous 
routes rapidly results in hind leg paralysis 
and death. With increasing age there is a 
gradual fall in the susceptibility of mice to 
lethal infection and RRV T48 will not kill 
4-week-old mice when inoculated in large 
doses (Taylor, 1972). 
We have compared the virulence of RRV 
T48 and RRV dE2 for day-old and week-
old mice in terms of LD50s, average survival 
times (AST), and severity of symptoms. In 
day-old mice the symptoms of hind leg pa-
ralysis were less severe for RRV dE2 than 
for RRV T48 in the dose range 0.02-20 PFU 
per mouse. In all dose ranges tested symp-
toms were independent of dose. LD50 values 
and ASTs were slightly greater for RRV 
dE2 than for RRV T48 (Table 2). In week-
old mice RRV dE2 appeared to be com-
pletely avirulent: the virus elicited no 
symptoms and did not kill even at high 
doses ('.::::'.8 X 106 PFU injected ip). By con-
trast the virulence of RRV T48 in week-old 
mice was not significantly different from 
that in day-old mice (Table 2). We conclude 
that RRV dE2 is markedly less virulent 
than RRV T48 in week-old mice and 
slightly less virulent than RRV T48 in day-
old mice. 
Growth of RRV dE2 and RRV T48 in Mice 
Day-old or week-old mice were injected 
subcutaneously with 100 PFU of RRV T48 
or RRV dE2 and virus assayed at daily in-
tervals in the blood, hind leg muscle, and 
brain tissues from each of three mice (Fig. 
6). Maximum titers were at 1-2 days after 
injection for both age groups and were 
highest in muscle tissues. In day-old mice, 
RRV T48 reached 1011-1012 PFU/g of mus-
cle; the corresponding RRV dE2 titer was 
10 
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FIG. 6. RRV dE2 and RRV T48 titers in the blood, 
brain, and hind leg muscle of day-old and week-old 
mice. WEHI mice were injected subcutaneously with 
100 PFU of virus and virus in the blood, brain, and 
hind leg muscle assayed at various times. Each time 
point represents the average of determinations made 
in three mice. Error bars are shown where the error 
is greater than 0.2 log units. e, RRV T48 titers in day-
old mice; 0, RRV dE2 titers in day old mice; • , RRV 
T48 titers in week-old mice; D, RRV dE2 titers in week-
old mice; *, titer less than 100 PFU/ml. 
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108-109 PFU/g. In brain tissue RRV T48 
and RRV dE2 reached approximately 1011 
and approximately 107 PFU/g, respec-
tively. In week-old mice RRV T48 and RRV 
dE2 reached peak muscle titers of approx-
imately 1011 and 109 PFU/g of muscle tis-
sue, respectively (Fig. 6). RRV T48 reached 
approximately 109 and approximately 1010 
PFU/g, respectively, in the brain and blood 
of week-old mice. However, maximum RRV 
dE2 titers in the blood and brain tissues of 
week-old mice were approximately 105 and 
104 PFU/g, respectively. The dramatic re-
duction in RRV dE2 virulence for week-old 
mice could be due to the decreased repli-
cation of RRV dE2 in brain tissue. 
DISCUSSION 
We have isolated a mutant of RRV T48 
which, from nucleotide sequence determi-
nation has a deletion of seven amino acids 
at positions 55-61, near the N terminus of 
the envelope glycoprotein E2. The existence 
of the mutant confirms predictions made 
in previous studies (Dalgarno et al., 1983). 
There have been previous reports of al-
phavirus mutants with structural proteins 
which are altered in their electrophoretic 
mobilities (Bracha and Schlesinger, 1978; 
Cancedda et al., 1981; Durbin and Stollar, 
1984; Eaton, 1982; Leone et al., 1980). The 
mobility changes have been ascribed to ad-
ditional carbohydrate (Cancedda et al., 
1981; Durbin and Stollar, 1984), an altered 
site of proteolytic cleavage in PE2 (Bracha 
and Schlesinger, 1978) and a deletion 
(Leone et al., 1980). Eaton (1982) was not 
able to establish whether a deletion or 
amino acid changes leading to enhanced 
SDS binding were responsible for the 
change observed in Sindbis virus (SIN) E2. 
The data presented demonstrate that 
amino acids 55-61 of RRV E2 are not es-
sential for infectivity. This is of interest in 
view of the conservation in the size and 
sequence of E2 between alpha viruses. RRV, 
SFV, and SIN E2 proteins are predicted to 
be 422, 422, and 423 amino acids long, re-
spectively (Dalgarno et al., 1983), and there 
is 69 and 42% homology between RRV E2 
and the E2 proteins of SFV and SIN, re-
spectively (Dalgarno et al., 1983). The 
amino acids deleted in RRV dE2 are in a 
region of moderate homology with SFV: 
three of the seven deleted are identical be-
tween RRV T48 and SFV (Dalgarno et al., 
1983). Although amino acids 55-61 are 
inessential for replication under laboratory 
conditions, the data on RRV dE2-induced 
viremia in mice suggest that transmission 
of such deletion mutants under field con-
ditions would be unlikely. 
Since RRV dE2 showed no major repli-
cation defects in BHK cells, its failure to 
reach high titers in mice was probably not 
due to a defect in intracellular events in 
virus replication. Nor did the poor growth 
of RRV dE2 appear to be the result of en-
hanced interferon induction since when 
RRV dE2 and RRV T48 were used to coin-
feet mice, the growth of RRV T48 was sim-
ilar to that obtained when it alone was used 
for infection (S. Vrati, unpublished data). 
The differences in titer were probably not 
the result of different degrees of inacti-
vation of the two viruses in vivo as there 
was no difference in the rate of loss of in-
fectivity of the two viruses after 2 hr in-
cubation in mouse serum at 37° (S. Vrati, 
unpublished data). It is unlikely that the 
low RRV dE2 titers in vivo resulted from 
an enhanced specific immune response to 
RRV dE2 since this would need to occur 
shortly after infection and be specific for 
RRV dE2. Polyclonal antibody will not dis-
tinguish RRV T48 and RRV dE2 in neu-
tralization tests (data not shown). 
We propose that the different growth 
profiles of RRV dE2 and RRV T48 in vivo 
reflect alterations in penetration due to 
structural changes in determinants on the 
surface of E2. The E2-specific monoclonal 
antibody 3C4 neutralized RRV dE2 infec-
tivity 1000 times less efficiently than RRV 
T48 infectivity. This, together with the 
marked reduction in thermal stability of 
RRV dE2 indicates that major changes 
have occurred in the conformation of the 
envelope glycoproteins of RRV dE2, par-
ticularly E2. These appear to have induced 
greater effects on in vivo replication than 
on patterns of growth and penetration in 
cultured cells, data consistent with results 
from Barie et al. (1981) and Olmsted et al. 
(1984). Barie et al. (1981) isolated a rapidly 
growing mutant of SIN by selecting for vi-
rus released early in infection of BHK cells. 
,I 
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The variant had an increased rate of pen-
etration into BHK cells (but not into other 
cell types), and from neutralization studies 
with monoclonal antibodies was probably 
altered in E2. Olmsted et al. (1984) showed 
that virus selected in this way was of re-
duced virulence for mice and that rapid 
penetration into BHK cells was strongly 
correlated with attenuation in mice. Barie 
et al. (1981) concluded that the class of cel-
lular receptors active in Sindbis virus up-
take in BHK cells is of low specificity com-
pared with that involved in penetration in 
vivo. 
It has previously been argued that RRV 
pathogenesis in infant mice is not typical 
of alphaviruses since it does not involve 
early and rapid replication in neural tis-
sues but, rather, is accompanied by exten-
sive replication in nonneural tissues, par-
ticularly skeletal (hind leg) muscle (Mims 
et al., 1973; Murphy et al., 1973). By contrast 
SFV produces widespread infection and 
necrosis in the central nervous system and 
death takes place before there is time for 
the evolution of the pathological changes 
seen with RRV (Mims et al., 1973). Murphy 
et al. (1973) proposed that the muscle le-
sions produced by RRV in newborn mice 
provide an adequate explanatory basis for 
the paralysis seen in RRV infection since 
the type of involvement of brain and spinal 
cord which could account for this paralysis 
was not seen. 
Using the same outbred strain of mice 
as that used by Murphy et al. (1973) we have 
shown that RRV dE2 accumulates to the 
same level (~108 PFU/g of tissue) in the 
hind leg muscle of day-old and week-old 
mice. However, RRV dE2 is apparently to-
tally avirulent for week-old mice although 
it is virulent for day-old mice (Table 2). 
The loss of virulence in week-old mice is 
accompanied by a sharp reduction in virus 
replication in brain tissue by comparison 
with that seen in day-old mice (Fig. 6). We 
have recently shown that, for certain RRV 
variants, the increase in virulence which 
occurs on serial passage of an avirulent 
strain of RRV in mice is accompanied by 
an increase in brain titers with little 
change in hind leg muscle titers (A. D. 
Meek, R. C. Weir, and L. Dalgarno, unpub-
lished data). Seay and Wolinsky (1982) and 
Kingston (1983) have reported that RRV-
induced central nervous system demyelin-
ation occurs in a way which suggests a 
causal relationship with paralysis. Thus 
RRV replication in brain tissue may be a 
more important determinant of viral vir-
ulence than the extent of replication in 
muscle. 
The attenuation of virulence of RRV dE2, 
together with the protection of RRV dE2-
immunized mice against lethal challenge 
with RRV T48 (S. Vrati, unpublished re-
sults), suggests that selection or generation 
of deletion variants may provide a useful 
route to stable (nonreverting) virus vari-
ants suitable for use as safe alphavirus 
vaccmes. 
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